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Embryonic stem cells (ESCs) are known for their ability to be maintained 
almost indefinitely in an undifferentiated, proliferating state with the potential 
to give rise to all the cell types. Current strategies for the differentiation of ESCs 
are limited by their inability to control differentiation resulting in a 
heterogeneous cell population. Addressing this limitation, it has been previously 
reported that treatment with HepG2-conditioned medium (HepG2-CM) 
enhances the formation of multipotent mesodermal progenitors from ESCs. This 
promotes greater control of ESC differentiation in a lineage-specific fashion 
possibly resulting in efficient skeletal differentiation, which is an observation 
demonstrated by our group. 
In this study, by regulating culture time, preferential differentiation to 
either the osteogenic or cardiomyogenic lineage from murine ESCs was 
achieved using HepG2-CM in a three-dimensional integrated bioprocess. In 
addition, an automatable and scalable bioprocess was developed through the 
design, fabrication, and testing of a novel perfusion bioreactor system that has 
improved mineralised cellular construct generation. Finally, an animal pilot 
study was conducted to evaluate the efficacy and toxicity of our mineralised 
cellular constructs. 
In conclusion, this thesis reports the development of a novel bioprocess 
that supports the transfer of the laboratory-based practices based on ESCs to in 
vivo application. 
 
 
 
 
 
5 
 
Declaration 
 
The work described in this thesis was carried out in the Department of 
Chemical Engineering, Imperial College London, United Kingdom between 
October 2005 and October 2009. Except where acknowledged, the material is 
the original work of the author and includes nothing, which is the outcome of 
work in collaboration, and no part of it has been submitted for a degree at any 
other university. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
Acknowledgements 
 
There are so many people I should thank for the warm supports over the 
period of my stay in Imperial College London. 
First of all, I deeply appreciate Sakis, my sole supervisor during my PhD as 
well as a mentor of my life. He wholeheartedly supported me in various forms 
for the last four and a half years. I have also learnt a number of things from him 
which are of importance in my research life; “How to think”, “How to plan my 
life”, and “How to manage people” etc. I cannot even list all of the lessons he 
has given to me so far. Thank you very much, Sakis. 
I acknowledge the kind assistances and collaborations to finish this piece 
of works; prof. Soo-ik Chang and prof. Jun Lee for the animal study; Dr. Andrew 
Chan and prof. Sergei Kazarian for the ATR-FTIR measurement; Raimundo Ho 
and Dr. Jerry Heng for the mechanical testing; and David Yeo for CFX simulations. 
I would also like to thank all of my lovely colleagues in BSEL. They have 
been so kind, supportive, and friendly all the time. I was really happy to work 
with them, and owed them so many things. I will never forget I was so lucky to 
be with them during my PhD course. Thank you all, my friends. We will 
definitely keep in touch wherever we belong to in the future. 
Lastly, the most heartfelt gratitude should go to my parents. What I have 
gotten from them during my entire life is just priceless. Nothing I can do is 
possible to reward all the devotion to their son. Thank you so much, father and 
mum. I love you so much. I will always be trying to be a proud son of you. 
 
 
7 
 
Publications 
 
1. Jae Min Cha, Andrew K.L. Chan, Raimundo Ho, Jun Lee, Jerry Y.Y. Heng, 
Sergei G. Kazarian, Manolis Heliotis, Eleftherios Tsiridis, Mi-hyang Nam, 
Dong-Ku Kang, Soo-Ik Chang, Athanasios Mantalaris “Production of 
Functional Three-dimensional Mineralized Cellular Constructs from 
Embryonic Stem Cells in a Novel Perfusion Bioreactor” Biomaterials (In 
submission) 
 
2. Jae Min Cha, David C.L. Yeo, Julia M. Polak, Athanasios Mantalaris “A Novel 
Design of Perfused Rotating Wall Vessel Bioreactor System: Three-
dimensional Expansion of Embryonic Stem Cells” Biotechnology and 
Bioengineering (In submission) 
 
3. Jae Min Cha*, Christian Bariani*, I-Ming Chung, Siti Ismile, Iliana Fauzi, David 
C.L. Yeo, Idtisak Paopo, Teresa Mortera Blanco, Maria Rende, Hugo M. 
Macedo, Supacharn Tangviriyasirikul, Athanasios Mantalaris “Bioprocessing 
applications to Embryonic Stem Cells: in vitro generation of bone, cartilage 
and heart cells” Expert Opinion on Biological Therapy (In submission) 
* equal contributors in the paper 
 
4. Joseph Pagkalos*, Jae Min Cha*, Yunyi Kang, Manolis Heliotis, Eleftherios 
Tsiridis, Athanasios Mantalaris “Simvastatin induces osteogenic 
differentiation of murine embryonic stem cells” the Journal of Bone and 
Mineral Research (In revision) 
* equal contributors in the paper 
 
8 
 
5. Jae Min Cha, Andrew K.L. Chan, Yu-Shik Hwang, Wesley Randle, Julia M. 
Polak, Sergei G. Kazarian, Athanasios Mantalaris “Effective in vitro Bone 
Tissue Formation from Embryonic Stem Cells by Controlling Spontaneous 
Differentiation Period after HepG2-Conditioned Medium Treatment using 
3D-integrated Bioprocess” Artificial Organs (in submision) 
 
6. Jae Min Cha, Julia M. Polak, Athanasios Mantalaris “Enhanced 
Cardiomyogenic Tissue Formation from Embryonic Stem Cells with 
Conditioned Medium Treatment in the Optimized Spontaneous 
Differentiation Period using 3D-Integrated Bioprocess” Tissue Engineering (in 
submission) 
 
7. Juan Zhang, Min Wang, Jae Min Cha, Athanasios Mantalaris “The 
Incorporation of 70s Bioactive Glass to the Osteogenic Differentiation of 
Murine Embryonic Stem Cells in 3D-bioreactors” Journal of Tissue 
Engineering and Regenerative Medicine 3(1):63-71, 2009 
 
8. Mark R Placzek, I-Ming Chung, Hugo M. Macedo, Siti Ismail, Teresa Mortera 
Blanco, Mayasari Lim, Jae Min Cha, Iliana Fauzi, Yunyi Kang, David C. L. Yeo, 
Chi Yip Joan Ma, Julia M. Polak, Athanasios Mantalaris “Stem Cell 
Bioprocessing: Fundamentals and Principles” Journal of the Royal Society 
Interface 6(32):209-32, 2009 
 
9. Wesley Randle, Jae Min Cha, Yu-Shik Hwang, Andrew Chan, Sergei Kazarian, 
Julia M. Polak, Athanasios Mantalaris “Integrated 3D-expansion and 
Osteogenic Differentiation of Murine Embryonic Stem Cells” Tissue 
Engineering 13(12):2957-70, 2007  
 
9 
 
Conference Proceedings 
 
1. Jae Min Cha, David Chen Yeo, Athanasios Mantalaris, “In vitro Bone Tissue 
Generation from Integrated 3D Bioprocess for Embryonic Stem Cell Culture 
using a Novel Perfused Rotating Wall Vessel Bioreactor System” 2nd TERMIS 
World Congress in conjunction with 2009 Seoul Stem Cell Symposium, Lotte 
Hotel World, Seoul, Korea, August 2009 
 
2. Jae Min Cha, David Chen Yeo, Supachan Tangviriyasirikul, Athanasios 
Mantalaris “Functional, Automatable, and Cost-effective Bioprocessing for 
3D Skeletal Tissue Engineering Applications” SET for BRITAIN Exhibition in the 
Biological and Biomedical Science Section, the House of Commons, London, 
UK, March 2009 
 
3. Jae Min Cha, Athanasios Mantalaris “Enhanced Cardiomyogenesis from 
Murine Embryonic Stem Cells Cultured in HepG2-conditioned Media using 3D 
Integrated Bioprocess” 8th World Biomaterials Congress, Amsterdam, The 
Netherlands, May 2008 
 
4. Jae Min Cha, Wesley Randle, Yu-Shik Hwang, Athanasios Mantalaris 
“Optimisation of an Integrated Bioprocess for 3D Bone Tissue Formation 
using Murine Embryonic Stem Cells Encapsulated in Hydrogels” International 
Congress in Biohydrogels, Viareggio, Italy, November 2007 
 
5. Jae Min Cha, Wesley L. Randle, Mark R. Plazcek, Yu-Shik Hwang, K. L. Andrew 
Chan, Serigei G. Kazarian, Julia M. Polak, Athanasios Mantalaris “Integrated 
3D Expansion and Osteogenic Differentiation of Murine Embryonic Stem 
Cells in a Simulated Microgravity Bioreactor” 2006 Annual Meeting of AIChE, 
San Francisco, California, USA, November 2006 
10 
 
Table of Contents 
Abstract  ....................................................................................................... 3 
Declaration ..................................................................................................... 5 
Acknowledgements ........................................................................................ 6 
Publications .................................................................................................... 7 
Conference Proceedings .................................................................................. 9 
List of Figures ................................................................................................ 15 
List of Tables ................................................................................................. 20 
Chapter 1. Literature Review ......................................................................... 21 
1.1. Tissue Engineering ....................................................................................... 22 
1.1.1. An overview ......................................................................................... 22 
1.1.2. Skeletal tissue engineering .................................................................. 24 
1.2. Cell Sources for Skeletal Tissue Generation ................................................ 28 
1.2.1. Mesenchymal stem cells (MSCs) ......................................................... 29 
1.2.2. Embryonic stem cells (ESCs) ................................................................ 32 
1.3. Differentiation Control for Skeletal Development from ESCs .................... 38 
1.3.1. Embryonic germ layer development in vivo ........................................ 38 
1.3.2. In vitro skeletal lineage differentiation from ESCs .............................. 40 
1.4. Three-dimensional Bioprocess for in vitro Skeletal Tissue Generation ...... 45 
1.4.1. Three dimensional scaffolds in tissue engineering ............................. 46 
1.4.2. Alginate bead encapsulation ............................................................... 47 
1.4.3. The development of three-dimensional bioprocess ........................... 51 
Chapter 2. Aims and Objectives ..................................................................... 68 
Chapter 3. Materials and Methods ................................................................ 71 
3.1. Optimisation of 3D-integrated Bioprocessing............................................. 72 
3.1.1. mESC maintenance .............................................................................. 72 
3.1.2. EB formation ........................................................................................ 72 
3.1.3. HepG2 conditioned medium (HepG2-CM) formulation ...................... 73 
11 
 
3.1.4. Alginate encapsulation of ESCs ............................................................ 73 
3.1.5. Three-dimensional culture for skeletal tissue generation .................. 74 
3.1.6. Fabrication of a perfusion RWV bioreactor ......................................... 76 
3.2. Biological Evaluation Techniques ................................................................ 78 
3.2.1. Live/Dead assay ................................................................................... 78 
3.2.2. Alkaline phosphatase (ALPase) activity analysis .................................. 78 
3.2.3 Alkaline phosphatase activity observation ........................................... 79 
3.2.4. DNA quantification ............................................................................... 79 
3.2.5. Immunocytochemistry staining ........................................................... 80 
3.2.6. Reverse transcription polymerase chain reaction (RT-PCR) ................ 82 
3.2.7. Quantitative PCR (qPCR) ...................................................................... 84 
3.2.8. Alizarin red S (ARS) and sirius red staining .......................................... 84 
3.2.9. ARS-based quantification of bone mineralisation ............................... 85 
3.2.10. Analysis of medium profiles ............................................................... 85 
3.2.10. Attenuated total reflection Fourier transform infrared (ATR FTIR) 
analysis .................................................................................................. 86 
3.2.11. Mechanical strength testing .............................................................. 87 
3.2.12. Statistical analysis .............................................................................. 87 
3.3. In vivo Testing of Bone-like Tissues from Bioreactor .................................. 88 
3.3.1. Animal care and preparation ............................................................... 88 
3.3.2. Surgical protocol .................................................................................. 88 
3.3.3. Micro-focus X-ray computed tomography (micro-CT) ........................ 90 
3.3.4. Histological evaluations ....................................................................... 90 
Chapter 4. Use of HepG2-CM for Heart and Bone Tissue Engineering in a fed-
batch 3D bioprocess ..................................................................... 92 
4.1. Introduction ................................................................................................. 93 
4.1.1. Aims ...................................................................................................... 95 
4.1.2. Experimental plan ................................................................................ 95 
12 
 
4.2. Enhanced 3D-cardiomyogenic Tissue Formation from ESCs using 
Conditioned Medium Treatment with the Optimised Spontaneous 
Differentiation Period .................................................................................. 97 
4.2.1. Characterisation of mESCs in hydrogel following HepG2-CM treatment
 ............................................................................................................... 97 
4.2.2. Comparisons of 3D-cardiomyogenic tissue generation ..................... 100 
4.2.3. Cell viability and morphology study in 3D-cardiomyogenesis ........... 102 
4.2.4. Immunocytochemistry and beating cellular colonies ....................... 103 
4.3. Effective 3D-bone Tissue Formation in vitro from ESCs by Controlling 
Spontaneous Differentiation Period after HepG2-Conditioned Medium 
Treatment .................................................................................................. 105 
4.3.1. Morphological observation and cellular Live/Dead assay ................. 105 
4.3.2. Three-dimensional osteogenesis of control group ............................ 107 
4.3.3. Mineralisation assessment of experimental groups ......................... 108 
4.3.4. Osteogenic gene expression profiles ................................................. 111 
4.4. Discussion .................................................................................................. 113 
4.5. Conclusions ................................................................................................ 119 
Chapter 5. Design and fabrication of a Perfusion Rotating Wall Vessel 
Bioreactor System ...................................................................... 120 
5.1. Introduction ............................................................................................... 121 
5.1.1. Aims .................................................................................................... 125 
5.1.2. Experimental plans ............................................................................ 125 
5.2. Design of Vessel and Perfusion System .................................................... 126 
5.2.1. Conceptual design of vessel for the effective oxygen supply ........... 126 
5.2.2. Assembly of perfusion rotating wall vessel system (BSEL) ................ 136 
5.3. Conclusions ................................................................................................ 140 
Chapter 6. Three-dimensional Scale-Up of ESCs: Comparison Study (I) of BSEL, 
a Fed-Batch RWV, and Static Culture ........................................... 141 
6.1. Introduction ............................................................................................... 142 
6.1.1. Aims .................................................................................................... 142 
13 
 
6.1.2. Experimental plan .............................................................................. 142 
6.2. Results ....................................................................................................... 145 
6.2.1. Morphology and viability analysis ..................................................... 145 
6.2.2. Growth kinetics .................................................................................. 151 
6.2.3. Oxygen tension variation ................................................................... 152 
6.2.4. Culture medium profiles .................................................................... 153 
6.2.5. Maintenance of pluripotency (“stemness”) ...................................... 157 
6.3. Discussion .................................................................................................. 162 
6.4. Conclusions ................................................................................................ 171 
Chapter 7. Formation of Bone-Tissue like Constructs from ESCs: Comparison 
Study (II) of BSEL, a Fed-Batch RWV, and Static Culture ............... 172 
7.1. Introduction ............................................................................................... 173 
7.1.1. Aims .................................................................................................... 173 
7.1.2. Experimental plan .............................................................................. 174 
7.2. Results ....................................................................................................... 176 
7.2.1. Growth kinetics .................................................................................. 176 
7.2.2. Oxygen tension variation ................................................................... 177 
7.2.3. Culturing medium profiles ................................................................. 178 
7.2.4. Mineralisation quantification based on Alizarin Red S (ARS) staining
 ............................................................................................................. 182 
7.2.5. Gene expression profiles ................................................................... 183 
7.2.6. Attenuated total reflection Fourier transform infrared (ATR FTIR) 
analysis ................................................................................................ 185 
7.2.7. Mechanical strength testing .............................................................. 187 
7.2.8. Immunocytochemistry with osteogenic markers .............................. 189 
7.3. Discussion .................................................................................................. 191 
7.4. Conclusions ................................................................................................ 196 
Chapter 8. Animal model: in vivo study of osteogenic constructs from BSEL 197 
8.1. Introduction ............................................................................................... 198 
14 
 
8.1.1. Aims .................................................................................................... 199 
8.1.2. Experimental and surgical procedures .............................................. 199 
8.2. Results ....................................................................................................... 201 
8.2.1. Biopsy isolation .................................................................................. 201 
8.2.2. Histological evaluations ..................................................................... 202 
8.2.3. Micro-focus X-ray computed tomography (micro-CT) ...................... 209 
8.3. Discussion .................................................................................................. 212 
8.4. Conclusions ................................................................................................ 216 
Chapter 9. Summary and Conclusions ......................................................... 217 
Appendix  ................................................................................................... 221 
Appendix 1. Standard curves ............................................................................ 222 
Appendix 1.1. ρNPP standard curve ............................................................ 222 
Appendix 1.2. DNA quantification standard curve ...................................... 223 
Appendix 2. Characterisation of HepG2-CM treated ESCs on two-dimensional 
culture ........................................................................................................ 224 
Appendix 2.1. Cell morphology observation ............................................... 224 
Appendix 2.2. Alkaline phosphatase (ALPase) staining ............................... 225 
Appendix 2.3. Immunocytochemistry with Oct4 ......................................... 226 
Appendix 2.4. Comparison of growth kinetics ............................................. 227 
Appendix 2.5. EB formation and gene expression profiles ......................... 228 
Appendix 3. Media analysis from Synthecon system ...................................... 229 
Appendix 4. Negative control for PCR analyses ............................................... 231 
References .................................................................................................. 232 
 
 
 
 
15 
 
List of Figures 
Figure 1. Regenerative medicine and its sub-categories ..................................... 23 
Figure 2. The historical progress and future direction of medical development 
(adapted from Jekins et al. 2003). ........................................................ 24 
Figure 3. A brief scheme of bone tissue formation in vitro. ................................ 26 
Figure 4. Various derivates from bone marrow stem cells. ................................. 31 
Figure 5. Extraction of embryonic stem cells from the blastocyst. ...................... 32 
Figure 6. In vitro application of embryonic stem cells. ........................................ 33 
Figure 7. Schematic diagram representing the major components of a defined 
culture milieu for directing the differentiation of stem cells (adapted 
from Heng et al. 2004a). ....................................................................... 37 
Figure 8. The in vivo process of embryogenesis in brief ...................................... 39 
Figure 9. Various signals relevant with in vitro derivation of mesodermal cells 
from ESCs. .............................................................................................. 41 
Figure 10. Selective mesoderm derivation from ESCs using HepG2-CM (adapted 
from Lake et al. 2000). .......................................................................... 43 
Figure 11. Various supplements for heart and bone formation from ESCs. ........ 44 
Figure 12. A schematic representation of the ‘‘egg-box’’ model in low and high 
CaCl2 concentration (adapted from Simpson et al. 2004). ................... 49 
Figure 13. Schematic representation of the different gel network structures of a 
Ca-alginate gel bed (adapted from Bienaime et al. 2003). ................... 50 
Figure 14. Various bioprocesses for the development of skeletal lineage tissues 
from ESCs. .............................................................................................. 53 
Figure 15. A dynamic culture environment of rotating wall vessel with low shear 
stresses and high mass-transfer rates (adapted from Martin et al. 
2004). ..................................................................................................... 57 
Figure 16. The effects of oxygen tension to ESC-cultures reported by various 
literatures. ............................................................................................. 64 
Figure 17. The effects of cell secretion accumulation to ESC-cultures reported by 
various literatures. ................................................................................ 64 
Figure 18. The effects of shear stress to ESC-cultures reported by various 
literatures. ............................................................................................. 65 
16 
 
Figure 19. The effects of feeding rate to ESC-cultures reported by various 
literatures. ............................................................................................. 65 
Figure 20. The effects of glucose concentration to ESC-cultures reported by 
various literatures. ................................................................................ 66 
Figure 21. The requirements for the development of 3D-bioprocess. ................ 67 
Figure 22. Conventional ESC-culture. ................................................................... 69 
Figure 23. A scheme of the integrated 3D-bioprocess. ........................................ 70 
Figure 24. 3D-integrated bioprocess with the use of HepG2-CM. ....................... 96 
Figure 25. Experimental time schedules and group organisation. ...................... 96 
Figure 26. mESCs in the alginate hydrogel observed under the light microscope 
observation............................................................................................ 97 
Figure 27. Comparisons of growth kinetics (A), and Alkaline phosphatase 
(ALPase) activity (B). Statistical analyses were performed by a student 
t-test (n=3). Asterisks indicate p < 0.05. ............................................... 98 
Figure 28. Gene expression characterisation in the early developmental process 
in vitro.................................................................................................... 99 
Figure 29. Relative quantification of the cardiomyogenic gene expressions in the 
groups on day 11 (A), day 15 (B), day 21 (C). ...................................... 102 
Figure 30. Live (green) and Dead (red) assay (A)-(F), and the investigation of 
cellular colony morphologies (a-f) on day 21. .................................... 103 
Figure 31. Immunocytochemistry of cm5D group. ............................................ 104 
Figure 32. Morphological observation of the encapsulated mESCs by the light 
microscope. ......................................................................................... 105 
Figure 33. The investigation of the cellular colony morphologies and Live/Dead 
assay on day 18. .................................................................................. 106 
Figure 34. Osteogenesis from the control group on day 29. ............................. 107 
Figure 35. Mineralisation comparisons. ............................................................. 110 
Figure 36. Results of qPCR for osteogenic genes on day 15 (A), day 21 (B), and 
day 29 (C). ............................................................................................ 112 
Figure 37. Need for perfusion culture system. .................................................. 124 
Figure 38. Scheme of the bioreactor vessel regarding the variables (C, z, and t) 
used for calculation of the dimensions. .............................................. 128 
17 
 
Figure 39. Application of Fick’s second law considering assumptions made 
according to the designed culture conditions. ................................... 129 
Figure 40. A plot of the relationship between diffusion distance (y-axis) and time 
(x-axis) from the calculation, setting the oxygen concentration in 
medium at 80% of the surface concentration. ................................... 130 
Figure 41. Dimension calculation of cell culture vessel. .................................... 131 
Figure 42. Depiction of dual-supply of oxygen to the culturing vessel. ............. 132 
Figure 43. Schematic diagram of the oxygenator tubing and application of Fick’s 
second law with the same boundary conditions set for vessel design in 
Figure 39. ............................................................................................. 133 
Figure 44. O2-saturation depending on the residence time of medium in 
oxygenator tubing. .............................................................................. 134 
Figure 45. The effect of using a gas-permeable membrane for oxygenation 
within the culture vessel. .................................................................... 136 
Figure 46. Spatial arrangement of the perfusion holes in the centre rod of the 
culture vessel. ...................................................................................... 137 
Figure 47. Assembly of perfusion rotating wall vessel system (BSEL). .............. 139 
Figure 48. Experimental scheme of three-dimensional ESC scale-up study. ..... 143 
Figure 49. Morphology of cellular colonies cultured in BSEL. ............................ 146 
Figure 50. Morphology of cellular colonies culture in HARV. ............................ 147 
Figure 51. Morphology of cellular colonies culture in a static condition. ......... 148 
Figure 52. Live and Dead assay of cells from BSEL, HARV, and static culture.... 149 
Figure 53. Morphology and Live/Dead assay of the cells cultured in Synthecon 
system. ................................................................................................ 150 
Figure 54. Growth kinetics of ESCs three-dimensionally cultured in pluripotent 
phase. Statistical analyses were performed by one-way ANOVA (n=3). 
Asterisks indicate p < 0.05................................................................... 151 
Figure 55. Variations of oxygen concentration in various culture conditions. 
Statistical analyses were performed by a student t-test (n=3). Asterisks 
indicate p < 0.05. ................................................................................. 153 
18 
 
Figure 56. Comparison of nutrient consumption during expansion period. 
Statistical analyses were performed by a student t-test (n=3). Asterisks 
indicate p < 0.05. ................................................................................. 154 
Figure 57. Comparison of pH variations during expansion period. Statistical 
analyses were performed by a student t-test (n=3). Asterisks indicate p 
< 0.05. .................................................................................................. 155 
Figure 58. Comparison of metabolite-accumulation during expansion period. 
Statistical analyses were performed by a student t-test (n=3). Asterisks 
indicate p < 0.05. ................................................................................. 156 
Figure 59. Comparison of alkaline phosphatase activity in pluripotent phase. 
Statistical analyses were performed by one-way ANOVA (n=3). 
Asterisks indicate p < 0.05................................................................... 158 
Figure 60. Gene expression comparisons in pluripotent phase. Statistical 
analyses were performed by one-way ANOVA (n=3). Asterisks indicate 
p < 0.05. ............................................................................................... 160 
Figure 61. Immunocytochemistry of the BSEL group on day 13. ....................... 161 
Figure 62. Experimental scheme of bone-tissue formation from ESC. .............. 174 
Figure 63. Growth kinetics of ESCs three-dimensionally cultured during 
osteogenesis. Statistical analyses were performed by a student t-test 
(n=3). Asterisks indicate p < 0.05. ....................................................... 176 
Figure 64. Variations of oxygen tension during osteogenesis. Statistical analyses 
were performed by a student t-test (n=3). Asterisks indicate p < 0.05.
 ............................................................................................................. 178 
Figure 65. Comparison of nutrient consumption during osteogenesis. Statistical 
analyses were performed by a student t-test (n=3). Asterisks indicate p 
< 0.05. .................................................................................................. 179 
Figure 66. pH variations during osteogenesis. Statistical analyses were 
performed by a student t-test (n=3). Asterisks indicate p < 0.05. ...... 180 
Figure 67. Comparisons of metabolite accumulation during osteogenesis. 
Statistical analyses were performed by a student t-test (n=3). Asterisks 
indicate p < 0.05. ................................................................................. 181 
Figure 68. Mineralisation evaluation. Statistical analyses were performed by 
one-way ANOVA (n=3). Asterisks indicate p < 0.05 (single) and p < 
0.001 (double) respectively. ................................................................ 182 
19 
 
Figure 69.Comparisons of gene expression on day 29 by qPCR and RT-PCR. 
Statistical analyses were performed by a student t-test (n=3). Double 
asterisks indicate p < 0.001. ................................................................ 184 
Figure 70. Hydroxyapatite distribution and relative quantification using 
Attenuated total reflection Fourier transform infrared (ATR FTIR) 
analysis. Statistical analyses were performed by one-way ANOVA (n=5). 
Asterisks indicate p < 0.05 (single) and p < 0.001 (double) respectively.
 ............................................................................................................. 186 
Figure 71. Mechanical strength analysis of bone-tissue like structure on day 29.
 ............................................................................................................. 188 
Figure 72. Immunocytochemistry of the BSEL group on day 29. ....................... 190 
Figure 73. Surgical procedures. .......................................................................... 200 
Figure 74. Biopsies of cranial vault at 1, 2, and 8 weeks after operation. ......... 201 
Figure 75. Hematoxylin and eosin staining of the group of osteogenic constructs 
at 1 week (A, B), 2 weeks (C, D), and 8 weeks (E, F). (NB: new bone, FI: 
fibrous interzone). ............................................................................... 203 
Figure 76. Hematoxylin and eosin staining of the group of negative control at 1 
week (A, B), 2 weeks (C, D), and 8 weeks (E, F). (NB: new bone, FI: 
fibrous interzone). ............................................................................... 204 
Figure 77. Immunohistochemistry for type I collagen at 1 week (A, B), 2 weeks (C, 
D), and 8 weeks (E, F). ......................................................................... 206 
Figure 78. Immunohistochemistry for insulin growth factor-1 at 8 weeks. ...... 207 
Figure 79. Immunohistochemistry for osteocalcin at 8 weeks. ......................... 208 
Figure 80. Images of the mineralised portions within the defects periodically 
obtained by micro-CT scanning. .......................................................... 210 
Figure 81. Bone regeneration in 8 weeks (three-dimensionally reconstructed 
from micro-CT). ................................................................................... 211 
 
 
 
 
20 
 
List of Tables 
Table 1. Current studies about ESC-culture using various bioreactors ................ 54 
Table 2. Culturing plans for cardiomyogenesis .................................................... 75 
Table 3. Culturing plans for osteogenesis ............................................................ 75 
Table 4. Specification of gas permeable membrane ............................................ 76 
Table 5. Information of materials ......................................................................... 77 
Table 6. Antibody list ............................................................................................ 81 
Table 7. Primers for osteogenesis ........................................................................ 83 
Table 8. Primers for pluripotency and cardiomyogenesis ................................... 83 
Table 9. Cardiomyogenic differentiation progress of the control group ........... 100 
Table 10. Perfusion culture system comparison between BSEL and Synthecon 
bioreactors .......................................................................................... 144 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1. Literature Review 
 
 
 
 
 
 
 
 
 
 
 
22 
 
1.1. Tissue Engineering 
 
1.1.1. An overview 
The loss or failure of an organ or tissue within the human body is one of 
the most frequent, devastating, and costly problems in health care. When 
disease, injury or infection causes damage to an organ or tissue that is beyond 
the reparative capacity for its endogenous mechanisms, an alternative source is 
needed for regeneration. Until the twentieth century, medical treatment was 
rarely capable of reversing a pathologic process that leads to loss of 
tissue/organ function, and surgical treatment was primarily extirpative, 
providing limited, if any, functional restoration of damaged tissues/organs. At 
the beginning of the twenty-first century, however, various advanced medical 
techniques, such as gene therapy, cellular therapy, tissue engineering, and 
organ transplantation which are currently included in the field of regenerative 
medicine (Figure 1), were building a platform for more complex tissue 
restoration (Vogel and Baneyx 2003). Surgeons now routinely reconstruct bone 
and soft tissue defects. Restoration of organ function is now possible through 
transplantation of heart, lung, liver, kidney, pancreas, and small bowel. Yet, 
allogeneic transplantation remains limited by the natural physiologic response 
to foreign tissues and by inadequate donor supply. With genetic or cellular 
manipulation, however, tissues and organs may be engineered to more closely 
represent an autologous status. Figure 2 depicts the historical progress and 
future direction of medical development, which is identical with the aim of 
tissue engineering (Jenkins et al. 2003). 
The clinical goal of tissue engineering, which has been developed so far, 
is the implantation of in vitro engineered tissues in the form of bioactive, 
bioresorbable, and biocompatible three-dimensional constructs that also 
23 
 
provide a biomechanical architecture enabling the seeded cells to produce an 
adequate extracellular matrix (ECM) for further regeneration (Stock and Vacanti 
2001). In order to fabricate a physiologic and functioning tissue/organ, the 
efforts of many researchers, such as cell biologists, engineers, material scientists, 
mathematicians, geneticists, and clinicians, should be combined (Fuchs et al. 
2001). It is strongly believed that tissue-engineered products would provide a 
life-long therapy and would greatly reduce the hospitalisation, and health care 
costs associated with drug therapy whilst simultaneously enhancing the patients’ 
quality of life. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Regenerative medicine and its sub-categories  
(adapted from Jekins et al. 2003). 
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Figure 2. The historical progress and future direction of medical development 
(adapted from Jekins et al. 2003). 
 
1.1.2. Skeletal tissue engineering 
Pathologies related to skeletal tissues affect people of all ages and sexes 
ranging from osteogenesis imperfecta by gene mutation to osteoporosis, sports 
injuries, work-related injuries, adult trauma, cancer, microbial infection, 
developmental abnormalities and malnutrition. Nearly all patients suffering 
pains from large defects of skeletal tissues require surgery such as a graft 
transplantation and pinning to bone tissues (Standaert and Herring 2000). The 
American Academy of Orthopaedic Surgeons reported in 1995 that three million 
musculoskeletal orthopaedic procedures were performed in US hospitals 
including fractures (15%), joint problems (22%) and spinal disorders (12%) etc., 
costing approximately $215 billion per year with the cost increasing over time. 
The United Nations declared the years 2000-2010 the “Bone and Joint Decade”, 
to draw attention to the increasing impact that orthopaedic conditions will have 
on the world’s health as life expectancy increases, and to the potential that 
current and future research have for eliminating these problems. 
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Many of the traditional strategies to repair skeletal damage include bone-
replacement using bone cements and metals and also various prosthetic 
implant devices as well as autologous or allogenic bone-grafting, facilitating the 
healing of fractures with various degrees of success (Yaszemski et al. 1996). The 
majority of bone lesions, such as fractures, can be restored using standard 
conservative or surgical therapies as stated above. However, the approaches of 
current orthopaedic surgeries are not always satisfactory because a variety of 
failures from synthetic devices have been gradually revealed in long term 
implantation mainly due to the problems with infection, device breakage or 
loosening, general wear and tear, and wear debris-induced bone resorption 
(osteolysis). Additionally alternative replacements for the failed devices require 
even more painful surgical procedures (Boskey 2001; Kneser et al. 2002). In 
order to overcome the problems, numerous investigations about biomaterials 
have led to the development of a number of bone-void filling and graft-
extending materials combined with osteo-conductive biosignals such as bone 
morphogenetic proteins (BMPs) and members of the transforming growth 
factor (TGF) β superfamily (Reddi 1998). Nevertheless, the approaches without 
functional osteogenic cells still suffer shortcomings to become mature, 
functional tissues, in that there is no further contribution of cellular metabolic 
mechanisms at a defected site including the secretion of soluble signals and 
bone-matrix molecules. Moreover, the current therapies of autograft, allograft, 
and xenograft transplantations still have inherent limitations, such as limited 
available graft quantity, donor site morbidity, host immune rejection, and the 
need for the proper vascularisation with being harmonised in the native tissues 
(Luyten et al. 2001). Therefore, the production of high quality tissue based on 
functional, healthy bone cells in sufficient numbers that avoids immunogenic 
problems would be an ideal alternative and also in agreement with the ultimate 
goal of bone tissue engineering. This field of research is gradually gaining in 
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importance due to the increased incidence of osteo-degenerative diseases in 
the rapidly aging populations of developed countries, albeit the clinical 
application is still in its infancy. 
Figure 3 briefly shows the scheme of the conventional in vitro bone 
formation in bone tissue engineering. Although the term of ‘tissue engineering’ 
is not restricted to living-cell based-constructs, cells are still an integral part of 
most of the tissue-engineering strategies in terms of the stable maintenance of 
their own functions and homeostasis after the transplantation of the construct.  
 
 
 
 
 
 
 
Figure 3. A brief scheme of bone tissue formation in vitro. 
 
The key factor lies in providing the defect site with osteogenic cells 
seeded in a suitable three dimensional delivery vehicle to ensure proper 
differentiation and optimal biosynthetic activity of bone matrix and growth 
factors. As depicted in Figure 3, it is of importance to consider several crucial 
factors in the formation of transplantable skeletal tissues in vitro: 
1) What kind of cell source is the most effective for the practical 
application to orthopaedic surgery? Cell sources need to be free from various 
pathogens and contaminations, and from an immune response in the patient. 
Crucial chemical factors for 
osteogenic maturation 
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They also should be in sufficient quantity to be formed as a tissue. Several cell 
sources have been used for bone tissue engineering such as osteoblasts, 
periosteal cells, stromal cells, mesenchymal stem cell (MSCs), and also 
embryonic stem cells (ESCs) (Bruder et al. 1994; Halstead et al. 1992; Kuznetsov 
et al. 1997). Each of those cell sources holds peculiar benefits and disadvantages 
which are not found in the other ones. 
2) Which type of matrix should be introduced to offer a three 
dimensional environment to the cells, which also could give rise to bone tissues? 
Cells are inherently sensitive to their surroundings so that the ECM plays a vital 
role in influencing cell and tissue function as well as mechanically supporting the 
three dimensional architecture (McDonald 1989). A number of specific 
requirements on the scaffold materials should be considered, such as bio-
compatibility, adequate mechanical property, and mass transport (Elisseeff et al. 
2005). 
3) How can we stimulate the cells to differentiate into osteogenic cells 
and scale up the cell number to form functioning bone tissues? Growth factors 
and chemical reagents to induce bone formation and maintain the integrity of 
bone have been well developed as the materials easily obtained commercially at 
the moment such as bone morphogenetic proteins, basic fibroblast growth 
factor, ascorbic acid, β-glycerophosphate, dexamethasone, etc. (Bourne et al. 
2004; Kim et al. 1997; Reddi 1992). In terms of tissue-engineered constructs, 
however, it could be a more applicable and attractive proposition that 
spontaneous differentiation and increased expansion of cells are driven by not 
using growth factors and cytokines but applying the specific physical stimuli, 
because there is the possibility to elicit a specific unknown cellular response in 
the tissue implanted into a host due to the external introduction of biochemical 
factors (Curran et al. 2006). 
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1.2. Cell Sources for Skeletal Tissue Generation 
 
Although the cells from a biopsy of a patient used to function properly in 
vivo, the limited proliferative capacity for the differentiated mature cells due to 
the accelerated telomere shortening is always problematic in providing 
sufficient cell numbers for transplantation therapy, which is closely dependent 
on the patient age (Muschler et al. 2004). For example, there have been some 
attempts to use primarily cultured osteogenic cells from an autologous biopsy 
of a patient in the therapeutic practice. However, in vitro cell expansion of the 
mature cells from the biopsy led inevitably to senescence and loss of phenotypic 
traits (Luyten et al. 2001). Progenitor cells could be considered as one of the 
alternatives for the mature donor cells due to their proliferative capacity. 
However, their proliferation carries on together with differentiation in an 
uncontrollable and arbitrary manner. This represents the expanded derivates 
from progenitor cells are highly unlikely to be genetically identical albeit a 
quantity of cells would be somehow scaled up. Additionally, progenitor cells are 
highly dependent on the physical condition of the biopsy obtained from patients. 
Currently, it is widely believed that the introduction of stem cells into 
tissue engineering could alleviate the problems that the previous cell sources 
have faced (Heng et al. 2004c). Stem cells can be distinguished from progenitor 
cells by a capacity for self-renewal and multi-lineage differentiation, whereas 
progenitor cells are capable only of multi-lineage differentiation without self-
renewal (Weissman 2000). This self-renewal ability can render stem cells 
particularly useful in the organisation of the transplantable tissues in vitro, since 
an unlimited and constant supply of donor material in theory could be provided. 
Increasing evidences support the hypothesis that stem cells could contribute to 
post-natal growth and participate in tissue homeostasis by replacing the sites 
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lost to physiological turnover, injury and senescence. Moreover, their 
differentiated derivatives possess much higher proliferative and regenerative 
potential compared with the mature somatic cells. This in turn is more likely to 
guarantee adequate regeneration and cell turnover at the transplantation site 
for an extended period of time, possibly a lifetime (Heng et al. 2004a). Adult 
stem cells derived from various tissue types, such as the endothelial, epithelioid, 
adipogenic, myogenic, and hematopoietic lineages, have been reported to be 
capable of trans-differentiating into the many skeletal lineages (Dragoo et al. 
2003; Labat et al. 1997; Mizuno and Glowacki 1996; Nathanson 1986; Schulick 
et al. 1998). However, at this point in time, the plasticity and trans-
differentiation of adult stem cells, except for MSCs, are a highly controversial 
issue, because of the evidence of cell fusion and heterokaryon formation 
(Goodell 2003; Ying et al. 2002). MSCs have been used with some success for 
autologous repairs as well as allogenic transplants in the regeneration of various 
skeletal tissues (Horwitz et al. 1999). The other possible source of stem cells is 
ESCs which are capable of giving rise to all of the cell types in a human body. 
The potential of ESCs in tissue engineering has been recently highlighted owing 
to their outstanding inherent capacity for prolonged self-renewal, which would 
solve the cell expansion problems (Bishop et al. 2002). 
 
1.2.1. Mesenchymal stem cells (MSCs) 
Bone marrow derived cells have been shown 1) to give rise to endothelial 
progenitor cells, which are used to induce neovascularisation of ischemic tissues, 
2) to regenerate myocardium, 3) to give rise to bone, cartilage and muscle cells, 
4) to give rise to neurons after migration into the brain (Brazelton et al. 2000; 
Kocher et al. 2001; Orlic et al. 2001; Pittenger et al. 1999) (Figure 4). MSCs are a 
population of non-hematopoietic cells that can be isolated from the bone 
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marrow and that when re-introduced in vivo are capable of differentiating into 
various skeletal lineages such as osteoblasts, chondrocytes, myocytes, and 
adipocytes. MSCs have a number of advantages over the fully differentiated 
cells including their ease in expansion, maintenance of their phenotype and lack 
of senescence. It was believed that potentially a large number of cells would be 
generated from a very small number of precursors, thereby being considered as 
an attractive clinical approach for the older population. With respect to a 
practical work, however, the putative MSCs from the bone marrow are in fact 
found in low numbers (approximately 1 in 100,000 cells) in the adult patients 
(D'Ippolito et al. 1999), and a highly heterogenous population with only a very 
limited proportion of cells being capable of differentiation into the osteogenic 
lineage. Moreover, in a clinical setting, their potential to proliferate and capacity 
to differentiate down specific cell lineages diminishes with patient age 
(Mcculloch et al. 1991; Quarto et al. 1995). If the capacity of the continuous self-
renewal is taken strictly into consideration as the defining criterion for stem 
cells, only an extremely low proportion of the bone marrow stromal cells can be 
considered as true stem cells. This would pose a major challenge in the 
development of isolation and purification protocols. Furthermore, it has also 
been reported that in vitro expansion of MSCs is restricted to a small number of 
passage due to rapid aging and loss of multipotency (Baxter et al. 2004; Bonab 
et al. 2006). In terms of the clinical orthopaedic work, these reasons would limit 
their usefulness in autologous cell-transplantation therapy for the treatment of 
the age-related osteo-degenerative diseases such as osteoporosis and 
osteoarthritis. Although conventional opinions suggest that directing MSCs into 
the skeletal lineages may be effective owing to their close stages in the 
developmental process, the major limitations in the use of MSCs leads us to 
think of ESCs as a cell source for tissue engineering. 
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Figure 4. Various derivates from bone marrow stem cells. 
 
 
Adapted from 
http://www.patentlens.net/daisy/Telomerase/2951/version/default/part
/ImageData/data/stemcell_figure3_lg.jpg  (cited on Aug, 2009)  
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1.2.2. Embryonic stem cells (ESCs) 
Cells isolated from the inner cell mass in the very early stage of 
developing embryos are called ESCs (Thomson et al. 1998) (Figure 5). ESCs are 
well known as versatile cells that have two very unique sets of properties: 
unlimited symmetrical self-renewal ability and differentiation capacity into all 
the cell types forming the origin of three germ layers (endoderm, mesoderm 
and ectoderm) as proven by injecting them into a blastocyst and showing the 
interesting production of chimera offspring in which all the tissues are arbitrarily 
formed (Heng et al. 2004d). The initial discovery of murine ESCs (mESCs) was 
over 25 years ago and the derivation of human ESCs (hESCs) was also promoted 
about 7 years later (Hirai et al. 2002; Keller 2005; Prelle et al. 2002). 
 
 
 
Figure 5. Extraction of embryonic stem cells from the blastocyst. 
 
 
Adapted from 
http://www.stemcellresearchfoundation.o
rg/WhatsNew/Pluripotent.htm (cited on 
Aug, 2007) 
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ESCs now represent a major advance not only in biology but also in 
regenerative medicine with their immense potential (Przyborski 2005). For 
example, ESCs can be used for the exploration of the whole genome that 
regulates the fate of an embryo (Fluckiger et al. 2006). Genomic sequence in 
ESCs can be manipulated to identify specific genes that regulate the expression 
of functional proteins during the developmental process. Genetically modified 
ESCs can be also used for high-throughput drug screening as well as for 
transmission and expression of specific genes in target organs, so that ESCs are 
also a powerful tool for drug discovery and gene therapy (Mitjavila-Garcia et al. 
2005; Yates and Daley 2006). Furthermore, their potential biomedical 
applications also includes almost all the sorts of clinical treatments such as 
diabetes, Parkinson’s disease, liver malfunction, heart failure, spinal cord injury, 
and large defects of body etc (Lund et al. 2006). Figure 6 shows the brief scheme 
representing possible clinical use of ESCs in vitro. 
 
Figure 6. In vitro application of embryonic stem cells. 
Inner cell mass extraction
Adapted from 
http://www.geron.com/showpage.asp
?code=prodst (cited on Nov. 2006) 
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ESCs lack the G1 check point in the cell cycle, so that they spend most of 
their time in the S phase of the cell cycle during which they synthesize DNA. 
Unlike differentiated somatic cells, ESCs do not require any external stimulus to 
initiate DNA replication. ESCs can be cultured for extended periods without loss 
of their pluripotent capacity (Evans and Kaufman 1981; Martin 1981). In vitro 
assays for detecting undifferentiated ESCs have been developed based on the 
cell surface expression of particular antigens, in vitro developmental capacity, or 
expression of genes associated with the properties of undifferentiated ESCs, 
such as stage-specific embryonic antigen (SSEA) series, tumour rejection antigen 
(TRA) series, cluster of differentiation 9 (CD9), alkaline phosphatase activity, 
octamer binding factor 3/4 (Oct3/4) (Keller 1995b; Scholer et al. 1991). Oct3/4 is 
the most established marker of undifferentiated ESCs, which is normally 
expressed exclusively in blastomeres, pluripotent early embryo cells, and germ-
line lineage cells (Yeom et al. 1996). Expression of Oct3/4 has been shown to be 
crucial to the establishment of pluripotential identity in the cells from the inner 
cell mass of the blastocysts and also in ESCs, activating or inhibiting a host of 
target genes to maintain ESCs in a proliferative, non-differentiating status 
(Nichols et al. 1998). Oct3/4 is down-regulated over the differentiation into both 
primitive ectodermal and trophectodermal cells and during gastrulation in vivo 
(Palmieri et al. 1994). A recent study has suggested the extent to which Oct3/4 
expression predicts the developmental potential of ESCs needs to be further 
defined. According to the study, the precise level of Oct3/4 expression can 
result in three separate ESC fates. A critical threshold of the expression of 
Oct3/4 is required to maintain ESC self-renewal. An increase in Oct3/4 
expression lower than two-fold causes differentiation into embryonic ectoderm 
and mesoderm, whereas repression of Oct3/4 expression induces loss of 
pluripotency and dedifferentiation into trophectoderm (Niwa et al. 2000). 
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ESCs cultured in vitro can differentiate into the three embryonic germ 
layers (ectoderm, mesoderm, and endoderm) followed by a broad spectrum of 
specific cell types through embryoid body (EB) formation periods (Hegert et al. 
2002; Takahashi et al. 2003a). The formation of EBs is one of the most robust 
methods to induce ESCs to spontaneously differentiate and form tissue-like 
spheroids (Dang et al. 2004a). EB differentiation has been shown to recapitulate 
the aspects of the early embryogenesis following the sequence of the lineage 
commitment events (Keller 1995b). The developmental rules which have 
already been established in vivo are reflected on the in vitro ESC-culture model 
through the formation of the complex three-dimensional arrangement where 
cell-cell and cell-matrix interactions are thought to play a crucial role in the 
development of the three embryonic germ layers and their derivatives 
(Itskovitz-Eldor et al. 2000; Keller 1995a). Hanging drop and static suspension 
cultures, which had been originally used for embryonic carcinoma cells, have 
been adopted for common EB culture practices among various in vitro 
differentiation methods. The hanging drop method for EB formation produces 
homogeneous cell aggregates by dispensing a defined number of ESCs in 
physically separated droplets of media suspended from the lid of a petri-dish 
(Hopfl et al. 2004). EBs are formed within each drop via gravity-induced cell 
aggregation. Notwithstanding, this technique is highly time-consuming and not 
easily amenable to scaling up due to many manual handling procedures, and 
also showed the additional limitation in manipulating the small volume of 
medium without disturbing the EBs. In contrast to the hanging drop method, a 
static suspension culture has been performed by simply pouring a suspension of 
ESCs to the low attachment grade plates such as a bacterial-grade petri-dish. 
This allows the ESCs to spontaneously aggregate themselves via cell–cell 
adhesions (Klug et al. 1996). Static suspension cultures produce a large number 
of EBs readily, but the size and shape of the resulting EBs are highly variable due 
36 
 
to the tendency of producing large and irregularly shaped masses of cells (Bratt-
Leal et al. 2009). It has been investigated that the length of EB-culturing periods 
links to the desired differentiation lineage because of the correlation with the in 
situ process of the post-implantation development (Keller 1995a). For example, 
it has been reported that mesodermal and ectodermal precursors appear to be 
formed in the early stage of EB maturation, whereas some endodermal cell 
types may be beneficially affected in more extended culturing time when most 
of the EBs have cavitated and become cystic (Abe et al. 1996).  
ESC–based techniques, however, are severely limited by our inability to 
control their differentiation although relatively robust techniques have been 
suggested to maintain the developmental potential of ESCs in vitro (Reubinoff et 
al. 2000; Thompson et al. 1989). The conventional methods of EB formation are 
still physically ineffective as fragmented, laborious procedures, and problematic 
in the heterogeneity of the cell population owing to the arbitrary differentiation 
to various types of cells. Applying ESCs to clinical practice requires the 
production of a homogeneous population in the targeted cell differentiation, to 
prove in vitro and in vivo efficacy (animal model), to have a safety test 
(teratoma formation), and to negate the innate rejection mechanisms of the 
human body (immune rejection) (Zandstra and Nagy 2001). Further study is 
necessary to examine the tumorigenic potential of the long-term transplants. In 
addition, a very sensitive ethical issue for research and clinical applications of 
ESCs have been emerged, because ESCs are derived from the destruction of an 
embryo. Currently, induced pluripotent stem (iPS) cells derived from skin cells 
with specific gene modifications are of particular interest as a desirable 
alternative in that they possesses the major benefits of ESCs without the ethical 
issues as well as the traditional immune rejection problem, although some 
complications remain from the side effects of using the viral vectors in the gene 
transfection process (Yamanaka 2007). In parallel with developing a desirable 
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source of pluripotent stem cells, many researchers have also attempted to 
develop various methodologies to most effectively derive ESCs to a specific 
target lineage so far. It is simply presented in Figure 7 that in order to direct 
stem cell differentiation in vitro, cytokines, growth factors and chemical 
reagents can be introduced to the tailored three-dimensional culture system 
which also can be combined with the benefits of autocrine or paracrine bio-
signaling from neighbouring cells (Heng et al. 2004a). 
 
 
Figure 7. Schematic diagram representing the major components of a 
defined culture milieu for directing the differentiation of stem 
cells (adapted from Heng et al. 2004a). 
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1.3. Differentiation Control for Skeletal Development 
from ESCs 
 
1.3.1. Embryonic germ layer development in vivo 
Embryogenesis normally proceeds through the following stages: 1) 
cleavage (vigorous cellular division of the fertilised egg), 2) morula (formation of 
a spherical mass of the cells), 3) blastocyst (cavity development in the spherical 
mass of the cells), 4) gastrulation (formation of three germ layers, endo-, ecto-, 
and mesoderm, that leads to differentiation towards all the cell types of the 
body) (Tam et al. 1993; Tam and Loebel 2007). 
In the stage of blastocyst, the inner cell mass is composed of pluripotent 
cells surrounded by the trophectoderm and the primitive endoderm. 
Subsequently, having severe biochemical signaling exchanges between them, 
the inner cell mass differentiates to the epiblast (also called primitive ectoderm 
in the late stage of epiblast (Rathjen et al. 1998)), and the primitive endoderm is 
derived to two different types of endoderm, parietal endoderm and visceral 
endoderm, and the visceral endoderm of them, localised in the anterior region 
during the stage of gastrulation, plays an essential role in regulating the 
developmental procedures. Prior to gastrulation, the primitive ectoderm in the 
late stage of epiblast is lined over the distal visceral endoderm layer and 
vigorously exchanges various biochemical signals (Tam and Loebel 2007) (Figure 
8). In the mean time, the stage moves into the next phase, gastrulation, and the 
posterior cells of the epiblast migrates into the space between the epiblast and 
the visceral endoderm to be ready for the formation of the primitive streak 
along the posterior axis of the embryo (Lawson and Schoenwolf 2003). 
Mesendoderm, the precursor of the mesoderm and endoderm, is derived while 
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the primitive streak is positioned, and ectoderm is also ready to be generated 
from the epiblast cells which have not migrated through the primitive streak 
(Tam and Loebel 2007). Because the skeletal tissues such as bone, cartilage, and 
various muscles are developmentally originated from the mesodermal lineage, 
people in the field of the skeletal tissue engineering are immensely interested in 
the study of the mesoderm development process in vivo. 
 
 
Figure 8. The in vivo process of embryogenesis in brief 
(adapted from Tam and Loebel 2007). 
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1.3.2. In vitro skeletal lineage differentiation from ESCs 
As the in vitro sequence of lineage commitment events in ESC-
differentiation closely mimics the in vivo development process (Keller 1995b), 
EB-based techniques have been shown to successfully form the embryonic germ 
layers in vitro. However, they also present certain limitations owing to their 
inability to precisely control the differentiation because the simultaneous 
formation of endo-, ecto-, and mesoderm would generate the developmental 
competition among them, resulting in the heterogeneity of the cell population 
in the EBs (Hwang et al. 2006). Various investigations about the activation or 
direct transfection of the variety of transcription factors ubiquitously expressed 
in the inner cell mass of the blastocyst and application of the selections of the 
growth factors and their appropriate antagonists relevant with the 
developmental process (Loebel et al. 2003) have been performed in order to 
differentiate ESCs to the mesodermal lineage. It has been shown, in particular, 
that the specific direction of ESC differentiation to mesodermal lineage can be 
controlled by the induction of transforming growth factor beta (TGF-β) proteins, 
accounting for the use of bone morphogenetic proteins (BMPs) and activins, 
and the regional coordination of canonical Wnt and Nodal pathways (Watabe 
2009) (depicted in Figure 9). Recent studies have also shown that the 
combination of BMP4 and activin A is able to promote the generation of a 
primitive-streak-like population from ESCs leading to the formation of 
mesodermal cells and also the further cardiomyogenic differentiation (Liu 1999). 
Moreover, it has also been reported that a lack of the gene coordination such as 
BMP5 and 7 delays the early heart morphogenesis (Zhang 1996) and the 
inactivation of BMP4 in mouse model has shown little mesodermal 
differentiation (Chen et al. 2004). The addition of BMPs during ESC-
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differentiation induced the development of the mesodermal population highly 
expressing Brachyury-T followed by Flk-1 expression (Park et al. 2004). The 
combination of BMPs and activins induces the dominant generation of posterior 
primitive streak progenitors. Activation of Nodal pathways by the addition of 
activins induced the expression of Foxa2 and Goosecoid, and the subsequent 
formation of the definitive endoderm (anterior streak) or mesoderm (posterior 
streak) depending on the concentrations of activins. As Wnt/β-catenin inhibition 
in the early phase of ESCs differentiation is known to hinder the expression of 
the osteo-chondral gene Runx2 and the cardiac marker genes Csx/Nkx-2.5, the 
induction of mesodermal derivatives from ESCs is also relevant with Wnt 
signaling system (Naito et al. 2006) (Figure 9).  
 
Figure 9. Various signals relevant with in vitro derivation of mesodermal 
cells from ESCs. 
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The co-culturing system has been attempted to allow ESCs to have a 
direct physical contact and to share paracrine factors with different cell types 
mimicking the natural developmental environments (Trounson 2006). For 
example, it is widely known that ESCs can self-renew in the co-culture 
conditions with various cell types such as mitotically inactivated murine 
fibroblasts, human fetal fibroblast (Richards et al. 2002) and bone marrow cells 
(Cheng et al. 2003). On the other hand, as stated above, various signals secreted 
by the visceral endoderm promote the activation of mesoderm development 
albeit the exact pathways to be proven are still obscure. Visceral endoderm-like 
cell line (END2) has been reported to produce activins and BMPs as it occurs in 
vivo in the adjacent mesoderm (Mummery et al. 2002b). ESCs have been co-
cultured with END2, and the results showed that more efficient formation of 
cardiomyogenic precursor cells (Mummery et al. 2002a; Mummery et al. 2003). 
It has also been demonstrated that co-culturing mESCs with foetal osteoblasts 
provided potent stimuli for osteogenic differentiation and enhanced bone 
nodule formation (Buttery et al. 2001). Moreover, the ability to differentiate 
hESCs into osteoblasts has been shown through the co-culturing with primary 
bone derived cells without any addition of the exogenous factors (Ahn et al. 
2006). However, a potential problem from co-culturing is that the intimate 
physical contact between cells may cause fusion of different cell types, resulting 
in the formation of heterokaryons as well as a strong risk of transmission of 
pathogens (Terada et al. 2002). 
In 1999, J. Rathjen et al. (Rathjen et al. 1999) reported that conditioned 
medium derived from human hepatocarcinoma cell line, HepG2, caused the 
transition of ESCs to a novel cell population in vitro considered as the second 
pluripotent stage holding similar behaviour to epiblasts in vivo (Rathjen and 
Rathjen 2001). Consistently, the bioactive components of HepG2-conditioned 
medium (HepG2-CM) have been verified as an equivalent to the signals relevant 
with the pre-gastrulation embryo or expressed by visceral endoderm-like cell 
 lines because of the similarities in terms of biochemical reactions between liv
cell lines and visceral endoderm
After ESCs were treated with
the absence of visceral endoderm in that they initially have been 
exogenous visceral endoderm
multipotent mesodermal progenitors at the expense of ectoderm during 
embryogenesis (Figure 
endoderm, which is believed to stimulate 
al. 2005; Grepin et al. 1997; Stary et al. 2005; Stary et al. 2006)
mesoderm formation from the use of HepG2
applied to the effective skeletal lineage
Figure 10. Selective mesoderm derivation from ESCs using HepG2
CM (adapted from Lake et al. 2000)
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(Ding and Schultz 2004) and Cardiogenol C (Wu et al. 2004). Similarly, the most 
widely used osteogenic supplements include BMP2, BMP4, interleukin-6 (IL-6), 
leptin and sortilin (Maeda et al. 2002; Rawadi et al. 2003; Sykaras and 
Opperman 2003; Taguchi et al. 1998; Thomas et al. 1999) are often combined 
with various chemicals such as dexamethasone, ascorbic acid, β-
glycerophophate, retinoic acid and 1,25-hydroxy vitamin D3 (Sottile et al. 2003; 
van Leeuwen et al. 2001; zur Nieden et al. 2003) (Figure 11). In particular, 
dexamethasone up-regulates several genes relevant with osteoblast 
differentiation such as Runx2, one of the transcription factors in osteoblast, and 
promotes osteogenic maturation while down-regulating genes associated with 
other lineages (Bielby et al. 2004). The combination of dexamethasone, ascorbic 
acid and β-glycerophosphate has been very widely used to activate ECM 
synthesis followed by mineralised nodule deposition resulting in the 
enhancement of the osteogenic differentiation (Heng et al. 2004b; Karp et al. 
2006; Sottile et al. 2003). BMP2 and BMP4 have also been reported to stimulate 
ESC differentiation towards the chondrogenic and osteogenic lineages up-
regulating Runx2 (Heng et al. 2004b; Kawaguchi et al. 2005; Kramer et al. 2000). 
 
Figure 11. Various supplements for heart and bone formation from ESCs. 
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1.4. Three-dimensional Bioprocess for in vitro Skeletal 
Tissue Generation 
 
Transferring ESC derivatives to a clinical application is technically 
challenging. One of the major reasons is the conventional two-dimensional 
culture system for ESCs which is not suitable for a large-scale production. Even 
though ESCs theoretically can be expanded indefinitely, traditional ESC-culture 
methods still suffer from their labor-intensive and time-consuming nature as 
well as the restricted available surface area resulting in a limited amount of cells 
to be obtained in vitro. In addition, three-dimensional interactions between 
ESCs and either ECMs or other neighboring cells as they normally exist in vivo 
would be also disrupted by a two-dimensional culture environment (Polak and 
Mantalaris 2008). Therefore, natural three-dimensional settings as in vivo are 
now required for the proper maintenance and expansion of viable ESCs, and 
also for the effective differentiation with regard to tissue engineering.  
On the other hand, developing an efficient way of nutrient supply for the 
massive three-dimensional cell culture is also required for the in vitro 
generation of the living tissues. It is impractical to offer three-dimensional 
cell/matrix hybrids a regular feeding condition, because it is closely related to 
the cell viability, metabolic activity, and other physiological reactions (Holy et al. 
2000; Ishaug-Riley et al. 1998). Furthermore, the growth of cells is always 
affected by the complex inter-linkage of nutrients, metabolites, and other 
environmental factors within the immediate cellular environment (King and 
Miller 2007); lactate and ammonia affect pH (Cormier et al. 2006b); oxygen 
tension influences cellular metabolism such as the consumption and production 
rate of glucose and lactate (Powers et al. 2008a). The development of a novel 
three-dimensional bioprocess for culturing ESCs appears to be a promising 
approach to tackle many of the limitations from the traditional culturing 
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systems. Bioreactors in tissue engineering are laboratory culture devices that 
provide cells/tissues with a mechanically active environment which is 
controllable and reproducible. A bioreactor can circumvent the potential 
problems such as spatial gradients of physicochemical parameters from lack of 
mixing and difficulties in the control of medium supplementation which is 
important in the effective differentiation of ESCs to the targeted lineage cells 
and also in the scalable production (Boheler et al. 2002; Czyz and Wobus 2001). 
In terms of the cultivation of the engineered tissues, bioreactors are known to 
improve the overall structural integration including construct size, cellularity, 
and molecular composition (Bursac et al. 2003; Pei et al. 2002b; 
VunjakNovakovic et al. 1996) with the enhanced mass transport of various 
nutrients (Obradovic et al. 1999; Radisic et al. 2003; Radisic et al. 2004) and 
growth factors (Gooch et al. 2001; Pei et al. 2002a).  
 
1.4.1. Three dimensional scaffolds in tissue engineering 
The standard approach in tissue engineering is to seed cells on a three-
dimensional scaffold usually composed of either synthetic polymers or 
naturally-derived biomaterials. The scaffold is designed to create a three-
dimensional environment that promotes tissue development from the cells 
seeded on or within the scaffold. As being familiar with tissue-engineered 
constructs, a number of specific requirements have been posed on the materials 
of scaffolds including the biocompatibility, temporal mechanical support, 
controlled degradation, and interstitial fluid flow for the adequate mass 
transport etc. (Elisseeff et al. 2005). For example, in terms of bone tissue 
engineering, initial attempts at creating alternatives to the conventional bone 
grafts (allografts and xenografts) were to develop synthetic bone replacements. 
Numerous investigations led to the development of a number of bone-void 
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filling and graft extending materials with current clinical availability. Many 
investigations by multiple research groups resulted in a long list of biomaterials 
with osteo-conductive properties, including titanium, natural/coralline 
hydroxyapatite, porous hydroxyapatite and calcium phosphates, 
photopolymerisable polyanhydrides, bioglass, and polyester copolymers, 
poly(lactic-co-glycolic acid; PLGA), etc. Further investigation revealed that 
modifications of the scaffold architecture and the material properties could 
affect bone growth (Eggli et al. 1988; Hollinger and Battistone 1986; Oonishi et 
al. 1997; Ripamonti 1991; Vehof et al. 2002). Additionally, a number of 
biomaterials have been modified with the adhesive peptide domains prevalent 
in the proteins of ECM. It has been found that a variety of cellular functions are 
affected by various surface properties of the polymeric scaffolds such as a 
complex texture, hydrophobicity, various charges and chemical compositions 
(Hollinger and Battistone 1986; Puleo and Bizios 1992; Rezania and Healy 2000). 
This led to a research thrust aiming at creating a novel scaffold material with 
bio-mimetic properties that would maintain high cellular viability as well as 
mimic the role of the ECMs in many cell functions, including adhesion, migration, 
proliferation, and also differentiation. Further engineering of biomaterial 
surface and bulk properties will allow bio-specific interactions between 
appropriate cell types and scaffold materials. 
 
1.4.2. Alginate bead encapsulation 
In many tissue engineering approaches, cells are seeded within three-
dimensional porous structures whilst expected to remodel into tissue-like 
structures (Mooney and Mikos 1999). However, most of the polymeric scaffolds 
are typically processed under severe conditions utilising toxic reagents. 
Moreover, it is relatively difficult to effectively incorporate a variety of 
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beneficial culture factors and to homogenously entrap cells in the solid porous 
structure. As an alternative, a variety of hydrogels, a class of highly hydrated 
polymer materials, are being employed as scaffold materials whilst overcoming 
the existing problems in using the solid-type of scaffolds (Drury and Mooney 
2003). Beneficial characteristics of the use of hydrogel in tissue engineering is as 
follows: 1) A low undesirable immune response, called a biocompatibility, 2) 
Controllable biodegradability, 3) Minimised mechanical or frictional irritation to 
the surrounding tissue due to the soft and pliable nature, 4) Convenient 
modulation of physical and chemical properties for adequate application to any 
case of surgery, 5) High permeability for transport of nutrients and metabolites, 
6) Homogeneous cell-distribution in the three-dimensional structure (Bienaime 
et al. 2003; Chia et al. 2000; Uludag et al. 2000). Cells can be encapsulated 
during the hydrogel formation process as a small bead format. This approach 
has the advantage that cells can be surrounded by a small amount of a 
physiologically relevant matrix, and can then be cultured and potentially 
injected into a wound site while still in this environment, facilitating application 
to tissue engineering strategies as a promising cell delivery system. While it may 
appear that the hydrogels do not have strong enough mechanical properties for 
application in the skeletal system, they provide a matrix for accelerated tissue 
formation which will in turn provide mechanical integrity. As with other 
biomaterials, the chemical and physical properties of the hydrogel scaffolds may 
be altered to improve tissue development (Elisseeff et al. 2005). 
Alginate material has been popularly used in the tissue engineering field 
as characterised by a macromolecular structure resembling ECMs in vivo 
(Glicklis et al. 2000; Leor et al. 2000). Alginate is a water-soluble linear 
polysaccharide extracted from brown seaweed and is composed of alternating 
blocks of 1-4 linked α-L-guluronic and β-D-mannuronic acid residues. An 
alginate solution turns into a hydrogel in the presence of multivalent cations, 
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usually divalent Ca
2+
, Ba
2+
 or Sr
2+ 
(Smidsrod 1975). These cations, mostly Ca
2+
, 
can take part in the interchain binding between the blocks of guluronic residues 
in alginate strands and give rise to a 3D network in the form of a hydrogel. 
Figure 12 describes the model of this network, “egg-box”, (Simpson et al. 2004). 
The “egg-box” model is represented by solid circles depicting calcium ions 
positioned between consecutive guluronic acid residues (V-shaped structures), 
while consecutive mannuronic acid residues are depicted by the curves at the 
end of the “egg-box”. 
 
Figure 12. A schematic representation of the ‘‘egg-box’’ model in low and 
high CaCl2 concentration (adapted from Simpson et al. 2004). 
 
This gel is a well-structured macromolecular construction supporting the 
oriented and regular geometric structure throughout the gel network, although 
the arrangements of polysaccharidic blocks would be different between the 
peripheral layers and the bead centre. Figure 13 shows a schematic 
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representation of the different gel network structures of a Ca-alginate gel bed 
(Bienaime et al. 2003). The formation of a Ca-alginate gel bead gives rise to the 
creation of a microcosm with heterogeneous characteristics: very dense gel 
sectors (superficial crust and subsurface), strong, medium and weak gelled 
zones, and regions with micro fractures, cavities, shafts, and shaft clusters. 
Briefly, there is the formation of a superficial crust first, acting as a spherical belt, 
progressively tightening the gel bead. Second, there is a reduction of the gel 
bead volume with water expulsion (syneresis), resulting from the reaction-
diffusion process between alginate macromolecules and calcium cations. Third, 
alginate molecules that have not yet reacted with calcium move progressively 
from the bead centre to the moving boundary of the reaction front, attracted by 
the accumulation of calcium cations. Fourth, all these phenomena produce a 
cascade of reaction-diffusion processes provoking the formation of micro 
fractures, shafts, shaft clusters and cavities. 
 
Figure 13. Schematic representation of the different gel network structures 
of a Ca-alginate gel bed (adapted from Bienaime et al. 2003). 
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The reaction-diffusion process during gelation provokes an internal 
rearrangement of alginate molecules. It could be presumed that when cells are 
present in the alginate solution, they move from the centre to the surface of the 
forming gel bead pulled by the movement of alginate molecules. A soft gel 
network of the hydrogels is advantageous in tissue-engineered constructs as 
spaces within a construct where cell growth and expansion are desired. Likewise, 
a hard gel network near the surface area of the bead is recommended for parts 
of a construct as a distinction between external and internal circumstances of 
the bead contributing isolated, independent vehicles of cells with desirable 
permeability. Gel densities, porosity, presence of cavities, and shafts can be 
easily controlled with several parameters, such as alginate solution 
concentration, ionotropic cation concentration, temperature, stirring, impurities 
content (Bienaime et al. 2003). Surprisingly, bead production is highly 
reproducible when the same conditions and reagent concentrations are used. 
More recently, alginate and gelatin have been considered to overcome the inert 
nature of alginate and increase bead integrity. Normally alginate hydrogels lose 
Ca
2+
 cations after prolonged culture but the incorporation of gelatin enables 
cell-mediated contraction and packing of the scaffold material (Awad et al. 
2004). The interactions between the alginate/gelatin matrix and embedded cells 
would play a major role in their morphological and physiological behaviour.  
 
1.4.3. The development of three-dimensional bioprocess 
The generation of three-dimensional tissue substitutes requires not only 
a biological consideration, such as an adequate source of proliferating cells with 
appropriate biological functions and a protocol of expanding cells with 
maintaining the tissue-specific phenotype, but also the technological 
development of culture strategies such as the use of bioreactor system (Ratcliffe 
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and Niklason 2002). Automated culture processes of the bioreactor system 
should include controllability, reproducibility, and scalability as well as consider 
the future routine manufacturing of tissues for clinical application (Martin et al. 
2004). Furthermore, each type of tissue constructs will likely require an 
individualised bioreactor design due to their specific functional, physicochemical 
characteristics in vivo (Ratcliffe and Niklason 2002). Therefore, tissue-specific 
bioreactors should be designed on the basis of comprehensive understanding of 
biological and engineering aspects. 
 
1.4.3.1. Various bioprocesses for the development of skeletal lineage 
tissues from ESCs 
Figure 14 shows various examples of bioprocess for ESCs which have 
currently been used to achieve ESC expansion in a large scale and also effective 
generation of the skeletal tissues from ESCs. Mostly, very simple well-mixing 
culture systems have been applied to ESC-culture in many studies so far, such as 
a stirred bioreactor (also called a spinner flask system). Kehoe et al. in 2008 
cultured mESCs in a serum-free condition particularly for a clinical adaptability 
using a stirred bioreactor and showed the effective expansion and 
differentiation into cardiac mesoderm (Kehoe et al. 2008). Schroeder et al. 
reported the feasibility of a large scale ESC-culture using a 2L-size bench scale 
stirred bioreactor in 2005, and Niebruegge et al. presented the comparison 
study between 250ml- and 2L-size vessels in terms of mESC expansion and 
differentiation into cardiomyocytes. Interestingly, the 2L-scale vessel showed 
higher differentiation efficiency compared to the 250mL one assumingly due to 
the facts that a higher cell density increases the efficient cardiomyogenic 
differentiation in EB formation and thus results in facilitating potential further 
53 
 
expansion of cardiomyocytes or progenies of heart cells (Niebruegge et al. 
2008c; Schroeder et al. 2005). Micro-carriers have been introduced in a stirred 
system to influence ESC adhesion because it is difficult for ESCs to have initial 
agglomerations in a suspension state (Fok and Zandstra 2005). In the results, 
high cell numbers could be obtained by more cellular aggregations bridging on 
the bead surfaces, but it appeared that the size of agglomerations is in huge 
variances. Recently, centrifugation of ESCs within round-bottomed 96-well 
plates was also attempted to induce ESC-aggregations more rapidly, but it still 
requires individual processing and manipulating of the resulting EBs (Ng et al. 
2005). Most of the current studies about ESC-culture using various bioreactor 
systems can be found in Table 1. 
 
Figure 14. Various bioprocesses for the development of skeletal lineage tissues 
from ESCs. 
Comparison between HARV and STLV (Wang et al. 2006)
Serum free (Kehoe et al. 2008)
Micro-carriers (Fok et al. 2005)
mESCs
EB size controlling with micro-wells
+ oxygen tension variances (Niebruegge et al. 2008)
Large scale culture with a 2L-size vessel (Schroeder et al. 2005)
+ comparison between 250ml- and 2L-size vessels (Niebruegge et al. 2008)
hESCs
Improved EB formation (Cameron et al. 2006)
Comparison between Stirred system and STLV (Yirme et al. 2008)
Cardiomyogenic
Improved EB formation
Encapsulation with bioglass (Zhang et al. 2009)
Osteogenic
Encapsulation and bypassing EB formation (Hwang et al. 2009)
Comparison between HARV and STLV (Gerecht-Nir et al. 2004)
Chondrogenic
Encapsulation and bypassing EB formation (Hwang et al. 2008)
Encapsulation and cyclic air compression (Terraciano et al. 2007)
Perfusion fed system (Bauwens et al. 2005)
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Table 1. Current studies about ESC-culture using various bioreactors 
Bioprocesses and Studies Cells Target References 
Stirred suspension 
: Serum free condition mESCs cardiomyogenic (Kehoe et al. 2008) 
Micro porous spheres in a simple agitator mESCs cardiomyogenic (Akashaa et al. 2008) 
Micro-carriers in a stirred flask mESCs cardiomyogenic (Fok and Zandstra 2005) 
HARV bioreactor 
: Encapsulation with hydrogel and bioglass mESCs osteogenic (Zhang et al. 2009) 
HARV bioreactor 
: Encapsulation with alginate hydrogel and bypassing 
EB formation period 
mESCs osteogenic (Hwang et al. 2009) 
Stirred bioreactor 
: Control of aggregate size with micro-printing technique 
and oxygen tension variance 
hESCs cardiomyogenic (Niebruegge et al. 2008a) 
Spinner flask system 
: Comparison of 250 mL and 2 L size vessels mESCs cardiomyogenic (Niebruegge et al. 2008c) 
Stirred bench scale bioreactor 
: Large scale culture with a 2 L vessel mESCs cardiomyogenic (Schroeder et al. 2005) 
STLV rotating bioreactor mESCs cardiomyogenic (Lu et al. 2008) 
STLV rotating bioreactor/HARV bioreactor hESCs EB formation (Gerecht-Nir et al. 2004) 
STLV rotating bioreactor/HARV bioreactor mESCs cardiomyogenic (Wang et al. 2006b) 
STLV rotating bioreactor/stirred bioreactor hESCs EB formation (Yirme et al. 2008) 
Micro-patterned plate 
: Control of aggregate size hESCs cardiomyogenic (Bauwens et al. 2008) 
Stirred bioreactor mESCs cardiomyogenic (Zandstra et al. 2003) 
Stirred bioreactor hESCs EB formation (Cameron et al. 2006) 
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Suspension bioreactor with agitation mESCs ESC expansion (Cormier et al. 2006a) 
Orbital rotary shaker mESCs EB formation (Carpenedo et al. 2007) 
Perfusion fed bioreactor 
: Control of oxygen tension, hydrogel encapsulation mESCs cardiomyogenic (Bauwens et al. 2005) 
A round-bottom glass bioreactor 
: Encapsulation with agarose and  various studies with 
3D porous scaffolds 
mESCs cardiomyogenic (Fromstein et al. 2008) 
HARV bioreactor 
: Encapsulation with alginate hydrogel mESCs osteogenic (Randle et al. 2007) 
HARV bioreactor 
: Encapsulation with alginate hydrogel and bypassing 
EB formation period 
mESCs chondrogenic (Hwang et al. 2008a) 
Two-stage perfusion fibrous bed bioreactor mESCs ESC expansion (Ouyang and Yang 2008) 
Mechanical Compression Bioreactor 
: Encapsulation with hydrogel and stimulation with 
cyclic air compression 
hESCs chondrogenic (Terraciano et al. 2007) 
HARV: high aspect ratio vessel 
STLV: slow turning lateral vessel 
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Although the use of stirred bioreactors in tissue engineering is very 
popular, the general disadvantages of stirred systems still remain, such as 
damaging cells/tissues and unpredictable results from the generation of 
turbulence by shear forces (2-40 dyne/cm
2
 based on the design of the impeller 
and rotation speed) (Dang et al. 2004b; Dang et al. 2002; Placzek et al. 2009; 
Wang et al. 2006b). It was reported that using a stirred-flask successfully 
resulted in an increase of chondrogenic ECM accumulation within the central 
regions of three-dimensional cellular construct as compared to static culture. 
However, a fibrous capsule was formed at the construct surface, potentially due 
to turbulent eddies generated in the stirred flask bioreactor (Martin et al. 1999). 
The rotating wall vessel (RWV) bioreactor systems such as the slow 
turning lateral vessel (STLV) and the high aspect ratio vessel (HARV) were 
developed by National Aeronautics and Space Administration (NASA) in the US 
to physically simulate the gravity-free environment in the outer space. 
Theoretically, the rotating vessel provides the compromise among the 
simultaneous gravitational, buoyant, centrifugal, Coriolis, and drag forces on 
constant free-fall, resulting in a nearly steady condition under very low shear 
force (less than 1 dyne/cm
2
) (Figure 15). Initially, the behaviours of mammalian 
cells within this micro-gravity environment were investigated in order to predict 
the health conditions of astronauts in space. Nowadays, bioprocess engineers 
adopted this technology to overcome the limitations from using the impeller 
type of bioreactor. This unique environment could have many beneficial effects 
on the three-dimensional tissue growth and heightened level of cell 
differentiation by minimising the unexpected errors from the generation of 
turbulence which can influence biological responses. Additionally, the nutrients 
in the medium can be deeply guided into the three-dimensional tissues by the 
inertia of Coriolis force resulting in the high mass transport in conjunction with 
the efficient mixing (Freed and Vunjaknovakovic 1995). There are some 
interesting studies that compare STLV and HARV bioreactor systems for ESC-
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culture. Gerecht-Nir et al. reported EBs from hESCs were formed well in both of 
the HARV and STLV. However, it was observed that numerous contacts and 
collisions of ESC-aggregates with the wall of STLV were caused due to a smaller 
aspect ratio (diameter/length) than HARV. In the results, EB agglomerations in 
HARV were larger than those in STLV system, furthermore showing necrotic 
portions in the centre. Therefore, they speculated that the culture condition of 
STLV might be preferable for the efficient productivity in terms of EBs’ maturity 
(Gerecht-Nir et al. 2004). Yirme et al. in 2008 compared various types of stirred 
bioreactor and STLV system in terms of EB formation and cardiomyogenic 
differentiation from hESCs. This study showed that a specific type of stirred 
bioreactor (which holds double glass boll bulb-shaped impeller) was superior in 
cell viability and differentiation efficiency. It was reported in this study that 
moderate shear forces could promote cellular growth by influencing cellular 
shape and physiology (even though it appears to be uncontrollable to occur to 
the same extent all the time). Unexpectedly, STLV bioreactor presented the 
slowest growth rate and lowest final cell concentration and survival potential. 
However, it can be accountable to the specific type of STLV bioreactor they used, 
which has a limitation of oxygen mass transfer (Yirme et al. 2008). 
 
Figure 15. A dynamic culture environment of rotating wall vessel 
with low shear stresses and high mass-transfer rates 
(adapted from Martin et al. 2004). 
  
*Fd: drag force, Fc: centrifugal force, Fg: net gravitational force  
58 
 
On the other hand, after passaging hESCs, cells are still colonies in a wide 
range of sizes owing to difficulty of single cell dissociation, possibly causing 
variability in the subsequent differentiation progress. A new approach for 
reproducible hESC-culture using micro-printing technology has been introduced 
to control ESC-aggregate size and further effective differentiation to 
cardiomyocytes (Bauwens et al. 2008; Niebruegge et al. 2008a). Micro-wells 
fabricated by the lithographic techniques yielded EBs in parallel at a much 
higher density than other physical separation methods. Forming EBs within 
micro-wells in a continuous volume of medium permitted batch processing, 
therefore significantly improving the throughput of EB formation (Ungrin et al. 
2008). Likewise, batches of EBs have been formed in micro-fluidic chambers 
which allow the temporal control of the molecular makeup in the medium 
through a semi-permeable membrane (Torisawa et al. 2007). 
Hydrogels in tissue engineering generally provide highly permeable 
structures with homogeneous pores where living cells can accommodate having 
the convenient exchanges of various culturing factors such as nutrients, 
metabolites, cytokines, and gaseous components. Hydrogels can be naturally 
dissolved or degraded over culture time, and thereby creating more space into 
which growing cells may penetrate and proliferate. Recently, it was 
demonstrated that by using hydrogels, the undifferentiated state of hESCs could 
be sustained over six months in the absence of mechanical or enzymatic 
passaging and without co-culturing feeder cells (Siti-Ismail et al. 2008). Dang et 
al. reported that surface molecules expressed on ESCs promote aggregations 
between EBs, and thereby inhibit cell growth and differentiation leading to 
incomplete EB differentiation (Dang et al. 2002). For the purpose of physical 
separation of EBs in a bulk semi-solid suspension media, there have been many 
attempts to encapsulate ESCs as a single cell suspension or small clusters in 
various hydrogels, such as methylcellulose (Keller et al. 1993), fibrin (Liu et al. 
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2006) and hyaluronic acid (Gerecht et al. 2007). Encapsulation was reported to 
provide a barrier between surface molecules which promote adhesion such as 
e-cadherins. Thus, individually separated EBs by that resulted in the overall 
synchrony and improved reproducibility of EB differentiation (Dang et al. 2004b). 
Encapsulation also can be combined with various bioreactor culture systems, so 
that laborious handling and disturbance during ESC-cultures can be minimized, 
potentially further contributing to scale-up and differentiation within an 
integrated bioprocess (Bauwens et al. 2005; Hwang et al. 2009; Hwang et al. 
2008a, b; Randle et al. 2007). 
Due to the complex architecture of the bone and cartilage, many 
challenges about well-defined culturing conditions have been left in skeletal 
tissue engineering with ESCs. It is believed that the mechanical stimulation can 
offer a proper functionality of chondrocytes with balancing ECM synthesis and 
degradation like in vivo (Buckwalter and Mankin 1998). Most of the previous 
studies, however, have been based on mesenchymal stem cells or mature 
chodrocytes/osteoblasts, so the response of ESCs on mechanical stimulation is 
currently largely unknown. Terraciano et al. studied the differential effects on 
chondrogenesis between encapsulated adult MSCs and hESCs after cyclic 
compression stimulation (Terraciano et al. 2007). Interestingly, hESCs started to 
show the response to the mechanical stimulation after the initial differentiation 
was triggered by chondrogenic medium, whereas adult stem cells responded 
immediately. It was hypothesized in the study that hESCs need to differentiate 
to the specific stage first in order to have mechanosensitive integrins or ECM 
molecules which facilitate the physical connections between the mechanical 
stimuli and the cells. 
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1.4.3.2. Controlling Culture Factors in ESC-culture 
Glucose is an essential source of energy for most of the living organisms. 
It was reported that the levels of glucose influence embryonic growth and fetal 
development to mesenchymal lineage relevant with cardiac and skeletal 
morphogenesis (Mobasheri et al. 2008). In vivo, the concentration of glucose 
circulating through blood vessels is approximate 1000 mg/L. However, 
supraphysiological glucose levels (4500 mg/L) have been frequently employed 
for ESC derivation and maintenance in vitro. Modified MEMα (Minimum 
Essential Medium alpha) containing high glucose (4500 mg/L) was reported to 
improve the efficiency of ESCs derivation remarkably maintaining their 
pluripotency in comparison with low glucose (1000 mg/L) MEM and Knockout 
DMEM (Kim et al. 2009). On the other hand, it was reported that the growth of 
EBs from hESCs at the physiological glucose concentration of 5.5 mM (~1000 
mg/L) yielded a greater growth rate than the high glucose concentration in 
Dulbecco’s Modified Eagle Media (DMEM containing 25 mM or 4500 mg/L) 
(Khoo et al. 2005). It can be suggested by combining these studies that 
supraphysiological glucose levels help ESC-maintenance in pluripotent phase, 
whereas physiological levels contribute to EB formation as well as further 
differentiation. The control of environmental factors within the immediate cell 
environment, where ESCs release metabolites, growth factors and other 
molecules, can also influence either their proliferative potential or 
differentiation accordingly (King and Miller 2007). A recent literature suggested 
that the accumulation of metabolites inhibits ESC expansion and reduces 
pluripotency. It was reported that daily media exchange helped to keep 
pluripotency of mESCs, while a decrease of pluripotent population was 
observed when they were cultured without daily media exchange, ascertained 
by the percentage of Oct4-GFP
+
 expressed in mESCs (Viswanathan et al. 2003). 
The accumulation of ammonia up to almost 2.5 mM was reported to be the 
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cause of a reduction in viable number of the mESCs (Cormier et al. 2006b). The 
differentiation of ESCs to a specific lineage can also be affected by feeding rate 
interestingly in the different way from the pluripotent stage. Niebruegge et al. 
reported that a lower medium throughput might be favorable for 
cardiomyocyte yield from mESCs. The authors attributed the lower 
differentiation rate to the abrupt removal of media containing autocrine factors 
leading to a disruption to a culture environment which promotes the 
differentiation of EBs (Niebruegge et al. 2008b). Accumulation of metabolites 
would result in a decrease of pH. Gradients in pH may have significant effects on 
the viability, growth and differentiation of ESCs towards certain lineages. 
However, the optimum range of pH has yet to be reported, differing in ESC-
expansion and differentiating cell types. 
It is well known that a fed-batch type culture system is problematic in 
controlling supplementation in media, avoiding metabolic waste accumulation, 
and maintaining cell-secreted beneficial factors (Abranches et al. 2007). 
Therefore, a perfusion feeding system is now considered as one of the essential 
parts in the future design of the bioprocess. A bioreactor system developed by 
Bauwens et al. for cardiomyogenic differentiation from mESCs involved medium 
perfusion, real time monitoring and control of dissolved oxygen concentration. 
This study showed that the perfusion culture system enabled a supplement 
monitoring and prevented metabolic waste accumulation, thereby reducing the 
major dilution of cell-secreted factors (Bauwens et al. 2005). More recently, 
Ouyang et al. also devised a perfusion bioreactor for mass production of ESCs. 
Briefly, ESCs were seeded in a fibrous bed, and feeder cells were cultured in a 
vessel which was separated but connected to the bed in order to maintain 
pluripotency of ESCs. Although they claimed to achieve an affordable ESC-
manipulation for the clinical need, the system appears to be complex and 
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inefficient especially in harvesting ESCs from the fibrous bed after the mass 
production (Ouyang and Yang 2008).  
Oxygen (O2) tension is also known to be an important determinant for 
ESC expansion as well as for a specific differentiation. ESCs are mostly cultured 
in normoxic conditions which is 142 mmHg of pO2 (about 20%), whereas 
embryos in vivo develop in lower levels of oxygen in the range of 0-30 mmHg 
(Powers et al. 2008b). Oxygen tension might affect the niches around ESCs and 
play a role as a developmental morphogen similarly to the roles of traditionally 
known growth factors and cytokines. Oxygen-sensitive pathways such as 
hypoxia-inducible transcription factors (HIF)-dependent pathways were 
investigated in ESC-culture, and it was verified that hypoxia results in the 
activation of Notch and Oct4 which are involved in the maintenance of ESCs 
(Simon and Keith 2008). It was previously reported that an environment under 
low O2 tensions contributed to larger size of inner cell mass in in vitro cultured 
bovine blastocysts (Harvey et al. 2004). Likely, it was shown by many studies 
that ESCs grow more efficiently under low O2 tensions with maintaining high 
pluripotency, as opposed to in ambient air (Bauwens et al. 2005; Ezashi et al. 
2006; Gibbons et al. 2006; Niebruegge et al. 2008a; Powers et al. 2008b; Prasad 
et al. 2009; Simon and Keith 2008; Wang et al. 2006a; Westfall et al. 2008). 
Kurosawa et al. reported that the culture condition under a high oxygen tension 
(40% O2) retarded the differentiation of ESCs and a normal oxygen tension (20% 
O2) allowed spontaneous cell differentiation (Kurosawa et al. 2006). It is also 
clear that O2 influences specific cell differentiation in the developmental process. 
For example, β-catenin is down-regulated by interaction with HIF-1α in hypoxia 
interrupting Wnt signaling pathways (Simon and Keith 2008), and this would be 
potentially used for controlling cardiomyogenesis (Bauwens et al. 2005; 
Niebruegge et al. 2008a). In terms of osteogenic development, it was reported 
that physiological O2 gradients (hypoxia) profoundly influence the earlier steps 
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in bone formation, such as the generation of cartilaginous primordial limb bud 
mesenchyme and chondrogenesis (Provot et al. 2007). Koay et al. investigated 
the effects of hypoxia on chondrogenesis from hESCs, and showed that hypoxic 
conditions (2% O2) enhanced the synthesis of various proteins related to 
chodrogenic progress (Koay and Athanasiou 2008). However, HIF response in 
ESCs after the expose to hypoxia is transiently stabilised, so that the sudden 
exposure to a hypoxic environment could harm the growth of ESCs by inducing 
apoptosis before the promotion of expansion through the pathways, although 
hypoxia stimulates hypoxic responsive genes which correlate with various steps 
in the development in vivo (Cameron et al. 2008). The effects of various 
culturing factors on ESC-cultures such as oxygen tension (Figure 16), cell 
secretion accumulation (Figure 17), shear stress (Figure 18), feeding rate (Figure 
19), and glucose concentration (Figure 20) stated in this sub-chapter are briefly 
summarised as various plots. 
The development of bioreactor systems is believed to accelerate the 
transfer of laboratory-based practices with ESCs to the clinic. Advances in 
optical technologies can also support bioreactor systems to have a real-time 
monitoring of all the operating conditions with non-invasive. Continuous 
evaluation of critical culture parameters may ensure that the culture is carried 
on within the optimal conditions (Aref et al. 2009; Kirouac and Zandstra 2008). 
Additional consideration will be the standardisation of common limiting values 
in the bioprocess, which leads to cost-effective manufacture of tissue-
engineered products (Pei et al. 2002b). Conclusively, a development of an 
automated, standardised bioprocess combined with the concept of Good 
Manufacturing Practice (GMP) can produce cellular tissue engineering 
constructs from ESCs in a manner of “off-the-shelf”, and effectively supply 
donor cells/tissues to many of the actual therapeutic procedures in daily clinical 
practice (Figure 21). 
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Figure 16. The effects of oxygen tension to ESC-cultures reported by 
various literatures. 
 
Figure 17. The effects of cell secretion accumulation to ESC-
cultures reported by various literatures. 
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Figure 18. The effects of shear stress to ESC-cultures reported 
by various literatures. 
 
Figure 19. The effects of feeding rate to ESC-cultures reported 
by various literatures. 
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Figure 20. The effects of glucose concentration to ESC-cultures 
reported by various literatures. 
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 Figure 21. The requirements for the development of 3D-bioprocess.
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Chapter 2. Aims and Objectives 
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Most of the conventional methods for ESC-culture involve the 
fragmented and laborious procedures comprising of three individual steps: 
expansion of ESCs in the maintenance of pluripotency, EB formation, and 
terminal differentiation (Figure 22). Furthermore, as introduced in Chapter 1, 
the two-dimensional culture system is not suitable for a large-scale production 
and differentiation of ESCs due to the restriction of available culture areas and 
disruption of typical three-dimensional interactions between cells and ECMs. 
 
 
Figure 22. Conventional ESC-culture. 
 
The aims of this project are to develop the effective methodology for a 
new generation of “off-the-shelf” cellular products from ESCs and to address 
the translational challenges in the bioprocess and in vivo testing for the clinical 
application. The objectives are summarised as follows: 
1. Optimisation of the integrated bioprocess using alginate encapsulation 
and HepG2-CM methodologies with the examination of the quality of 
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skeletal tissue constructs from ESCs as well as reproducibility of the 
process. 
2. Designing, building, and testing an automatable perfusion bioreactor that 
is amenable to continuous feeding and effective gas-exchange by a 
computer-controlled operation in order to achieve ESC scale-up and 
osteogenic tissue generation (Figure 23). 
3. Development of animal models to evaluate the mineralised cellular 
constructs from the newly designed bioreactor in terms of bone repairing 
capacity in vivo through integration with the host tissue. 
 
 
 
Figure 23. A scheme of the integrated 3D-bioprocess. 
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Chapter 3. Materials and 
Methods 
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3.1. Optimisation of 3D-integrated Bioprocessing 
 
3.1.1. mESC maintenance 
E14 thioguanine resistance 2 mESC (E14Tg2α) cell line was routinely 
cultured on tissue culture flasks coated with 0.1% gelatin (Sigma-Aldrich, Poole, 
UK) in a humidified incubator set at 37
o
C and 5% CO2. Undifferentiated mESCs (< 
passage 20) were passaged every 2 or 3 days and fed every day with the fresh 
maintenance medium based on high glucose Dulbecco's Modified Eagle Medium 
(DMEM) without sodium pyruvate (Invitrogen, Paisley, UK) containing 10% (v/v) 
of fetal bovine serum (FBS) batch-tested (Invitrogen), 1% (v/v) of penicillin and 
streptomycin (Invitrogen), 2 mM of L-glutamine (Invitrogen), 0.1 µM of 2-
mercaptoethanol (Sigma-Aldrich) and 1000 units/ml of Leukemia Inhibitory 
Factor (LIF) (Chemicon, Hampshire, UK).  
 
3.1.2. EB formation 
Embryoid body formation involved careful preparation of mESCs prior to 
suspension culture and was well documented (Desbaillets et al. 2000; Martin 
and Evans 1975b). Nonetheless, empirical determination of the correct 
conditions before suspension was established with the E14Tg2α cell line. Briefly, 
cells in monolayer culture should be around 70% confluent on either day 2 or 3 
of culture and morphologically undifferentiated. Cells were shortly trypsinised 
for 1-2 minutes ensuring cell clumps. The clumps were then centrifuged at 300g 
for 3 minutes at room temperature and then re-suspended in EB formation 
medium based on Minimum Essential Medium Alpha (α-MEM) (Invitrogen) 
containing 15% (v/v) of FBS (Invitrogen), 1% (v/v) of penicillin and streptomycin 
100 units/ml (Invitrogen) and distributed evenly into two 90 mm diameter 
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bacteriological grade petri dishes. The first exchange of medium was done on 
day 3, and every two days afterward.   
 
3.1.3. HepG2 conditioned medium (HepG2-CM) formulation 
HepG2 cells (ATCC HB-8605) were cultured in the same way with our 
previous work (Hwang et al. 2006). Briefly, cells were initially cultured in a 
density of 5.0 × 10
4
 cells/cm
2
 with DMEM containing 10% (v/v) FBS and 1% (v/v) 
of penicillin and streptomycin. The culturing medium was not changed for the 
following 4 days and then collected to the 0.22-μm filter-unit (VWR 
International, Poole, UK) for filter-sterilization followed by supplementing 0.1 
µM of 2-mercaptoethanol and 2 mM of L-glutamine. HepG2-CM was formulated 
with 50% (v/v) of the fresh mESC growth medium and 50% (v/v) of the medium 
from the culture above, and subsequently 1000 units/ml of LIF was added in the 
mixture (Rathjen et al. 1999). 
 
3.1.4. Alginate encapsulation of ESCs  
Undifferentiated mESCs were trypsinized from T-flasks, counted, and re-
suspended at 2.5 x 106 cells/ml (20,000 cells/bead) in 0.22-μm sterile filtered 
solution composed of 1.1% (w/v) alginic acid (Sigma-Aldrich) and 0.1% (v/v) 
porcine gelatin (Sigma-Aldrich) (all dissolved in PBS, pH 7.4) as described in our 
previous study (Randle et al. 2007). The cell-sol solution was passed through a 
peristaltic pump (Model P-1, Amersham Biosciences, Buckinghamshire, UK) and 
dropped in the solution for cross-linking hydrogel, composed of 100 mM 
calcium chloride (CaCl2; Sigma-Aldrich) and 10 mM N-(s-hydroxyethyl) 
piperazine-N-(2-ethane sulfonic acid) (HEPES; Sigma-Aldrich) at pH 7.4. A flow 
rate of a peristaltic pump was empirically confirmed to produce proper single 
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droplets using a 25-gauge needle (Becton Dickinson, Oxfordshire, UK) and a 
drop height was 15 mm. Before the processes, tubes were autoclaved and then 
sterilized with 1 M of NaOH (Sigma-Aldrich) for 30 minutes and washed three 
times with sterile phosphate buffered saline (PBS). The droplets containing cells 
were gelled immediately on contact with the Ca
2+
 solution as a shape of bead 
(approximate diameter size: 2.3mm), and then remained in the gently stirred 
solution for 5 minutes at room temperature. The beads were washed three 
times in PBS and placed into the normal mESC culture medium (NM) or HepG2-
CM respectively regarding the experimental group arrangement.  
 
3.1.5. Three-dimensional culture for skeletal tissue generation 
Encapsulated cells subsequently were transferred to a 55-ml High Aspect 
Ratio Vessel (HARV) bioreactor (fed-batch type) (Cellon, Bereldange, 
Luxembourg). Each reactor contained five-hundred beads and rotation rate of 
the culturing vessel varied following cell growth kinetics previously tested, in 
order to avoid increasing shear stress forces inside, in that the beads were 
getting heavier with the cells growing through the culturing period. The beads 
were dissolved at each time point for sample collecting using depolymerization 
buffer consisting of 50 mM tri-sodium citrate dihydrate (Fluka, Poole, UK), 77 
mM sodium chloride (BDH Laboratories Supplies, Poole, UK) and 10 mM HEPES 
(Sigma-Aldrich) (Magyar et al. 2001). 
Normal medium or HepG2-CM was applied in each vessel for the first 3 
days to get cell expansion with keeping their pluripotency, and then 
spontaneous differentiation was triggered using alpha Minimal Essential 
Medium (α-MEM; Invitrogen) containing 15% (v/v) of FBS and 1% (v/v) of 
penicillin and streptomycin, which has been commonly used for EB formation 
(Desbaillets et al. 2000; Martin and Evans 1975a). To perform specific 
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differentiation to cardiomyogenesis, 100 µM of L-ascorbate-2-phosphate 
(Sigma-Aldrich) was supplemented in the EB formation medium (Takahashi et al. 
2003b), and to osteogenesis 50 µg/ml of L-ascorbate-2-phosphate (Sigma-
Aldrich) and 10 mM β-glycerophosphate (Sigma-Aldrich) were added in EB 
formation media from the onset of osteogenic differentiation, and 1 µM 
dexamethasone (Sigma-Aldrich) was additionally supplemented 7 days before 
the end of the culture. The time plans for heart and bone developments are 
described in Table 2 and 3 respectively. Growing cells in beads were 
photographed using a Leica DM IL microscope (Leica, Wetzlar, Germany) and 
analysis^D software (Olympus, Munich, Germany), and beating colonies in 
beads (about 50-70 beads per group) were filmed using CamStudio, a free 
screen recording software (CamStudio.org, Essex, UK). 
 
Table 2. Culturing plans for cardiomyogenesis 
 
 
Table 3. Culturing plans for osteogenesis 
 
control 3 days X 5 days 13 days
cm0D X 3 days X 18 days
cm5D X 3 days 5 days 13 days
cm7D X 3 days 7 days 11 days
group
Maintenance with LIF Spontaneous 
differentiation
Cardiomyogenic 
differentiationNormal growth 
medium
HepG2-conditioned 
medium
ESC-EB
cm-EB
3 days
X
X
3 days
18 days
18 days
X
control 3 days X 5 days 14 days 7 days
cm0D X 3 days X 19 days 7 days
cm5D X 3 days 5 days 14 days 7 days
cm7D X 3 days 7 days 12 days 7 days
group
Maintenance with LIF
Spontaneous 
differentiation
Osteogenic differentiation
Normal growth 
medium
HepG2-conditioned 
medium
L-ascorbate/
β-glycerophosphate Dexamethasone
76 
 
3.1.6. Fabrication of a perfusion RWV bioreactor 
A novel computer-controlled RWV bioreactor was developed, which is 
amenable to continuous oxygenation, supply of nutrients, and removal of 
metabolic wastes through medium-perfusion as well as a convenient gas 
exchange using a gas-permeable membrane. Designing and fabricating the new 
bioreactor system are detailedly described in Chapter 5. The specification of 
materials used for the gas-permeable membrane and all parts of bioreactor can 
be found in Table 4 and 5. 
 
Table 4. Specification of gas permeable membrane 
Parameter Value(s) 
Dimensions of membrane 16 x 6cm  
Membrane thickness 
0.004 inch polydimethylsiloxane  
0.001 inch polytetrafluoroethylene 
0.005 inch total thickness  
Surface area of gas permeable 
membrane 
6030 cm
2
 or 0.603 m
2 
 
Membrane permeability @ 
atmospheric pressure (speed of 
O2 permeating through 
membrane) 
1.1 E-2 cms
-1
 or 1.1 E-6 ms
-1
 
Supplier information 
SPECIALTY SILICONE PRODUCTS 
INC. 
3 McCREA HILL ROAD 
BALLSTON SPA,NY 12020, USA 
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Table 5. Information of materials 
Parts Materials 
Base Plate White Delrin/Acetyl Plastic 
Support Walls  White Delrin/Acetyl Plastic  
Oxygenator  White Delrin/Acetyl Plastic  
Tubing for 
Oxygenator  
Platinum Cured Silicone Rubber Tube (3mm ID x 4mm 
OD)  
Culturing Vessel  Virgin PTFE (Teflon)  
Steal Rods  1/8" OD x 0.028" Wall. 316 Stainless Steal Tubing
 
 
The Other Tubings  Silicon tubing,Tygon (1.6mm ID x 4.8mm OD)  
Supplier 
Information  
Metal & Plastic Ltd (Delrin, Teflon) 
- PO Box 432 
  Watford, Hertfordshire WD1 8YP, United Kingdom 
London Fluid System Technologies Swagelok London 
(St steal tubing) 
- Kingley Park, Station Road, Kings Langley, Herts WD4 
8GW 
  United Kingdom 
Silex Ltd (silicon tubing) 
- Unit 5 Broxhead Trading Estate, Lindford, Bordon,  
  Hampshire GU35 0NY, United Kingdom 
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3.2. Biological Evaluation Techniques 
 
3.2.1. Live/Dead assay 
Viability of cells inside hydrogels was evaluated using LIVE/DEAD 
Viability/Cytotoxicity Kit from Invitrogen. Briefly, membrane-permeant 3',6'-
Di(O-acetyl)-2',7'-bis[N,N-bis(carboxymethyl) aminomethyl] fluorescein, 
tetraacetoxymethyl ester (calcein AM) is cleaved in live cells by esterases to 
yield cytoplasmic green fluorescence, whereas membrane-impermeant 
ethidium homodimer-1 (EthD-1) labels nucleic acids of membrane-compromised 
cells with red fluorescence. Sample beads were collected and washed with PBS. 
A 4mM EthD-1 and 2mM calcein AM solution diluted in PBS was added to PBS-
washed beads and incubated at 37
o
C with gentle shaking for 30 minutes in the 
dark. A negative control was conducted using 100% (v/v) methanol (VWR 
International) for 5 minutes in place of PBS. After incubation, the solution was 
aspirated and a small amount of PBS was added to the beads to prevent 
dehydration. Samples were then photographed, within 30 minutes using 
Olympus BX51 fluorescence microscope (Olympus) and processed using 
analysis^D software (Olympus). The cellular viability was assessed through the 
entire area of the beads whilst focal points of observation varied. 
 
3.2.2. Alkaline phosphatase (ALPase) activity analysis 
ALPase activity was measured using ρ-nitrophenol phosphate (ρNPP, 
Sigma-Aldrich) as a substrate. Cellular ALPase was determined colorimetrically 
by ρNPP contents according to the reaction. Three beads (n=3) were collected 
from each group and dissolved in the depolymerisation buffer. The cells from 
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beads were incubated in 200 μl of ALPase buffer (Sigma-Aldrich) and 200 μl of 
ρNPP solution at 37oC for 30 minutes with gentle shaking in the dark. 400 μl of 3 
N sodium hydroxide (NaOH; BDH Laboratory Supplies) solution was added to 
each sample to stop the reaction and then 100 μl of the final solution was read 
at 410 nm with ELISA reader (MRX II plate reader; Dynex technologies, West 
Sussex, UK). The enzyme activity was calibrated with ρNPP standard curve 
(Appendix 1.1) and expressed as micromoles of reaction product per minute per 
total cell number obtained from DNA quantification. 
 
3.2.3 Alkaline phosphatase activity observation 
The expression of ALPase activity was also shown simply by Alkaline 
Phosphatase Detection Kit (Chemicon, USA). Briefly, the cells cultured on plates 
were fixed with 4% (w/v) paraformaldahyde (Sigma-Aldrich) for 1 min followed 
by three washes with 1X TBST buffer (20mM Tris-HCl, 0.15M NaCl, and 0.05% 
Tween-20 set at pH 7.4). The fixed cells were stained with Naphtal/Fast Red 
Violet solution prepared according to manufacturer’s instruction for 15 min in 
dark followed by a PBS wash. Images of stained cells were taken using Leica 
inverted microscope (Leica, UK) equipped with Olympus DP50 digital camera 
(Olympus, Tokyo, Japan), and analysed using analysis imaging software (Soft 
Image System GmbH, Germany). 
 
3.2.4. DNA quantification 
Total DNA content was measured using Quant-iT PicoGreen dsDNA 
Reagent and Kits (Invitrogen), as an indirect method of evaluating the increase 
in cell number. After collecting ten beads from each group (n=2) and dissolving 
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in the depolymerisation buffer, samples were digested in 50 µg/ml proteinase-K 
(Sigma-Aldrich) solution based on 100 mM dibasic potassium phosphate, pH 8.0 
(K2HPO4; Sigma-Aldrich) overnight at 37
o
C. Proteinase-K was inactivated by 
heating at 90
o
C for 10 minutes. The samples were then centrifuged at 12,000g 
for 10 minutes. 100 μl of the sample supernatant was placed in a DNase/RNase 
free eppendorf tube along with 100 μl of PicoGreen reagent which had been 
diluted in DNase free TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5), and 
vortexed for 2-3 minutes. 100 μl aliquot of the solution was then read using a 
fluorometer (MFX microplate fluorometer; Dynex technologies) with the 
excitation wavelength at 480 nm and the emission wavelength at 520 nm. The 
amount of total DNA produced from routinely cultured mESCs was enumerated 
in order to calibrate the number of cells per sample (Appendix 1.2). 
 
3.2.5. Immunocytochemistry staining 
Three-dimensionally cultured samples were collected and fixed for 40 
minutes at room temperature in 4% (w/v) paraformaldehyde (PFA; BDH 
Laboratory Supplies). The fixed samples were dehydrated in increasing 
concentrations of ethanol and subsequently immersed in xylene (BDH 
Laboratory Supplies) followed by a common process of paraffin embedding. The 
paraffin-embedded blocks were serially sectioned (4 µm) onto Vectabond-
coated glass slides (Vector Laboratories, Orton Southgate, UK). The sections 
were then placed in xylen and decreasing concentrations of ethanol to be 
deparaffinised and rehydrated. For antigen retrieval, they were submerged into 
10 mM tri-sodium citrated dehydrate buffer (pH 6.0; Sigma), followed by 
autoclave. The sections were treated with 0.2% (v/v) Triton-X-100 (BDH 
Laboratory Supplies) for 45 minutes at room temperature and washed twice 
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with PBS. The samples were then incubated with 3% (v/v) blocking goat or 
rabbit serum (Vector Laboratories) for 30 minutes at room temperature in 
primary diluents composed of 0.05% (w/v) bovine serum albumin (BSA; Sigma-
Aldrich), 0.01% (w/v) NaN3 (Sigma-Aldrich) in PBS. The serum solution was 
removed and the samples were incubated with primary antibodies diluted in 
primary diluents at 4
o
C overnight followed by two washes and incubation with 
secondary antibodies diluted in secondary diluents consisting of 0.05% (w/v) 
BSA in PBS for 1 hour at room temperature in the dark. For dual staining, the 
same steps after the first treatment of primary antibody were repeated for the 
second reaction. Finally, the samples were washed twice in PBS and mounted 
using Vectashield TM with 1.5 μg/ml 4',6' diamidino-2-phenylindole (DAPI) 
(Vector Laboratories) (See Table  6 for the information of antibodies).  
 
Table 6. Antibody list 
 
 
 
Antigens Primary antibodies (dilutions) Secondary antibodies (dilutions)
α-actinin
(Sarcomeric)
Mouse monoclonal (Sigma-Aldrich) 
(1:100) 
Goat anti-mouse IgG FITC (Sigma-Aldrich) 
(1:64)
Connexin 43 Rabbit affinity-isolated (Sigma-Aldrich) (1:400)
Donkey anti-rabbit IgG Texas Red (Santa 
cruz Biotech, Calne, UK) (1:200)
Tropomyosin Mouse monoclonal (Sigma-Aldrich) (1:100)
Goat anti-mouse IgG FITC (Sigma-Aldrich) 
(1:64)
Oct4 Rabbit polyclonal (Santa cruzBiotech) (1:80)
Goat anti-rabbit IgG FITC (Santa cruz
Biotech) (1:150)
SSEA1 Mouse monoclonal (Santa cruzBiotech) (1:80)
Donkey anti-mouse IgG Texas Red (Santa 
cruz Biotech) (1:150)
OB-cadherin Rabbit polyclonal (Santa cruzBiotech) (1:80)
Goat anti-rabbit IgG FITC (Santa cruz
Biotech) (1:150)
Type I 
Collagen
Rabbit plolyclonal Santa cruz
Biotech) (1:80)
Donkey anti-rabbit IgG Texas Red (Santa 
cruz Biotech) (1:150)
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3.2.6. Reverse transcription polymerase chain reaction (RT-PCR)  
After dissolving beads, total RNAs from the samples were extracted by 
using RNeasy kit (Qiagen, West Sussex, UK), according to the manufacturer’s 
instructions. RNA was reversed transcribed into complementary DNA (cDNA) 
using the Reverse Transcription System (Promega, Southampton, UK) following 
the manufacturer’s recommendations with some modifications. Briefly, 
Mastermix for cDNA synthesis was prepared with 1 μg of RNA adding 5 mM 
MgCl2, 1 mM of 2'-deoxynucleoside 5'-triphosphate (dNTP) mixture, 1 unit/μl 
recombinant RNasin ribonuclease inhibitor, 15 units/μl AMV reverse 
transcriptase and 0.5 μg/μl random primers in a total volume of 20 μl per 
reaction. The RNA samples were heated at 70
o
C for 10 minutes, briefly 
centrifuged and cooled on ice for 5 minutes. After the mastermix was added to 
RNA samples, they were incubated at 25
o
C for 10min, and then reverse 
transcription was performed at 42
o
C for 40 minutes followed by denaturation at 
90
o
C for 5 minutes and a cooling step at 4
o
C for 5 minutes.  
50 µl of cDNA samples containing the mastermix, 1x PCR Buffer, 0.2 mM 
dNTP mixture, 1.5 mM MgCl2, 0.2 µM each primer (sense and anti-sense), 1 unit 
of Platinum Taq DNA Polymerase, and DNase free water (all supplied by 
Invitrogen) were amplified with the following PCR conditions: Taq polymerase 
activation, 94
o
C for 10 min; thermal cycling, 94
o
C for 30 sec, annealing 
temperature (AT) for 30 sec, 72
o
C for 60 sec; followed by a final elongation step 
at 72
o
C for 10 min. The RT-PCR products were analysed and visualized on a 1.5% 
(w/v) agarose gel by ethidium bromide staining with ultra-violet light. The 
information of specific PCR conditions is indicated on Table 7 and 8. 
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Table 7. Primers for osteogenesis 
 
Table 8. Primers for pluripotency and cardiomyogenesis 
 
 
Genes Sequences Size (bp) AT (oC)
Collagen I (fwd) CGTGGCGACCAAGGTCCAGT (rvs) AGGGAGACCCAGAATACCGGGAG 165 58
Osterix (fwd) TTGAGGAAGAAGCTCACTATGGCTCCAG (rvs) GCTGAAAGGTCAGCGTATGGCT 142 58
Bglap1 (fwd) CAGCGGCCCTGAGTCTGACAAA (rvs) TCACAAGCAGGGTTAAGCTCACACTG 150 58
Runx2 (fwd) TCGTCAGCATCCTATCAGTTCCCA (rvs) CCATCAGCGTCAACACCATCATTCTGGTTAG 146 58
GAPDH (fwd) CATGGCCTTCCGTGTTCCTACCC(rvs) CCTCAGTGTAGCCCAAGATGCCCT 146 58
Genes Sequences Size (bp) AT (oC) Cycles
Nanog (fwd) CCT GAT TCT TCT ACC AGT CCCA(rvs) GGC CTG AGA GAA CAC AGT CC 123 58
Oct4 (fwd) GGC TTC AGA CTT CGC CTCC(rvs) AAC CTG AGG TCC ACA GTA TGC 211 58
Rex1 (fwd) CGT GTA ACA TAC ACC ATCCG(rvs) GAA ATC CTC TTC CAG AATGG 129 58 27 cycles 
FGF5 (fwd) AGT TTC CAG TGG AGC CCTTC(rvs) AAT TTG GCA CTT GCA TGGAG 236 58 27 cycles
Genes Sequences Size (bp) AT (oC) Cycles
GATA4 (fwd) CTC CTA CTC CAG CCC CTACC(rvs) GTG GCA TTG CTG GAG TTACC 571 58 30 cycles
Brachyury T (fwd) AA GGA ACC ACC GGT CATCG(rvs) CGT GTG CGT CAG TGG TGT GTA ATG 321 56 27 cycles
Flk-1 (fwd) CCT GGT CAA ACA GCT CATCA(rvs) AAG CGT CTG CCT CAA TCACT 599 55 30 cycles
Goosecoid (fwd) ATG CTG CCC TAC ATG AACGT(rvs) CAG TCC TGG GCC TGT ACATT 516 53 33 cycles
Nkx2.5 (fwd) AGCAACTTCGTGAACTTTG (rvs) CCGGTCCTAGTGTGGA 343 56
αMHC (fwd) ACCGTGGACTACAACAT(rvs) CTTTCGCTCGTTGGGA 286 56
βMHC (fwd) ACCCCTACGATTATGCG(rvs) GGTGACGTACTCGTTGCC 318 56
ANF
(fwd) GGGGGTAGGATTGACAGGAT
(rvs) CAGAGTGGGAGAGGCAAGAC 272 56
GAPDH (fwd) CATCACCATCTTCCAGGAGC(rvs) ATGCCAGTGAGCTTCCCGTC 500 56 27 cycles
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3.2.7. Quantitative PCR (qPCR)  
After extracting total RNAs from Qiagen kit, mastermix for qPCR 
containing 1X SensiMix One-Step and SYBR Green I solution, 0.2 µM of each 
pair of primers (sense and anti-sense), 2 mM of MgCl2, and 10 units of RNase 
inhibitor was prepared with 80 ng of RNA sample for each reaction based on the 
manufacturer’s instruction of SensiMix
TM
 One-Step Kit (Quantace, London, UK). 
Roughly collected quantitative gene expression data after PCR process were 
organized and relatively compared using the 2
-∆∆CT
 method (Livak and 
Schmittgen 2001). Briefly, ∆CT (delta threshold cycle number) value is 
determined by the difference between  CT (target gene) and CT (endogenous 
reference gene). Here, target genes are the genes for relative comparison and 
endogenous reference gene is glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). ∆∆CT value for each sample is determined by subtracting ∆CT value of 
the calibrator from the ∆CT value of the sample. The calibrator group of each 
comparison is indicated on the correspondent figure legend. To sum, each gene 
expression of the samples was normalised with GAPDH from the same sample, 
followed by a further normalisation with the correspondent gene expression in 
the calibrator group, which had been already normalised with its GAPDH. All the 
quantification was statistically analyzed (n=3). 
 
3.2.8. Alizarin red S (ARS) and sirius red staining 
Paraffin-embedded slides were prepared in the same way described in 
3.2.5. After deparaffinization and rehydration, the slides were immersed in a 40 
mM alizarin red S (Sigma-Aldrich) solution (pH 4.2) for 20 minutes at room 
temperature agitating gently. The solution was removed and then the slides 
were washed with flowing water. After dried, the slides were mounted with 10% 
(v/v) glycerol (Sigma-Aldrich) and observed on the microscope. For sirius red 
staining, the slides after deparaffinization and rehydration were stained with 0.1% 
(w/v) of sirius red (Direct Red 80, Sigma-Aldrich) in picric acid (Sigma-Aldrich) for 
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1 hour and washed twice with 0.5% (v/v) of acetic acid (Fisher Scientific, 
Leicestershire, UK). Most of water trace was physically removed before 
mounting process and observation. 
 
3.2.9. ARS-based quantification of bone mineralisation 
Mineralisation of ESC-based osteogenic constructs was quantified by the 
method developed by Gregory et al (Gregory et al. 2004), which is based on ARS 
assay, with some modifications. Twenty beads from each group on day 21 and 
29 were collected (n=3), dissolved in the depolymerization buffer, and 
centrifuged at 400g for 10 min. The cell pellets were immerged in 4% 
paraformaldehyde at room temperature for 20 min and washed with PBS 
followed through centrifugation in the same way above. 2 ml of 40 mM ARS (pH 
4.2, filtered) was added on the PBS-washed cells and incubated with shaking at 
RT for 20 min, followed by 3 times washing process with double distilled water. 
0.8 ml of 10% acetic acid was added to each sample which is subsequently 
incubated with shaking at room temperature for 30 min, followed by incubation 
at 85
o
C for 10 min and centrifugation at 20,000g for 15 min. The measurement 
with 150 µl of the each supernatant was done in 96 well plates at 405 nm using 
ELISA reader (Dynex technologies) after adding 200 µl of 10% (v/v) ammonium 
hydroxide. 
 
3.2.10. Analysis of medium profiles  
Culture media from all groups was collected during culturing time periods 
(n=3) and analysed by measuring glucose, glutamine, lactate, ammonia, 
glutamate, and pH using BioProfile Analyser 400 (Nova Biomedical, MA, USA). 
1.5 ml of culture media was collected directly from each culture vessel of 
bioreactor and petri-dishes. The media which has never used for culture was 
measured as a control and indicated in each plot by a dotted line. 
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Oxygen was measured (n=3) using Dissolved Oxygen Meter (Extech 
Instruments Co., MA, USA). Because oxygen tension in the samples could vary 
easily if they were collected in air, a specially designed socket was used. This 
socket links to a syringe and by suctioning, medium inside culture vessels can be 
collected to the oxygen sensor without the exposure to air. As a control, the 
media in the bottle was measured and also indicated in the plot by a dotted line. 
 
3.2.10. Attenuated total reflection Fourier transform infrared (ATR 
FTIR) analysis 
Attenuated total reflection Fourier transform infrared (ATR-FTIR) imaging 
was conducted using a continuous scan FTIR spectrometer (Varian 7000 FT-IR, 
Varian Inc. CA, USA) in conjunction to a large sample compartment extension 
(Varian LS) and a 64 x 64 focal plane array (FPA) detector. Further details about 
the ATR-FTIR imaging setup can be found elsewhere (Kazarian and Chan 2003). 
Sample beads were cut in half using a razor blade and placed onto the 
measuring surface of the ATR crystal (oil analyser, Specac Ltd., Kent, UK) with 
the cut surface in contact with the crystal. Excess water was removed and the 
sample was enclosed to prevent further evaporation, thus ensuring that the half 
bead remains hydrated during the measurement. Spectra were acquired with 8 
cm
-1
 spectral resolution with 32 co-adding scans. Under this condition, a 
measurement would typically require less than 1 minute to acquire. Five beads 
(n=2) were measured from each sample. Spectral data was analysed using the 
Isys software (Spectral Dimension, Malvern, Aus). Factor analysis was applied to 
the spectral region of 1200-965 cm
-1
 in a similar manner as described in other 
work (Zhang et al. 2007). All results were analysed simultaneously by 
concatenating all images together before applying factor analysis. Therefore 
direct comparison can be made between images. An image showing the 
distribution of the hydroxyapatite formed in the beads is extracted using factor 
analysis. From this image, a binary image is generated with a threshold of 10% 
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to outline the pixels that are considered to have detected hydroxyapatite. The 
relative amount of hydroxyapatite in each of the bead was compared by 
calculating the percentage area of the bead that was registered with the 
presence of hydroxyapatite. 
 
3.2.11. Mechanical strength testing 
A micro-deformation apparatus, developed in Dr. Williams’ earlier work 
(Andrei et al. 1996; Briscoe et al. 1998), was used to measure the force-
displacement characteristics of the alginate hydrogels that are compressed 
between two rigid parallel plates. The apparatus permits continuous and 
simultaneous measurements on the responsive force (measured with a 
cantilever transducer of 10 µΝ resolution) and the applied displacement 
(monitored by the computer with a resolution of 0.1 µm). The alginate 
hydrogels were subjected to a maximum deformation of up to 20%, and were 
continuously monitored by a high-resolution video camera during manipulation 
and deformation to ensure that the alginate hydrogels were not damaged. 
Deformation measurements were carried out immediately on the alginate 
hydrogels after harvest to minimise effects on the alginate hydrogel compliance 
due to swelling. At least, eight force-displacement measurements were taken 
for each type of alginate hydrogels (n=2), and all the experiments were 
conducted under ambient conditions (T = 20 ± 2
o
C). Young’s modulus of each 
sample was calculated based on the measurements, and the mechanical 
strength (as stiffness) was compared. 
 
3.2.12. Statistical analysis 
Samples for the quantitative analyses were measured in duplicate. Error 
bars on all graphs represent the standard deviation (SD) of the mean. Each 
comparable value from each group was statistically analysed with student t-test 
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or analysis of variance (ANOVA) for each proper case at a level of significance of 
p < 0.05 or p < 0.001 (single or double asterisks respectively). 
 
3.3. In vivo Testing of Bone-like Tissues from Bioreactor  
 
Most of the procedures related to the animal study including osteogenic 
graft surgery, X-ray micro-computed tomography, and histological evaluations 
were performed in collaboration with Dentistry department, Wonkwang 
University, Iksan, Korea. 
 
3.3.1. Animal care and preparation 
Adult New Zealand white rabbits (n=1 in each time interval, 4 animals 
total) approximately 3 kg in weight were used in this study. The public policy on 
use of animals for health science and animal welfare regulations provide the 
primary regulatory basis for the existence and function of the institutional 
animal care, which must be established at any institution which conducts 
animal-based research. In this study, all the animals were cared by following the 
criteria of the Animal Care Committee of Wonkwang University for the care and 
use of laboratory animals in research. 
 
3.3.2. Surgical protocol 
All the experiments of surgical procedures were performed in an aseptic 
condition according to the guidelines of the Animal Research Committee of 
Wonkwang University. Before surgery, intramuscular injection of 2.0 mg/kg 
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(body wight) of ketamine (Youhan Yanghang, Seoul, Korea) was undertaken 
followed by the general anesthesia procedure. Cranial area was shaved and 
then local anesthesia was induced with 1.8 ml of 2% (v/v) lidocane with 
1:100,000 epinephrine. For avoidance of infection, a povidone iodine solution 
and drape were introduced within the surgical area. As the central region was 
incised, the cranial bone was widely exposed, and four round-shaped holes 
(diameter: 8 mm, depth: 2-3 mm) were generated to make the standardised 
cranial defects. All the surgical procedures were very carefully undertaken in 
order to circumvent the defects that might be generated on the dura or 
midsagittal sinus.  
Bone-tissue like beads were generated from the newly developed 
perfusion RWV bioreactor system (demonstrated in Chapter 7). After 29 days of 
culture period, the osteogenic constructs were collected from the bioreactor, 
and immediately injected into the defects (about 10 beads per defect). Alginate 
beads without cells were also introduced as a negative control in the bone 
healing process. Fibrin glue was used to fix all the grafts. Periosteal 
approximation was undertaken with 4-0 nylon (Ethicon, Norderstedt, Germany) 
followed by dermal suture using 3-0 silk (Youhan Yanghang, Seoul, Korea). 
During the first three days, antibiotic treatment (3mg/kg (body weight) of 
Cefazedone, Sam Shin Chemical, Ansan, Korea) was applied through 
intramuscular for the prevention of infection. 
The rabbits were sacrificed using Urethane (Sigma-Aldrich) at 1 week, 2 
weeks, 8 weeks for the periodical observation of the restoring progress. The 
cranial vault and attached pericranium was carefully removed from each animal, 
and the gross inflammation on both the cranial and dural sides was visually 
examined using photography. 
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3.3.3. Micro-focus X-ray computed tomography (micro-CT) 
X-ray micro-computed tomography (micro-CT) is based on the general 
computerised axial tomography (CAT-scan or CT-scan) well-established in the 
medical field in conjunction with acquisition of three-dimensional structural 
information of an object. In this study, the images of the mineralised portions 
within the defects were periodically obtained by micro-CT scanning (Harmony 
130G-P3-5, DRGEM co., Seoul, Korea), set as 5 µm of focal spot size, 10.5 mm of 
field of view, reconstruction image size 2048 X 2048 pixels, 16 bit of depth of 
reconstruction image, and 130 kV of tube voltage. Three-dimensional structures 
of the defects at 8 weeks were reconstructed using Cone-beam volumetric 
reconstruction algorithm. 
 
3.3.4. Histological evaluations 
 
3.3.4.1. Preparation 
The cranial vault removed from a rabbit was immersed in 10% (w/v) 
formalin (Sigma-Aldrich) followed by the second fixation with 4% (w/v) 
paraformaldehyde (Sigma-Aldrich) for 72 hours. After washed with flowing 
water, the fixed tissue was incubated for 5 days within a mixed solution 
composed of 4% (w/v) HCl and 4% (w/v) formic acid (Sigma-Aldrich), and 
subsequently treated with 0.1% (w/v) NH4
+
 solution for 30 min followed by 
washing process using flowing water. The conventional paraffin embedding and 
slide-sectioning procedures were then followed as described in Chapter 3.2.5. 
Histological examinations were performed by conventional hematoxylin and 
eosin (H&E) staining. 
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3.3.4.2. Immunohistochemistry 
The sections obtained from paraffin embedding procedures were 
deparaffinised and rehydrated followed by antigen retrieval using the previous 
methodologies described in Chapter 3.2.5. The sections were then incubated at 
37
o
C for 1 hour within a mixed solution composed of 0.3% (v/v) Triton-X-100 
(BDH Laboratory Supplies) and 5% (v/v) blocking horse or goat serum (Santa 
Cruz Biotech) dissolved in PBS-based diluents containing 1% (w/v) BSA (Sigma-
Aldrich). The serum solution was removed and the samples were incubated with 
primary antibodies diluted in the diluents, such as type I collagen (Col1a, 1:200, 
Santa Cruz Biotech), insulin-like growth factor-1 (IGF1, 1:100, Santa Cruz 
Biotech), osteocalcin (OCL, 1:100, Santa Cruz Biotech) at 4
o
C overnight followed 
by PBS washes. The secondary antibodies such as biotinylated anti-rabbit IgG 
and biotinylated anti-mouse IgG (1:200, ABC Elite kit, Vector Laboratories) were 
treated at 37
o
C for 2 hours. After a PBS-wash, a solution of the avidin-biotin 
mixture (ABC complex, Vector Laboratories) was added, and the incubation in 
the same condition of the secondary antibody treatment was conducted, 
followed by three PBS washes. The colours were developed by peroxidase 
reaction after incubation with 3',3'-diaminobenzidine-4HCl (DAB, Sigma-Aldrich) 
for 3-5 min. All slides were mounted with Permount (Shandon, PA, USA) before 
microscopy observation (Leica). 
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Chapter 4. Use of HepG2-CM for 
Heart and Bone Tissue 
Engineering in a fed-batch 3D 
bioprocess 
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4.1. Introduction 
 
Within conventional suspension culture, ESCs can be induced to 
differentiate into EBs where three embryonic germ layers (ectoderm, mesoderm 
and endoderm) are formed. The sequence of lineage commitment events of 
ESCs closely mimics the in vivo development process, suggesting that the in vitro 
ESC-culture model follows developmentally established rules (Keller 1995b). 
Although it has offered enormous contribution to the advanced study of 
mammalian developmental processes, ESC-based technologies in regenerative 
medicine still confront limitations to obtain a homogeneous population of the 
desired lineage cells due to a lack of controllability of ESC-differentiation. 
Furthermore, EB suspension culture to differentiate ESCs also requires complex 
culture processes and experimenter intervention, involving three fragmented, 
laborious culture steps: pluripotency maintenance, EB formation, and specific 
lineage differentiation (Polak and Mantalaris 2008; Reubinoff et al. 2000; 
Thompson et al. 1989). The development of a novel bioprocess appears to be 
crucial to overcome the shortcomings of the current ESC-tissue engineering 
methodology. 
In the development process in vivo, primitive ectoderm is lined over the 
distal visceral endoderm layer prior to the stage of epiblasts. The two layers 
have a vigorous biochemical signaling exchange that lead to a subsequent 
gastrulation stage where all the germ layers are eventually formed (Tam and 
Loebel 2007). Mummery’s group presented that the use of co-culture or 
conditioned medium treatment using a visceral endoderm-like cell line (END-2) 
contributed to the efficient formation of cardiomyogenic precursor cells from 
ESCs following the role of visceral endoderm in the adjacent mesoderm as it 
occurs in vivo (Filipczyk et al. 2007; Mummery et al. 2002a; Mummery et al. 
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2003). It has been reported that liver cell lines show similarities with the pre-
gastrulation embryo or visceral endoderm-like cell lines in terms of biochemical 
signals (Rathjen and Rathjen 2001; Rodda et al. 2002). Rathjen et al. reported 
that a conditioned medium derived from culturing human hepatocarcinoma cell 
line, HepG2, caused the transition of ESCs to a novel cell population in vitro 
considered as the second pluripotent stage (Rathjen et al. 1999). Those cells 
showed correspondent behaviour with early primitive ectoderm in vivo (Rathjen 
and Rathjen 2001). Interestingly, initial treatment of HepG2-conditioned 
medium (HepG2-CM) to ESCs resulted in the selective formation of multipotent 
mesodermal progenitors whilst EBs were formed in suspension culture (Rodda 
et al. 2002). This finding demonstrates the feasibility of controllable ESC 
differentiation programmed in a lineage-specific fashion possibly followed by 
the effective skeletal differentiation. With respect to this background, our group 
has previously reported that mESCs, initially treated with HepG2-CM, were 
effectively approaching skeletal lineages through the specific enhancement of 
mesodermal formation, such as osteogenic, chondrogenic and also 
cardiomyogenic differentiation depending on different EB formation periods 
(Hwang et al. 2006). 
Three-dimensional culture systems within a suspended and controlled 
environment using bioreactors offer attractive advantages of scalability and 
relative simplicity that can improve the viability and promote turnover of 
specific stages and types of stem cells (Zandstra and Nagy 2001). More natural 
three-dimensional settings promise to be closer to what really occurs in vivo, 
whereas a conventional two-dimensional culture may alter cellular behaviours 
due to the disruption of natural interactions between ECMs and cells (Abbott 
2003; Yamada and Clark 2002). Recently, it has also been documented that the 
use of bioreactors for hESC-culture provides an advantageous three-
dimensional environment in various manners leading to obtaining the higher 
productivity (Gerecht-Nir et al. 2004). Alginate encapsulation has been 
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frequently studied as a biodegradable delivery vehicle which is adaptable to 
three-dimensional culture systems for the application to tissue engineering. It 
has been reported that the incorporation of gelatin with alginate can help the 
structure of cell/hydrogel hybrids to keep mechanical stability after prolonged 
culture (Balakrishnan and Jayakrishnan 2005). Magyar et al. formed discoid 
colonies and cystic EBs from mESCs encapsulated in hydrogel, and 
demonstrated that alginate encapsulation provides ESCs with adequate three-
dimensional residential space to grow up like in vivo (Magyar et al. 2001). Our 
group has also previously developed a simplified, integrated, and reproducible 
bioprocess for three-dimensional osteogenesis from ESCs using encapsulation 
with alginate/gelatin hydrogel and rotating wall vessel (RWV) bioreactor system 
(HARV, Cellon, Bereldange, Luxembourg) (Randle et al. 2007). 
 
4.1.1. Aims 
The aims of this chapter are: 1) to establish the three-dimensional 
bioprocess in a fed-batch type RWV bioreactor using HepG2-CM to initiate the 
early enhancement of mesodermal development, and 2) to optimise the 
selective production of cardiomyogenic or osteogenic tissue-like structures by 
controlling the spontaneous differentiation periods. 
 
4.1.2. Experimental plan 
HepG2-CM was applied to mESCs encapsulated in alginate hydrogels 
followed by various spontaneous differentiation periods before triggering 
terminal differentiation towards cardiomyogenic or osteogenic lineage. As 
shown in Figure 24, all cultures were performed in the fed-batch type of RWV 
bioreactor (HARV). 
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Figure 24. 3D-integrated bioprocess with the use of HepG2-CM. 
Figure 25 shows the experimental time schedules and group 
organisations including control groups (also shown in Table 2, 3). 
 
Figure 25. Experimental time schedules and group organisation. 
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4.2. Enhanced 3D-cardiomyogenic Tissue Formation from 
ESCs using Conditioned Medium Treatment with the 
Optimised Spontaneous Differentiation Period 
 
4.2.1. Characterisation of mESCs in hydrogel following HepG2-CM 
treatment 
Encapsulated mESCs were cultured in normal growth medium (NM) or 
HepG2-CM for the first three days, and then the culture medium was changed 
to EB formation media for the following 18 days in order to characterise the 
behaviour of mESCs spontaneously differentiating in the hydrogel. Both ESC-EB 
and cm-EB groups on day 1 (Figure 26A,E) were likely to show single cell 
suspension well distributed in the hydrogel. The cellular colonies appeared to 
become bigger over time, although the size of cellular colonies in the group of 
cm-EB was likely to be larger than that in the group of ESC-EB on the same day 
(Fig. 26C,D,G,H). 
 
Figure 26. mESCs in the alginate hydrogel observed under the light microscope 
observation. 
ESC-EB (A)-(D), and cm-EB (E)-(H) on day 1, day 3, day 8, and day 11 
each. The scale bars represent 300 µm. 
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The growth kinetics of mESCs (Figure 27A) showed that cm-EB had 
significantly higher cell numbers than ESC-EB from day 3. Alkaline phosphatase 
(ALPase) activities in both group (Figure 27B) decreased after day 3 as they 
moved into the differentiation phase in the absence of LIF. The group of cm-EB 
on day 8 showed a significantly lower ALPase level, possibly indicating faster 
initial differentiation of HepG2-CM treated group in the early development 
procedure. 
 
 
Figure 27. Comparisons of growth kinetics (A), and Alkaline phosphatase 
(ALPase) activity (B). Statistical analyses were performed by a 
student t-test (n=3). Asterisks indicate p < 0.05. 
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Various gene expressions in ESC-EB and cm-EB during the period of 
spontaneous differentiation (up to day 13) were investigated as shown in Figure 
28. Rex1 expression as a marker of pluripotency decreased over time in both 
groups. It was found in cm-EB group that HepG2-CM initiated mESCs to regularly 
express FGF5 for the next stage of developmental process. GATA4 also showed 
stronger expression in cm-EB at earlier time, suggesting that it would possess a 
higher potential to be driven to cardiomyogenic lineage differentiation. The 
evidence of enhanced mesodermal development by HepG2-CM was also 
suggested by the expressions of Brachyury T, Flk-1, and Goosecoid in the group 
of cm-EB which were stronger and earlier than those of ESC-EB group. 
 
 
Figure 28. Gene expression characterisation in the early developmental 
process in vitro. 
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4.2.2. Comparisons of 3D-cardiomyogenic tissue generation 
In order to induce cardiomyogenic differentiation, 100 µM L-ascorbate 
was supplemented in the EB medium after the spontaneous differentiation 
period of each experimental group. Quantitative PCR data of the control group 
with various cardiomyogenic marker genes (Table 9) shows the general progress 
of cardiomyogenic differentiation progress in the three-dimensional hydrogel 
without the introduction of HepG2-CM. Each gene expression on day 15 and 21 
was normalised by the correspondent gene expression on day 11. Expression of 
the cardiomyogenic genes increased over the culture time. Some genes, such as 
alpha-myosin heavy chain (αMHC), atrial natriuretic factor (ANF), showed the 
consistent tendency to keep increasing until the end of the culture, whereas the 
others (Nkx2.5, beta-myosin heavy chain (βMHC)) did not show significantly 
different expressions after day 15 but more highly expressed than day 11. 
 
Table 9. Cardiomyogenic differentiation progress of the control group 
(All values were presented after being normalised by the control group on D11. 
Statistical analyses were performed by a student t-test (n=3)). 
 
On the other hand, HepG2-CM treated groups, such as cm-EB, cm0D, 
cm5D, and cm7D, generally showed significantly different cardiomyogenic gene 
expressions from ESC-EB and a control (Figure 29). In all comparisons of gene 
expression, the control group was used as a calibrator indicated at level 1 on 
each graph. In the early differentiation period, day 11 (Figure 29A), cm0D 
showed high expression in most of the genes even though some of them were 
Nkx2.5 αMHC βMHC ANF
D15
D21
47.02 ± 0.7
42.69 ± 15.7
45415 ± 2225
76688 ± 16411
1778 ± 95.8
1610 ± 243.8
2.45 ± 0.48
5.21 ± 0.74
significance 
(p < 0.05) x o x o
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not significantly higher than the others. Through the following cardiomyogenic 
culture period up to day 21 (Figure 29B,C), the highest cardiomyogenic gene 
expressions were found in cm5D group. In particular, cm5D showed higher gene 
expressions in αMHC, βMHC, and ANF from day 15. The early evidence of 
cardiomyogenesis, the expression of Nkx2.5, however, did not show its 
significant difference in HepG2-CM treated groups from day 15. 
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Figure 29. Relative quantification of the cardiomyogenic gene expressions in 
the groups on day 11 (A), day 15 (B), day 21 (C). 
Every group was normalised by Control group (represented as level 
1 in all graphs), and relatively compared each other based on the 2-
∆∆CT
 method. Statistical analyses were performed by one-way 
ANOVA (n=3). Asterisks indicate p < 0.05. 
 
4.2.3. Cell viability and morphology study in 3D-cardiomyogenesis 
In order for the evaluation of cell viability in the hydrogels, Live/Dead 
assay was undertaken on the last day of the culture, day 21. Generally, most of 
the cells were viable in every group (Figure 30). Difference in the morphology of 
cellular colonies, however, was observed between HepG2-CM treated groups 
(Figure 30B,C,E,F), ESC-EB and a control (Figure 30A,D), although cells were well 
agglomerated as tissue-like constructs. It was found in the groups HepG2-CM 
was applied that the cellular networks between colonies seemed to be well 
connected and organised through the whole area of bead. However, individual 
large cellular colonies were scattered in the hydrogel in ESC-EB and the control 
group. 
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Figure 30. Live (green) and Dead (red) assay (A)-(F), and the investigation 
of cellular colony morphologies (a-f) on day 21. 
ESC-EB (A,a), cm-EB (B,b), cm0D (C,c), Control (D,d), cm5D (E,e), and 
cm7D (F,f). The scale bars represent 200 µm. 
 
4.2.4. Immunocytochemistry and beating cellular colonies 
Immunocytochemistry was performed representatively with cm5D group 
for further confirmation of cardiomyogenesis on day 21. Anti-tropomyosin 
(Figure 31b) and anti-sarcomeric α-actinin (Figure 31d) were used as common 
cardiomyogenic differentiation markers and Connexin 43 (Figure 31c) was also 
dual-stained with tropomyosin in order to show well-connected 
electrophysiological networks between cells of the cardiomyogenic colonies in 
the hydrogel (Figure 31A), as well-networked cellular colonies were shown in 
the morphological observation (Figure 30). Beating cellular colonies in the 
cardiac-tissue like structures were also captured in the hydrogel of cm5D (Fig. 
31C), whereas never shown in the other groups (from the observation of 50-70 
beads for each group), supporting the other results in this study. 
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Figure 31. Immunocytochemistry of 
cm5D group. 
Anti-tropomyosin (b) and anti-connexin 
43 (c) were dual-stained with FITC and 
Texas Red respectively (A), and anti-
sarcomeric α-actinin was separately 
stained with FITC (B,d). Nuclei of the 
cells were indicated with DAPI (blue) (a, 
e, f-1, g-1). Negative controls for FITC (f-
2) and Texas Red (g-2) were performed. 
Beating cellular colonies in the hydrogel of cm5D group were filmed and 
captured (C). The dashed circle indicates a strong beating site in the cellular 
colonies. The scale bars for immunostaining and movie-capture represent 
20 µm and 200 µm respectively. 
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Figure 33. The investigation of the cellular colony morphologies and 
Live/Dead assay on day 18. 
Morphologies: control (A) cm0D (C), cm5D (E), and cm7D (G). Live 
(green, a) and dead (red, b) assays: control (B), cm0D (D), cm5D (F), 
and cm7D (H). The scale bars represent 200 µm. 
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4.3.2. Three-dimensional osteogenesis of control group 
Figure 34 shows the general osteogenesis results on day 29 of the control 
group cultured without HepG2-CM application. In terms of 
immunocytochemistry, positive staining with OB-Cadherin antibodies was 
successfully shown (Figure 34A). Every hydrogels containing osteogenic cells 
became whitened and appeared to be physically brittle in contrast to the initial 
alginate gel property (Figure 34B). Furthermore calcified components and 
widely spread collagen distribution in the osteogenic beads were also shown by 
ARS and sirius red staining respectively (Figure 34C,D). 
 
Figure 34. Osteogenesis from the control group on day 29. 
Immunocytochemistry of OB-cadherin (FITC) along with DAPI (blue) 
(A) (DAPI (a-1) and negative control of FITC (a-2)), a photo of bone-
tissue like constructs (B), and alizarin red S (ARS) (C) and sirus red (D) 
staining. The scale bars represent 100 µm (A, a-1, a-2), 3 mm (B), 
and 400 µm (C), (D) respectively. 
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4.3.3. Mineralisation assessment of experimental groups 
Having general osteogenesis results from the control group, the 
quantitative comparisons among all groups were undertaken by ARS-based 
quantification, ALPase activity analysis, qPCR with various osteogenic genes, and 
ATR-FTIR spectroscopy. The group of cm0D showed the best results in terms of 
cumulative calcified proportions in the osteogenic beads (Figure 35A). The cm0D 
has already shown a significantly higher outcome on day 21, and reached about 
five-fold higher accumulation of calcified deposit than the control on day 29. 
The group of cm5D also showed significantly higher accumulation than the 
control, but it was still significantly lower than cm0D. During bone development, 
ALPase activity increases at the onset of osteogenesis and decreases when 
calcification and mineralisation occur. In this study, ALPase activity analyses 
indirectly show the progress of osteogenic differentiation and mineralisation of 
every group (Figure 35B). In the control group, an increase of ALPase activity 
was shown on day 15 and its level was maintained without significant 
differences till the end of culture. Similar behaviour with the control was 
observed in cm5D. However, the level on day 29 was not significantly different 
from that on day 10, suggesting its decreasing tendency from day 15. The level 
of ALPase activity in cm0D have already reached a significantly higher level on 
day 10 than the other groups (indicated by a hash mark), and significantly lower 
levels were shown from day 21 to the end of culture. The cm7D group showed 
the late peak of ALPase activity on day 21 and rapid reduction on day 29. These 
ALPase activity trends of all groups were correspondently matched with the 
cumulative mineralisation results shown in ARS quantification. The gene 
expression of collagen type I which is one of the representative components in 
bone tissues was presented by normalisation with the values from the control 
group on the correspondent time course (a dashed line on level 1 in the graph 
indicates the control group) (Figure 35C). cm0D also showed significantly higher 
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gene expression of collagen type I at the earlier time of osteogenesis on day 15. 
Compared to the control, all the HepG2-CM treated groups showed much 
higher gene expression during the culture period. Spectra from FTIR confirmed 
that the comparison of mineralisation in this study was based on the true 
calcified hydroxyapatite components (Figure 35D). They were characterised by 
the specific spectral band at 1026 cm
-1
 which is comparable with pure 
hydroxyapatite and human bone as previously reported (Karp et al. 2006; 
Rehman and Bonfield 1997). 
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Figure 35. Mineralisation comparisons. 
 Quantitative ARS-based mineralisation assay (A). Alkaline 
phosphatase (ALPase) activity analyses (B). Relative quantification 
of type I collagen gene expression (C). Every group was normalised 
by the control group on each day (indicated by the dashed line in 
the graph), and relatively compared each other based on the 2-∆∆CT
 
method. FTIR spectra of PO4 (at between 1026 and 1035 cm
-1
) of 
all groups (D). All the statistical analyses were performed by one-
way ANOVA (n=3). The significant differences by time are 
indicated by dual (p < 0.001) or single asterisk (p < 0.05). The 
difference between all groups on day 10 in (B) was indicated by a 
hash mark at p < 0.05. 
*
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4.4. Discussion 
 
In the mouse development process in vivo, at about 4.5 days post coitum, 
inner cell mass in the blastocyst experiences very complicated developmental 
program closely in contact with visceral endoderm layer. This phase leads to the 
formation of the primitive ectoderm prior to epiblast stage, where rapid cell 
proliferation occurs before the gastrulation process (Pelton et al. 2002; Snow 
and Bennett 1978). Correspondently with in vivo situation, cells in cm-EB 
affected by initial visceral endodermal signals from HepG2-CM were expanded 
faster compared to ESC-EB. This cell growth tendency was also similarly 
reported on two-dimensional culture (Hwang et al. 2006). With regard to this 
faster proliferation ability of cm-EB in the early period of culture, it was able to 
be expected that triggering differentiation would be more effectively regulated, 
in that cell to cell contact is one of the crucial factors to derive pluripotent stem 
cells to the next advanced stage (Smith 1992). Alkaline phosphatase activity 
analysis and Rex1 and FGF5 gene expression data also showed that mESCs of 
cm-EB were driven to turn into the intermediate pluripotent stage by HepG2-
CM to be effectively followed by specific lineage differentiation, and the 
previous two-dimensional studies also reported this behaviour of mESCs 
(Hwang et al. 2006; Pelton et al. 2002; Rathjen et al. 1999; Rathjen and Rathjen 
2001; Rodda et al. 2002).  
Much stronger GATA4 expression in cm-EB than in ESC-EB is also one of 
the interesting findings in this study. GATA4 is well known as an early marker of 
cardiomyogenesis in the mammalian developmental process together with 
Nkx2.5 and the other parietal endoderm markers such as SPARC and S100A4 
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(Brewer et al. 2005; Grepin et al. 1997; Stary et al. 2005; Stary et al. 2006). In 
many previous works, GATA4 and Nkx2.5 genes were strongly expressed in the 
early stage after introducing visceral endodermal signals to ESC-culture using 
HepG2 or END-2 cell line, resulting in the effective cardiomyogenesis (Filipczyk 
et al. 2007; Rathjen et al. 1999; Rathjen and Rathjen 2001). Moreover, Lake et al. 
previously reported that while EBs were formed after HepG2-CM treatment, 
SPARC was heavily localized to an outer endodermal cell layer with very few 
alpha fetoprotein (AFP) traces (visceral endoderm indication), followed by high 
beating muscle generation (Lake et al. 2000). With agreement to the previous 
studies, HepG2-CM treatment in our three-dimensional culture also derived 
ESCs to cardiomyogenic lineage more effectively than control group with their 
early expressions of GATA4 and Nkx2.5. 
In vivo, after the stage of epiblast which has been severely influenced by 
visceral endodermal signaling, the future mesodermal lineage fraction tends to 
get farther from the epithelial monolayer and traverse the primitive streak 
along the posteriodistal axis of the embryo, an area of localized ECM breakdown 
(Ciruna et al. 1997; Ciruna and Rossant 2001). Rodda et al. reported that mESCs 
differentiated to primitive ectoderm-like cells by HepG2-CM, and then EB-
differentiation progressed in the absence of visceral endoderm when cultured in 
EB formation medium. This environment would situate a loss of contact 
between cell and epithelial layer or ECM, which is similar with in vivo situation 
when the potential mesodermal fraction starts migrating from posterior epiblast. 
This speculation can well link to the selective mesoderm formation in the EBs 
derived from HepG2-CM treated mESCs (Rodda et al. 2002). On the other hand, 
Lake et al. has also showed an interesting finding that EBs which were formed 
not in EB formation medium but consecutively in HepG2-CM were predisposed 
115 
 
to enhanced ectodermal lineage portion (Lake et al. 2000). These findings 
suggested an efficient method to control lineage-specific differentiation 
introducing HepG2-CM to ESC-culture. In this study, the enhanced expression of 
mesodermal development markers in cm-EB is correspondent with the previous 
findings above, and this selective mesodermal development in our three-
dimensional culture can have an easy link to the specific skeletal tissue 
construction including cardiac tissues, which also agreed with the results of our 
previous works (Hwang et al. 2008a, b). 
Our qPCR data of control group showed that L-ascorbate supplement 
contributed on cardiomyogenesis more effectively than ESC-EB cultured without 
L-ascorbate. This result was correspondent with previous two-dimensional 
study (Takahashi et al. 2003b), not only in the increasing expression of all the 
cardiomyogenic genes by culturing time but also in the tendency of gene 
expression. However, control group still holds shortcomings to form a specific 
functional cardiac tissue in vitro, because the cellular colonies would consist of 
arbitrary cell population from all the embryonic germ layers.  
It has been reported that the selective terminal osteogenic or 
cardiomyogenic differentiation could be effectively controlled by varying EB 
formation period after HepG2-CM treatment on mESCs (Hwang et al. 2006). 
Briefly, increasing EB formation period up to 5 days resulted in more beating 
colonies, whereas osteogenic differentiation was enhanced in the shorter 
period of EB formation. This study suggested that 5 days of EB formation period 
after HepG2-CM treatment corresponds with the time long enough to trigger 
mesoderm formation; so that once mesoderm starts dominating the EB 
constructs as a main component, osteogenic differentiation might be 
suppressed by spontaneous cardiomyogenic differentiation. 
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In Chapter 4.2, the relative comparison of the gene expressions from 
qPCR showed that most of the cardiomyogenic genes were highly expressed in 
HepG2-CM treated groups. With regard to this fact, it could be speculated that 
the early differentiation of HepG2-CM treated mESCs to the next stage of 
development continued to affect specific cardiomyogenic differentiation. As 
reported from many references about cardiomyogenesis (Ameen et al. 2008; 
Arai et al. 1997; Brewer et al. 2005; Hofner et al. 2007), Nkx2.5 expression was 
relatively more dominating over the other cardiomyogenic gene expressions in 
the early differentiation stage on day 11 than it was on day 15 and day 21. In 
terms of αMHC, βMHC, and ANF on day 11, cm0D showed its superior level of 
expression, reason being that 5 or 7 days earlier treatment of cardiomyogenic 
medium in cm0D physically resulted in the faster commencement of specific 
lineage differentiation. However, the specific differentiation in cm5D was more 
effectively accelerated from day 15 representing significantly higher expression 
of cardiomyogenic genes. Furthermore, the results from cm5D can be also 
compared to the ones from cm7D cultured in EB medium for 7 days, regarding 
the optimised timing to trigger cardiomyogenesis. However, the specific 
differentiation in the cm5D group was effectively accelerated from day 15 
showing significantly higher expression of cardiomyogenic genes. The 
development process of heart-relevant tissues commences from distinct 
mesodermal populations at different times.(Cai et al. 2003; Kelly et al. 2001; 
Mjaatvedt et al. 2001) It was reported that the developmental stage in which 
both Brachyury-T and Flk-1 are expressed can be specified as the onset of 
embryonic blood cell development.(Huber et al. 2004; Kattman et al. 2006; 
Kouskoff et al. 2005) Vascular component formation subsequently occurs as the 
progeny for cardiomyogenic development whilst Brachyury-T expression 
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diminishes.(Kattman et al. 2006) In our study, cardiomyogenic differentiation in 
the cm5D group was triggered when GATA4 was expressed but mesodermal 
marker genes were about to be initiated, whereas the cm7D group experienced 
the strong expression of both Flk-1 and Brachyury-T before triggering 
cardiomyogeneic differentiation. It was speculated in this study that the cm5D 
group was driven to cardiomyogenesis without the interruption of the blood 
formation progress when mesodermal differentiation was initiated, whilst cells 
in the cm7D group may have experienced the developmental competition 
between hematopoietic and cardiomyogenic developments. As verified in the 
cardiomyogenic gene expression comparisons and beating cellular colony 
observation on day 21, the optimal cardiomyogenesis in our study comes to the 
time course of the cm5D group. 
General osteogenesis from mESCs was also successfully performed in our 
three-dimensional bioprocess following the popular protocol for osteogenesis 
using L-ascorbate, β-glycerophosphate, and dexamethasone supplements as 
previously reported (Randle et al. 2007). Nonetheless, the previous osteogenic 
products from ESCs still require to be improved in terms of the productivity and 
purity of targeted differentiation such as the effective cardiomyogenesis from 
control shown in Chapter 4.2. Three-dimensional osteogenesis study in Chapter 
4.3 showed that the initial introduction of HepG2-CM to mESCs generally 
resulted in more generation of bone-relevant ECM and higher expression of 
osteogenic genes than control. As shown in cardiomyogenesis study, it is also 
speculated that the faster rate of proliferation in HepG2-CM treated groups 
resulted in well-organized contact between cells, followed by well-regulated 
promotion to the next advanced stage in the earlier differentiation period than 
control (Smith 1992). Furthermore, HepG2-CM treated mESCs were 
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subsequently guided to the selective formation of mesodermal progenitors, so 
that skeletal tissue construction was ready to be derived. However, longer 
spontaneous differentiation period after HepG2-CM treatment resulted in the 
evidence of early cardiomyogenesis such as GATA 4 and Nkx2.5 expression, as 
demonstrated in Chapter 4.2 and also correspondent with the previous two-
dimensional cultures which suggested that a long EB formation period up to 5 
days resulted in more beating colonies, whereas osteogenic differentiation was 
enhanced after the shorter periods of EB formation such as 1 and 3 days (Hwang 
et al. 2006). Although all the groups from HepG2-CM treatment generally 
showed similar levels of osteogenic gene expressions from day 21 onward, this 
potential competition between cardiomyogenesis and osteogenesis in cm5D 
and cm7D would come to strikingly heterogeneous cellular complexes in the 
hydrogels. Meanwhile, a particular group, cm0D, in which mESCs were 
stimulated directly in osteogenic medium without the spontaneous 
differentiation phase, showed the highest proportion of cumulative mineralised 
deposit among all groups. It was reported that co-expression of ALPase and type 
I collagen has the synergetic effect on bone matrix formation (Murshed et al. 
2005). This result agrees with our ALPase activity on day 10 and 15, and type I 
collagen gene expression on day 15, showing the clues of the earliest activation 
of mineralisation in cm0D group. 
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4.5. Conclusions 
 
The encapsulation of alginate hydrogel used in this study would link to 
the applicable injectable manipulation of tissue-engineered constructs in the 
clinical procedure. This study demonstrated that encapsulated mESCs were 
controllably derived to cardiomyogenic or osteogenic tissues through selective 
mesodermal lineage development using HepG2-CM, which can be a guide line 
for the development of the three-dimensional bioprocess to improve quality, 
productivity and reproducibility of skeletal tissue generation. However, it is still 
an imperfect culturing system due to the shortcomings from the use of fed-
batch bioreactors such as a lack of control in the maintenance of desirable 
culture environments, although the a RWV bioreactor used in this study offered 
a three-dimensionally well-mixed condition to form tissue-like structures. From 
the next chapter, the development processes of a novel perfusion bioreactor 
system will be introduced in order to improve the efficacy in engineering 
skeletal tissues under our established three-dimensional bioprocess. 
 
 
 
 
 
 
 
 
 
 
120 
 
 
 
 
 
 
 
 
 
 
Chapter 5. Design and fabrication 
of a Perfusion Rotating Wall 
Vessel Bioreactor System 
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5.1. Introduction 
 
Mixing of culture media via convective flow has been proven to improve 
cellular and bio-molecular composition in three-dimensional cell-based 
constructs by enhancing mass transport of oxygen, nutrients, and metabolites. 
Stirred bioreactors or spinner flasks have been commonly used in tissue 
engineering, and achieved a certain degree of success (Cameron et al. 2006; Fok 
and Zandstra 2005; Kehoe et al. 2008; Niebruegge et al. 2008a; Niebruegge et al. 
2008c; Schroeder et al. 2005). However, the general disadvantages of the simple 
impeller system design still remain, such as its disruptive effect to cells/tissues 
and unpredictable operation conditions from the generation of turbulence by 
shear forces (in the range of 2-40 dyne/cm
2
 depending on the design of the 
impeller and/or rotational speed) (Dang et al. 2004b; Dang et al. 2002; Placzek 
et al. 2009; Wang et al. 2006b). 
The rotating wall vessel (RWV) bioreactor system was developed by 
National Aeronautics and Space Administration (NASA) in the US to physically 
simulate the gravity-free environment of outer space. Theoretically, the rotating 
vessel provides the compromise between the simultaneous gravitational, 
buoyant, centrifugal, Coriolis, and drag forces on constant free-fall, resulting in a 
nearly steady condition under very low shear force (less than 1 dyne/cm
2
). 
Initially, the behaviour of mammalian cells within this environment were 
investigated in order to predict the health conditions of astronauts in space. 
Nowadays, tissue engineers adopted this technology to overcome the 
limitations from using the impeller type of bioreactor. This unique environment 
could have many beneficial effects on the three-dimensional tissue growth and 
heightened level of cell differentiation by minimising the unexpected errors 
from the generation of turbulence which can influence biological responses. 
Additionally, the nutrients in the medium can be deeply guided into the three-
dimensional tissues by the inertia of Coriolis force resulting in the high mass 
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transport in conjunction with the efficient mixing. It has been shown in many 
studies that using a RWV bioreactor, large three-dimensional constructs or 
construct-explant composites could be stably suspended within the culture 
medium, whilst experiencing an efficient mixing predominately under the 
laminar flow condition (Freed and Vunjaknovakovic 1995; Gerecht-Nir et al. 
2004; Hwang et al. 2009; Lu et al. 2008; Randle et al. 2007). 
Oxygen tension in the range of 0-30 mmHg (about 0-5%), i.e. hypoxia, has 
been reported to exhibit improved yield of inner cell mass cells during in vitro 
culture of bovine blastocysts (Harvey et al. 2004). Similarly, research has shown 
that ESCs grow more efficiently under a hypoxic environment with high 
pluripotency, as opposed to ambient air (142 mmHg of pO2, (about 20%), i.e. 
normoxia) (Bauwens et al. 2005; Ezashi et al. 2006; Gibbons et al. 2006; 
Niebruegge et al. 2008a; Powers et al. 2008b; Prasad et al. 2009; Simon and 
Keith 2008; Wang et al. 2006a; Westfall et al. 2008). In order for further study, 
O2-sensitive pathways such as hypoxia-inducible transcription factors (HIF)-
dependent pathways were investigated in ESC-culture, and it was verified that 
hypoxia results in the activation of Notch and Oct4 which are involved in the 
maintenance of ESCs (Simon and Keith 2008). However, because HIF responds in 
a transient way, the sudden exposure to a hypoxic environment could harm the 
growth of ESCs by inducing apoptosis before the promotion of expansion 
through the pathways. Therefore, it has been suggested that controlling only 
the oxygen tension might not be sufficient to improve the general efficacy in 
ESC-cultures (Cameron et al. 2008). 
With regards to differentiation, it has been reported that physiological 
oxygen gradients (i.e., hypoxia) also profoundly influence the precursors of bone 
formation, such as the generation of cartilaginous primordial limb bud 
mesenchyme and chondrogenesis (Provot et al. 2007). It was found in 
chondrogenesis from hESCs that hypoxia enhanced the synthesis of various 
proteins that are relevant to chondrogenic progress in development (Koay and 
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Athanasiou 2008). However, Kurosawa et al. reported the different aspect of 
the response of ESC-differentiation upon the variances of oxygen tensions, 
claiming that culture conditions under high oxygen tension (40% oxygen) retard 
the differentiation of ESCs whilst normal oxygen tension conditions (20% oxygen) 
trigger spontaneous cell differentiation (Kurosawa et al. 2006). 
It is yet unlikely that the cumulative information of the effects of oxygen 
tension in ESC-cultures can suggest the optimal conditions to promote 
expansion and differentiation due to the controversy aroused from the 
inconclusive previous results. However, the control of oxygen tension is still a 
requirement since ESCs are affected by their niche in which oxygen tension 
certainly plays a role. Therefore, the design feature of our perfusion bioreactor 
has been conceptualised to be capable of allowing an immediate equilibrium of 
the oxygen tension between the culture vessel and a variable gaseous 
environment. 
Most bioreactor systems that currently have been used in the field of 
tissue engineering are a fed-batch type because of the simplicity in application. 
However, this system lacks control of the parameters in culture medium such as 
nutrients, metabolites, and oxygen etc., and has limitations in the maintenance 
of the cell-secreted beneficial factors with unavoidable metabolic waste 
accumulation which can be toxic for cells at inhibitory level (Abranches et al. 
2007). Furthermore, cells in a batch bioreactor can be affected by high stress 
from the abrupt change of the culture environment which can occur during 
exchange of medium. As cells grow over the culture time, the degree of stress 
for cells can become higher due to increasing rates of nutrient and oxygen 
consumption, and metabolite accumulation in a batch (Figure 37). Many studies 
have shown that perfusion culture systems enable 1) controlling and monitoring 
of the medium supplementation in real time, 2) prevent metabolic waste 
accumulation, 3) eliminate the potential stress caused by medium-exchange, 4) 
reduce the major dilution of cell-secretion, facilitating the stable maintenance 
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of a desirable environment that benefits both expanding and differentiating 
cells (Bauwens et al. 2005). Medium perfusion in a culture system is thus 
considered an essential feature in the future design of any bioprocess. 
 
Figure 37. Need for perfusion culture system. 
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5.1.1. Aims 
This chapter aims at the development of a novel perfusion RWV 
bioreactor in order to overcome limitations arising from the fed-batch type of 
bioreactor and improve the efficiency of in vitro tissue culture. 
 
5.1.2. Experimental plans 
This chapter contains the description of conceptual design of culture 
vessel, calculations to optimise the dimensions of culture vessel, simulations to 
evaluate oxygenation efficiency, and assembly process of each part of 
bioreactor. Briefly, Fick’s second law was used to determine the optimal 
dimensions of culture vessel based on oxygenation efficiency. Subsequently, an 
oxygenator was developed and combined to the bioreactor. The benefit of dual 
oxygenation was simulated by Computational Fluid Dynamics (CFD) software. 
Other necessary parts for the perfusion RWV bioreactor system were selected 
and organised in a base plate including a servo motor to rotate vessels, 
peristaltic pumps to perfuse culture medium, and a computer system. 
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5.2. Design of Vessel and Perfusion System 
 
5.2.1. Conceptual design of vessel for the effective oxygen supply 
A bioreactor with the effective gas-exchange can introduce different 
oxygen tensions to ESC-culture depending on the need and purpose of the 
experiment by simply changing external gas condition in an incubator. The 
perfusion bioreactor presented herein incorporates a simple but effective 
feature that enables the direct gas-exchange through a gas-permeable outer 
membrane that covers the culture vessel, hence avoiding the need for external 
gas cylinders individually connected to the culture vessel. Fick’s second law was 
used to determine the optimal dimensions of the cell culture vessel. It estimates 
how quickly oxygen can diffuse and distribute within the vessel to have ESCs 
shortly exposed to the gaseous environment controlled by an incubator setting. 
Fick’s law is briefly explained below. 
 
 Fick’s law: Fick's first law relates the diffusive flux to the concentration 
field, by postulating that the flux goes from regions of high concentration to 
regions of low concentration, with a magnitude proportional to the 
concentration gradient (spatial derivative). In one (spatial) dimension, this is 
simply:                                                        
 
where 
J is the diffusion flux, which measures the amount of substance that will flow 
through a small area during a small time interval.  
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D is the diffusion coefficient or diffusivity which is proportional to the squared 
velocity of the diffusing particles. 
φ (or C) is the concentration in the assumption of a well-mixing environment. 
x is the position (diffusion length). 
Fick's second law, derived from the first law combining mass balance to 
the solute, predicts how diffusion causes the concentration field to change with 
time: 
 
 
where 
φ (or C) is the concentration  
J is the diffusion flux, which measures the amount of substance that will flow 
through a small area during a small time interval.  
t is time.  
D is the diffusion coefficient or diffusivity which is proportional to the 
squared velocity of the diffusing particles. 
x is the position (diffusion length). 
Fick’s second law with initial/boundary conditions presents how far a 
specific oxygen density (C) has propagated in a certain direction (z) by diffusion 
in time (t), followed by the decision of the optimal vessel dimensions. The 
assumptions applied in our culture system are as follows: 
 - Because oxygen concentration in the
than that of the cell culture medium, the direction of gas diff
air to medium in the vessel.
- Medium is assumed to be 
constant. 
- The initial oxygen 
- The oxygen concentration at the contact surface between air and 
medium is set as the same concentration of oxygen
- The diffusion coefficient of 
value with the water
medium is composed of water.
 
Figure 38 depicts 
detailed dimensions are 
Figure 39. 
 
Figure 38. Scheme of the bioreactor 
used for calculation
 incubator is assumed to be higher 
 
well-mixed, and gas concentration
concentration in the medium is assumed as zero.
 in air.  
oxygen in the medium is assumed as the same 
-oxygen system at 37
o
C as more than 99% of culture 
 
the conceptual design of the culture vessel. The 
decided based on the following calculation
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The partial differential equation with all the assumptions can be derived 
from the error function followed by the final equation (equation (1), Figure 39). 
Time (t), length of diffusion (z), and oxygen concentration in medium (CO2) vary 
together in this equation. For example, one day (86400 seconds) after oxygen 
diffusion starts, 67% of the surface concentration of oxygen can be achieved  in 
a depth of 1 cm, according to the calculation. 
 
 
Figure 39. Application of Fick’s second law considering assumptions made 
according to the designed culture conditions. 
(where erfc is the complementary error function) 
 
First of all, the desired oxygen concentration in the culture vessel should 
be set in order to estimate the relationship between diffusion length (z) and 
time (t). A plot can be drawn by setting the minimal oxygen concentration in the 
vessel as 80% of the surface concentration (Figure 40). According to the plot, 
the medium at up to a distance of 1.5 cm can be saturated with 80% of the 
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surface oxygen concentration in about 3 days. Therefore, the depth from the 
surface to the perfusion rod of the culture vessel (R-r in Figure 41)) can be 
determined as 1.5 cm with allowing 3 days of the oxygen-saturation time. This 
length also corresponds to the depth of a 55-ml High Aspect Ratio Vessel (HARV) 
used in Chapter 4, which was designed to have sufficient gas-exchange through 
the membrane on the back of the vessel. The other dimensions of the cell 
culture vessel were derived on basis of the diffusion length and the volume 
(approx. 55ml size), and further modified due to technical reasons for 
fabrication. The design of the inner cartridge of the cell culture vessel is 
confirmed by the equation (2) in Figure 41. 
 
 
Figure 40. A plot of the relationship between diffusion distance (y-axis) and 
time (x-axis) from the calculation, setting the oxygen concentration 
in medium at 80% of the surface concentration. 
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Figure 41. Dimension calculation of cell culture vessel. 
 
A gas-permeable membrane is rolled and attached on the frame of the 
cell culture vessel in order to allow for sufficient gas-exchange through the wide 
surface area as determined in the previous section. The membrane is made of a 
silicon material, and one side of that is coated with polytetrafluoroethylene 
(PTFE, Teflon) in order to prevent fouling by various bio-molecules present in 
culture medium or secreted by cells. The detailed specifications of the 
membrane can be found in Table 4. 
 
 
 
r = 1cm  R = 2.5cm
from equ(1),
5.25L = 17.31
L = approx. 3.5cm
l = approx. 3.3cm
Volume = approx. 60ml
{ }
51.172.0)25.23(
)(55)5.1(2.0)25.23(
2.0
5.1
)(
2
32
22
=+−
=−+−=
+=
+=
−=
rLR
cmmlRLRV
lL
rR
lrLRV
tot
tot
pi
pi
-- equation (2)
l
L
R
r
132 
 
In addition, the other oxygen supply to the culture vessel is introduced by 
the perfusion of oxygen-saturated culture medium using an external oxygenator 
(Figure 42). 
 
Figure 42. Depiction of dual-supply of oxygen to the culturing vessel. 
 
The external oxygenator is composed of a spiral roll of gas-permeable 
silicon tubing with a wall thickness of 0.5 mm. The length of the tubing roll is 
designed to be long enough (approx. 3.4 m) to saturate the culture medium 
with oxygen whilst the medium passes through the oxygenator. Figure 43 
resumes the calculation made to determine the oxygenation efficiency by the 
external oxygenator, which is based on the boundary conditions set for the 
vessel design (described in Figure 39). 
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Figure 43. Schematic diagram of the oxygenator tubing and application of 
Fick’s second law with the same boundary conditions set for vessel 
design in Figure 39. 
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The ratio of oxygen concentration at the centre of tubing (CO2) to the 
oxygen concentration in air (Cair) can be plotted versus the residence time of the 
medium in the oxygenator based on the calculations above (Figure 44). Given 
that 55 ml/day (a similar feeding rate with a fed batch system used in Chapter 4) 
is set as perfusion rate in the culture vessel, the residence time of medium in 
the oxygenator would be about 600 min for a total length of 3.4 m. Therefore, 
the oxygenator is capable of providing fresh medium in the culture vessel with 
about 90% of oxygen saturation according to the plot. 
 
 
Figure 44. O2-saturation depending on the residence time of medium in 
oxygenator tubing. 
 
A Computational Fluid Dynamics (CFD) software (CFX 11.0, ANSYS, UK) 
was used to simulate the transport of oxygen in the culture vessel. Two 
scenarios were assessed: a model of supplying oxygen only by perfusion mode 
and a model of supplying oxygen by both permeable membrane and perfusion. 
This modelling framework has been adapted from previous work (Ma et al. 
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2007), with modifications in terms of the dimensions and parameters. Herewith 
are the parameters that have been introduced in the simulation.  
- Initial oxygen concentration in the vessel: 0 mol/m
3
 
- Medium perfusion rate: 55 ml/day 
- Concentration of feeding oxygen at the condition of fully saturated 
oxygen supply (20% of oxygen tension in the medium): 0.26 mol/m
3
 
- Membrane oxygen permeability: 1.343 × 10
-5
 cm/sec
 
 
- Diffusivity of oxygen in water at 37
o
C: 3.29× 10
-5
 cm
2
/sec 
- Both models are set to rotate during the time period (24 hours) 
 
According to the simulation results (Figure 45), the oxygenation in the 
vessel is more effectively achieved by the use of a gas-permeable membrane. 
Briefly, the oxygen tension in the culture vessel with a membrane generally 
reaches higher than 10% within 6 hours, whilst the one without a membrane 
has approximately 5% of oxygen tension. High homogeneity of the distribution 
of oxygen is shown in the vessel with a membrane, whereas the absence of the 
membrane results in irregular distribution of oxygen in the vessel. At the end of 
18 hours of oxygenation, the vessel with a membrane appears to have a 
homogeneous distribution of 20% oxygen, suggesting that oxygenation has 
been completed with the equilibrium to the oxygen tension in air. However, in 
terms of the vessel without a membrane, the maximum of oxygen 
concentration reaches still about 15%, and the distribution of oxygen is also 
inhomogeneous. 
Previously, Figure 40 has shown that three days are required to achieve 
80% of oxygen saturation in the medium, if a gas-permeable membrane is the 
only source of oxygen supply. However, as shown in the CFD-based calculations 
(Figure 45), the dual-supply of oxygen through both the membrane and oxygen-
 saturated medium perfusion
tension with an atmosphere 
Figure 45. The effect of using a gas
within the culture vessel
 
5.2.2. Assembly of perfusion rotating wall vessel system (BSEL)
All parts of BSEL were 
and disassembled easily. The 
- Ease of wash and sterilise
- Ease of discarding and 
- Ease of fabricating
- Use of biocompatible materials.
Herein, the details 
the brief information of material are introduced.
 can offer more effective equilibrium of oxygen 
set by an incubator in less than 24 hours
-permeable membrane for
. 
fabricated as separate parts that can 
advantages of this kind of design are
; 
replacing disposable parts; 
 the complex features of each part; 
 
about the assembly of each part of the bioreactor 
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 oxygenation 
 
be assembled 
: 
and 
 5.2.2.1. Culture vessel assembly
The inner cartridge part where cells will be
parts: the frame of cartridge, 
frame and centre rod are made of PTFE which is biocompatible and 
autoclavable. The centre rod has 
alternately perpendicular way to 
medium whilst the vessel rotates (Figure 
Figure 46. Spatial arrangement of 
the culture vessel
 
After the gas-permeable membrane is 
the surface of the inner cartridge, the assembly is tightly held by an outer 
chamber, also made of PTFE, and 
 
5.2.2.2. Perfusion system assembly
Two of the cell culture vessels 
They rotate alongside by a main servo motor system. The rotation speed 
adjusted from 10 rpm to
 
 cultured is composed of three 
a centre rod, and a gas-permeable membrane. The 
eight perfusion holes arranged in an 
facilitate an effective mixing of perfused 
46). 
the perfusion holes in the centre rod of 
. 
glued with a silicon sealant
sterilised together by autoclaving
 
can be mounted on a single 
 150 rpm. However, the actual experimental range of 
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 onto 
 (Figure 47). 
base plate. 
can be 
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the rotation speed was set between 10 rpm and 20 rpm based on the stability of 
suspended cellular constructs within the vessel. Apart from the setting of vessel 
rotation, the two culture vessels are independent and can be used in individual 
experiments as each of them has its own set of peristaltic pumps, oxygenators, 
and fresh/wasting medium bottles (Figure 47). Perfusion of the culture medium 
is performed by the peristaltic pump in the rates of between approximately 60 
ml/day and 500ml/day. It can also be adjusted along the experimental period, 
based on the cell growth. The medium passes through the following pathway: 
collected from a fresh medium bottle, through an oxygenator, perfused into the 
culture vessel, and finally discarded in a wasting medium bottle. All the electric 
units are controlled and monitored by a computer system using a tailor-made 
software. The information of materials used in our perfusion bioreactor system 
is briefly listed in Table 5. 
The development of bioreactor systems is considered to be essential in 
the field of tissue engineering for the transfer of laboratory-based practices to 
the clinic. In this project, we have developed an automatable RWV-based 
perfusion culture system that has flexibility to be introduced in various cultures 
of three-dimensional tissue-like constructs. From the next chapter, a set of 
experiments about scale-up of ESCs and formation of bone-tissue like constructs 
from ESCs are conducted using the perfusion bioreactor system in comparison 
with other traditional techniques such as a static culture and fed-batch type 
bioreactor system. 
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Figure 47. Assembly of perfusion rotating wall vessel system (BSEL). 
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5.3. Conclusions 
 
In this chapter, the processes of designing and fabricating a novel 
perfusion RWV bioreactor system have been introduced. This new culture 
system offers a state of free-fall in the culture vessel as well as prevention of 
metabolic waste accumulation in conjunction with continuous medium supply 
by perfusion. The culture vessel was designed to have the effective oxygenation 
through both a gas-permeable membrane mounted on the surface of the vessel 
and oxygen-saturated medium perfusion. All parts of the bioreactor system can 
be easily assembled and disassembled for the regular maintenance and the 
operation procedures can be controlled by a computer system. This newly 
developed culture system would be usefully applied to tissue engineering with 
improvement of the efficiency in in vitro tissue culture. 
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Chapter 6. Three-dimensional 
Scale-Up of ESCs: Comparison 
Study (I) of BSEL, a Fed-Batch 
RWV, and Static Culture  
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6.1. Introduction 
 
It is required for successful implementation of stem cell-based 
technologies that culture systems must be designed to produce expanded stem 
cells with uniform properties. Therefore, the key to large-scale, long-term 
culture lies on the development of well-defined and controlled culture 
conditions (King and Miller 2007). For example, providing cells with an adequate 
oxygen supply is necessary to maintain a homogeneous culture environment 
against the detrimental effects from continuous oxygen consumption over the 
culture period. Sensitivity to the build-up of metabolic byproducts, exhaustion 
of essential nutrients, and associated changes in pH must also be considered. 
A novel perfusion bioreactor (BSEL) was developed to satisfy the existing 
requirements for an ideal culture condition as described in the last chapter. In 
this chapter, ESCs encapsulated in the hydrogels were three-dimensionally 
expanded sustaining their pluripotency within BSEL system. 
 
6.1.1. Aims 
The aim of this chapter is to compare the novel perfusion bioreactor with 
a commercially available perfusion culture system (Synthecon), a fed-batch 
bioreactor (HARV), and a fed-batch three-dimensional static culture (Static) in 
terms of three-dimensional ESC-expansion. 
 
6.1.2. Experimental plan 
ESCs were encapsulated in alginate hydrogels as described in Chapter 4, 
and cultured in different culture systems for 13 days in mESC-growth medium 
 containing LIF. Various assays 
medium profiles, oxygenation in the medium, and maintenance of pluripotency
 
Figure 48. Experimental scheme of three
 
A pre-incubation with 
conditions at least for 24 hours before the 
After the cultures started, the systems of a fed
static condition were fed by 
fed cells with continuous
(approx. 60 ml/day). On the other hand
continuous feeding was not available 
used medium to the culture vessel by perfusion.
medium was replaced every single day
medium-perfusion in Synthecon system 
1440 ml/day) which is the
culture conditions between 
found in Table 10. 
 
were performed to evaluate cell growth, culture 
-dimensional ESC scale
the culture medium was applied to all culture 
inoculation of encapsulated cells. 
-batch type such as HARV and a 
55 ml of medium-exchange every single day. BSEL 
ly perfused fresh medium at a rate of 0.7
, in terms of Synthecon perfusion system
because it was designed 
 Therefore, 60 ml of
 by exchanging the medium bottle
was conducted at 16.5 µ
 minimum rate of the system. A brief comparison 
HARV, Static, BSEL, and Synthecon system
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Table 10. Perfusion culture system comparison between BSEL and Synthecon bioreactors 
 
 
 
BSEL HARV Static SYNTHECON
Way to feed Continuous feeding of the fresh medium Exchanging medium (55ml per day) Exchanging medium (55ml per day) Recycling medium
Rate of 
perfusion
58 ml/day – 500 ml/day N/A N/A Minimum 1440 ml/day
Oxygenation
O2-saturated medium perfusion + 
diffusion through a gas-permeable 
membrane from air.
Diffusion through a gas-permeable 
membrane from air
Diffusion through the surface of 
culture medium from air
O2-saturated medium perfusion
Controlling
operation
Real-time monitoring of all the operation 
conditions using a computer system
Analog controller N/A Analog controller
Culture volume two of 58ml-culture vessel A single 55ml-culture vessel
A petri-dish with 55ml of culture 
medium
A single 55ml-culture vessel
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6.2. Results 
 
6.2.1. Morphology and viability analysis 
Morphology and viability of cells were mainly compared between BSEL, 
HARV, and Static groups at various culture time points because the Synthecon 
system did not show comparable cellular viability during the culture period. As 
shown in the previous chapter, ESCs encapsulated in the hydrogel formed 
colonies, and the agglomerations appeared to grow in all groups over the 
culture period. However, ESCs cultured in a static culture tended to form 
smaller sized cellular colonies than those of the other two well-mixed conditions 
(HARV and BSEL). Although, cells near the surface of the hydrogel were 
relatively well agglomerated in all groups, the observation in a focal point near 
the centre of the beads revealed the difference in the cellular colony 
morphology between well-mixed condition groups and the Static group (Figures 
49, 50, 51). 
Viability of cells was shown by Live/Dead assay (Figure 52). In agreement 
with the microscopy analysis, the Static group likely showed smaller viable 
cellular colonies (approx. 100-300 µm) than the other two groups (approx. 300-
500 µm). Cellular colonies in HARV generally showed more dead-cell population 
than BSEL, although most of the cells appeared to be viable in all groups. 
ESC-colony morphology in the Synthecon system did not grow, showing 
relatively small sizes without viable cellular agglomeration as evaluated by 
Live/Dead assay. They were scattered throughout the entire area of hydrogel 
even on day 6 (Figure 53). 
 
  
Figure 49. Morphology of cellular colonies cultured in BSEL
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Figure 50. Morphology of cellular colonies culture in HARV
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Figure 51. Morphology of cellular colonies culture in a static condition
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Figure 52. Live and Dead assay of cells from BSEL, HARV, and static culture
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Figure 53. Morphology and
Synthecon system
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6.2.2. Growth kinetics 
The growth kinetics of ESCs in the pluripotent state were investigated 
comparing BSEL, HARV, Static, and Synthecon systems (Figure 54). The growth 
kinetics of ESCs in Synthecon had little increase until day 6, while the other 
groups showed an exponential increase on day 6. A lack of cell viability after day 
6 in samples from Synthecon prevented further collection and analysis. 
On the other hand, the other three groups of BSEL, HARV, and Static 
showed similar trends without significant differences until day 9. However, BSEL 
started showing a significant difference in cell numbers per bead as compared 
to the Static on day 11, and became significantly higher on day 13 even 
compared to HARV. Statistical analysis was performed by one-way ANOVA (p < 
0.05). 
 
Figure 54. Growth kinetics of ESCs three-dimensionally cultured in 
pluripotent phase. Statistical analyses were performed by 
one-way ANOVA (n=3). Asterisks indicate p < 0.05. 
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6.2.3. Oxygen tension variation 
Oxygen tension in the culture medium collected from each culture 
condition was measured over time at various time intervals. Oxygen 
concentrations in air (8.7 mg/l, approx. 20%) and fresh culture medium (5.6 
mg/l) were also measured as standards for the comparison and indicated by 
dotted lines in the graph (Figure 55). The cultures for the comparison of oxygen 
variation were separately carried out from the other studies. 
Because of the pre-incubation process for 24 hours before cell-
inoculation, the oxygen levels in BSEL, HARV, and STATIC groups were similar at 
the start of the culture which was close to the oxygen saturation in air. However, 
the oxygen level from Synthecon on day 0 indicated about 5 mg/l which was 
similar or even lower than the level in the fresh medium. The oxygen tension 
variation in HARV showed a rapid decrease with significant differences from day 
3 to day 13, whereas BSEL and Static groups showed steadily decreasing trends 
compared to HARV during culture period. On the other hand, the oxygen 
tension in Synthecon showed the increasing variation which is the opposite 
tendency from the other groups. Asterisk in the graph indicates the statistical 
difference between HARV and BSEL from day 3 to day 13, and statistics were 
performed by a student t-test (p < 0.05). 
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Figure 55. Variations of oxygen concentration in various culture 
conditions. Statistical analyses were performed by a student t-test 
(n=3). Asterisks indicate p < 0.05. 
 
6.2.4. Culture medium profiles 
Culture medium from each group was collected and analysed with a bio-
profiler during the culture period in order to evaluate the effectiveness of 
culture environment maintenance. All cultures for medium-profiling were 
carried out separately from the other studies. A dotted line on each graph 
represents the correspondent concentration of fresh culture medium. The 
comparisons and statistical evaluations were undertaken mostly between HARV 
and BSEL by a student t-test (p < 0.05).  
 
6.2.4.1. Nutrient (glucose and glutamine) consumption profiles 
In terms of the glucose profile with respect to time, BSEL was able to 
maintain a high level of the initial glucose concentration up to day 13, whereas 
HARV showed a rapid decrease between day 3 and day 6 eventually reaching 
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that the concentration of glutamine in HARV 
culture period with a significant d
Figure 56. Comparison of nutrient consumption
Statistical analyses were performed by a student t
Asterisks indicate p < 0.05.
at the end of culture despite the fact that
In general, glutamine consumption rate was 
 However, it is still consistent
was also decreasi
rop from that of BSEL by day 13 
 during expansion period
-test (n=
 
154 
 
ly shown 
ng during the 
(Figure 56). 
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3). 
 6.2.4.2. pH variation profile
In terms of pH varia
to 7.2, whereas the pH level
which was significantly lower than that in BSEL 
Figure 57. Comparison of pH variations
analyses were performed by 
p < 0.05. 
 
6.2.4.3. Metabolite (lactate, ammonia, and glutamate) 
accumulation profile
In terms of metabolite
ammonia (NH4
+
), and glutamate) 
approximately a three-
increases in ammonia and glutamate concentrations from day 3 to day 13.
the other hand, BSEL showed a steady trend without 
levels of metabolites. The culture medium in HARV maintained significantly 
higher concentrations of all the metabolites than those in BSEL 
culture period (Figure 58
 
tion, the levels in BSEL varied approximately from 7.5 
s in HARV dropped below 6.6 by the end 
(Figure 57). 
 during expansion period.
a student t-test (n=3). Asterisks indicate 
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6.2.5. Maintenance of pluripotency (“stemness”) 
All the examinations about scale-up of ESCs have been undertaken in the 
basic assumption that cells should be pluripotent. Therefore, their maintenance 
of functionality as pluripotent ESCs was evaluated during the culture period by 
the analysis of alkaline phosphatase (ALPase) activity (Figure 59). Various gene 
expressions were quantitatively compared between the different three-
dimensional conditions (Static, HARV, and BSEL) using a qPCR analysis. Briefly, 
the expression levels of the pluripotency marker genes such as Oct4, Nanog, 
and Rex1 were compared (Figure 60). Furthermore, a maker gene in the early 
developmental progress, FGF5, was also examined in order to compare how 
much spontaneous differentiation occurred. Finally, immunocytochemistry was 
also performed in order to show the expressions of Oct4 and SSEA1 in the 
cellular colonies cultured for 13 days in the BSEL system (Figure 61). Synthecon 
system was exempted in these comparisons because of the difficulty to collect 
enough live cells from Synthecon system due to their low viability. Statistical 
analyses in each evaluation day were performed by one-way ANOVA (p < 0.05). 
 
6.2.5.1. Alkaline phosphatase (ALPase) activity  
In the beginning of the culture, three-dimensionally encapsulated ESCs 
generally showed lower ALPase activity compared to ESCs which were 
conventionally cultured on a two-dimensional plate for three days (collected at 
approx. 70% of confluency). In particular, ESCs in BSEL started growing with 
lower ALPase activity than those in Static as shown in the level on day 3. 
However, both the well-mixed culture conditions maintained ESCs with high 
levels of ALPase activity from day 6, and it was increasing up to higher or similar 
levels compared to that of two-dimensional control as culture time passed by. 
On the other hand, the levels of ALPase activity in
 decreasing tendency through
significantly lower level of expression 
Figure 59. Comparison of alkaline phosphatase activity
Statistical analyses were performed by one
Asterisks indicate p < 0.05.
 
6.2.5.2. Gene expression profiles
The expressions of pluripotency marker genes (Oct4, Nanog, and Rex1) 
and a marker gene for initiative differentiation i
process (FGF5) were quantified by qPCR (Figure 
corresponds to the level of gene expression from
In terms of Oct4 expression, there was no significant difference between 
the experimental groups on day 6. However, BSEL showed significantly higher 
expression of Oct 4 than Static on day 11. Static on the same day had the similar 
level of Oct4 expression to that of two
expression, the three groups showed 
out the culture period ending up with a 
in the end (Figrure 59). 
 
 in pluripotent phase
-way ANOVA (n=3). 
 
 
n the early 
60). A dotted line on each graph 
 the two-dimensional control.
-dimensional control. In terms of Nanog 
similar levels of expression on
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although only Static had a level of the expression close to that of two-
dimensional control. As for Rex1 expression, all groups showed little difference 
in the levels on day 6. However, they showed significant differences on day 11; 
higher levels of expression in BSEL and HARV than Static. Furthermore, the level 
in Static was even lower than that in two-dimensional control. The absolute 
level of each gene expression generally did not vary with time apart from Rex1 
expression in HARV and Static that showed differences between day 6 and day 
11. 
In terms of FGF5 expression comparison, the expression level in HARV 
was highest on day 6 with the significant difference from Static. The difference 
between HARV and BSEL became even higher on day 11. Static also showed 
significantly higher expression than BSEL on day 11. On the other hand, FGF5 
expression in three-dimensional cultures was much lower compared to the two-
dimensional control as HARV showed only approximately level 0.15 which was 
the highest level on day 11 among all groups. 
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Figure 60. Gene expression comparisons in pluripotent phase. 
Statistical analyses were performed by one-way ANOVA 
(n=3). Asterisks indicate p < 0.05. 
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6.2.5.3. Immunocytochemistry analysis 
In order to re-confirm the best results of BSEL group in the maintenance 
of plurpotency, the samples were collected from BSEL after 13-day culture, 
immunocytochemistry staining with pluripotency markers, Oct4 and SSEA1 was 
conducted (Figure 61). Both the markers were dual-stained by FITC and Texas 
Red respectively as shown in Figure 61A. The positive staining of Oct4 was 
clearly shown in the regions of nuclei (Figure 61B) corresponding to DAPI 
staining (Figure 61a), and the staining of SSEA1 was also well conducted 
showing its correct localisation on the cell membrane area (Figure 61C). 
 
 
Figure 61. Immunocytochemistry of the BSEL group on day 13. 
Oct4 (B) and SSEA1 (C) were dual-stained with FITC and Texas Red 
respectively (A). Nuclei of the cells were indicated with DAPI (blue) (a, 
b-1, c-1). Negative controls for FITC (b-2) and Texas Red (c-2) were 
conducted. The scale bars represent 100 µm. 
(A) (B)
(C)
a
b-1 b-2 c-1 c-2
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6.3. Discussion 
 
In terms of cell growth behaviour, the three-dimensional static culture 
group (Static) showed less vital and smaller cellular agglomerations than the 
HARV and BSEL especially at the centre core of the hydrogel. In static culture 
conditions, diffusion is the only way for nutrients to penetrate into three-
dimensional cellular structure due to a lack of mixing of the culture medium. It 
has been reported by many researchers that by diffusion alone, the mass 
transfer of nutrients and metabolic waste products is limited in the region near 
the surface of three-dimensional structure so that only the outer layer of the 
tissue constructs remains viable; a necrotic centre results (Li et al. 2000; 
Zimmermann et al. 2002). Additionally, a hypoxic necrotic centre can also be 
generated by a lack of oxygen supply in the core (Wendt et al. 2005). In this 
study, the hydrogel encapsulation technique was adopted because hydrogels, 
which are mostly consisting of water, have high diffusivity. Initially when the cell 
density was low, the Static group showed the similar cellular colony 
morphologies, viability, and growth kinetics with the other well-mixed culture 
groups (HARV and BSEL). This supports the well-known effective mass transfer 
in the hydrogels even with a poorly mixed external environment. However, the 
gradients of physicochemical parameters between the hydrogel and 
surrounding medium would become smaller in the static culture due to a lack of 
mixing whilst the rates of nutrient consumption and metabolite accumulation 
become faster as cells grow. Observation of locally changed medium-colour in a 
petri-dish is consistent with this situation, and also supports the necessity of 
good-mixing using a bioreactor. Although a culture of large cellular constructs is 
generally known to require a ‘capillary network’ as part of the structure through 
induced angiogenesis or vascularisation (Placzek et al. 2009), the well-mixed 
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culture conditions which offer an external force for mass transport such as 
convection can also reduce a diffusion limitation faced in a static culture 
condition. This is demonstrated by the higher vitality of cell colonies found in 
the BSEL and HARV in this study. 
ESCs in the HARV and BSEL were well agglomerated and regularly 
distributed throughout the whole area of hydrogel, as a well-mixed culture 
condition provided by the rotating wall vessel (RWV) system promoted effective 
mass transport penetrating into the constructs within homogeneously mixed 
medium. However, Live and Dead assay on day 11, interestingly, showed that a 
high population of dead cells was generated in the HARV. Correspondingly, as 
shown in growth kinetics data, cell numbers in the HARV stopped increasing 
from day 9, and eventually showed significantly lower levels from that in the 
BSEL on day 13. As shown in ammonia (NH4
+
) accumulation, the HARV contained 
more than 2 mM from day 6 which is known to be inhibitory to cell growth in 
ESC-culture (Cormier et al. 2006b). This ammonia concentration in HARV 
reached almost 2.5 mM in the end of culture, and thus could be relevant to the 
increase in dead cell population. Furthermore, the decrease of pH level in HARV 
was from 7.6 to 6.6. This severe increase in acidity was reported to contribute to 
the cell death (Cormier et al. 2006a). The high accumulation of lactate in HARV 
during culture period may also have reached a level that is detrimental to ESC 
viability. Cells in HARV were fed every single day with 55 ml of fresh medium. 
Initially, the culture environment within 55 ml of medium appeared to be 
sufficient to feed all the cells in the vessel for a day. However, as cell population 
continued to expand with time, the capacity for maintenance of a regular 
culture environment was restricted by a certain amount of medium 
supplemented in a batch (in this case, 55 ml). Once the cell density went over 
the capacity of the culture environment to feed cells, cells suffered stress under 
a lack of nutrients and highly accumulated metabolites in a batch. The degree of 
164 
 
stress can continue to increase as the rates of nutrient/oxygen consumption and 
metabolite accumulation become higher with culture time as shown in the 
culture medium profiles of the HARV. On the other hand, continuous perfusion 
feeding and the use of a gas permeable culture have been shown to be 
beneficial in culture performance by the continuous replacement of depleted 
nutrients/oxygen and removal of inhibitory metabolic by-products (Xie et al. 
2006; Zhao and Ma 2005; Zhao et al. 2005). In this study, the constant metabolic 
demands of the cell constructs can be satisfied by continuously refreshing the 
culture medium through the aid of a perfusion system. It is well shown in the 
culture medium profile data that the BSEL bioreactor offered a much more 
homogeneous culture condition with little variations in the levels of nutrients 
and metabolites throughout the whole culture period. 
Synthecon perfusion culture system was devised to provide a RWV 
bioreactor with medium perfusion. Although a fed batch type of RWV 
bioreactor has been widely used to achieve a three-dimensional suspension 
culture within its micro-gravity condition (Chen et al. 2007; Hwang et al. 2009; 
Randle et al. 2007), very few examples in using the perfusion type RVW have 
been shown so far (Wurm et al. 2007). In this study, the commercialized 
perfusion culture system (named Synthecon as a group) was used as a 
comparison for three-dimensional ESC-expansion. As described in Chapter 6.1, 
differences in the functional specifications between the Synthecon and BSEL are 
as follows: the method of oxygenation, rate of medium perfusion, and 
continuous feeding of fresh medium. In terms of oxygenation, the Synthecon 
started culturing cells with low levels of oxygen tension at the start of the 
culture. Every culture vessel was conditioned before the cell-inoculation by a 
pre-incubation process of 24 hours using ESC-growth medium. During this 
period, culture vessels and tubing system can be washed and adapted to the 
right pH for culturing ESCs, and the oxygenators can be adjusted to the right 
165 
 
conditions such that it provides sufficient oxygen to the culture vessels. The 
oxygen measurements in this study suggested that Synthecon could not achieve 
the proper conditions in the oxygen tension equilibrated with air during the pre-
incubation process. This result was consistent with the calculation result of 
oxygenation (Chapter 5.2.1). The time for culture medium to pass through the 
tubing of oxygenator can be deduced as 25 min by the estimation based on 
perfusion rate (16.5 µl/sec) and oxygenator tubing dimensions (3.4m (length) X 
0.03 m (diameter)). According to the calculation of oxygenation by the 
oxygenator (Figure 44), medium in the oxygenator can be saturated only up to 
about 50% of oxygen concentration in air while it passes through the 
oxygenator for 25 min, whereas BSEL was able to provide about 90% of oxygen 
concentration in air for a duration of 550 min at the perfusion rate of 0.7 µl/sec. 
Taking all the clues into consideration, the perfusion rate which was offered as 
the minimum value by Synthecon is likely too fast to provide sufficient 
oxygenation in the oxygenator, so that the culture vessel was not properly 
supplied with oxygen. 
There are many reports showing that low oxygen tension in culture 
results in rapid expansion of ESCs with the maintenance of high pluripotency 
(Dang et al. 2004b; Dang et al. 2002; Forsyth et al. 2006; Gibbons et al. 2006). 
Hypoxia inducible factors (HIFs) are global regulators of oxygen sensing 
response. They are to be activated within the exposure of decreased oxygen 
tensions (Semenza 2004). HIF is known to be a heterodimer consisting of two 
subunits: the inducibly expressed HIFα and the constitutively expressed 
HIFβ (Gu et al. 1998). HIF-2α which is one of the HIFα subunits was shown to 
uniquely regulate the expression of pluripotency markers of ESCs such as Oct-4, 
followed by HIF-1α expression which is post-translationally regulated (Covello et 
al. 2006; Simon and Keith 2008). However, most of the studies on ESCs under 
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hypoxia were not performed in a three-dimensional culture conditions. 
Furthermore, those previous studies did not seem to include an increasing ESC-
growth with time, which could accelerate the oxygen consumption rate thereby 
affecting the oxygen tension in the culture. In this study, any evidence of 
stimulating ESC-expansion could not be found in Synthecon although the level 
of oxygen tension in the culture vessel was the lowest among the groups. On 
the other hand, BSEL showed the best ESC-expansion although the oxygen level 
in BSEL showed the highest value among the groups. Cameron et al. reported an 
interesting finding about transient response of hypoxia-relevant gene 
expression after hESCs were exposed to low oxygen concentration (Cameron et 
al. 2008). Because HIF responds in a transient way, the sudden exposure to a 
hypoxic environment may harm the growth of ESCs by inducing apoptosis 
before expansion is promoted. They speculated that this opposite result from 
the previous reports about ESC-behaviours in hypoxia could be obtained by the 
uncontrollable aggregation culture of hESCs. Because intact colonies of hESCs 
keep remaining while being passaged, it is likely to be difficult to have the 
homogeneous adaptation to the new environment as those in a single cell level. 
Therefore, the irregular aggregations of hESCs may not be able to overcome the 
impact of apoptotic induction by lack of oxygen in a hypoxic condition. This 
speculation is likely to be similar to the complexity of our three-dimensional 
culture process using encapsulation. Additionally, it was also reported by the 
other studies that prolonged hypoxic exposure more than 5 days was shown to 
induce apoptosis in mEBs and human umbilical vein endothelial cells (HUVEC) 
((Carmeliet et al. 1998; Lee et al. 2005). In our study, Synthecon tended to grow 
cells by day 3 having similar cell density with the others. However, they failed to 
have adequate cellular aggregations like the other groups, and the expansion of 
cells stopped on day 6 showing low viability. 
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In terms of perfusion rate and the use of recycled medium, it is still 
controversial to make a universal conclusion on the ideality of culture condition. 
There are some studies about the effect of perfusion rate to cellular growth and 
differentiation, although the perfusion rates used in the previous culture 
systems cannot be comparable to the BSEL in that many aspects are physically 
different. Zhao et al. reported that higher perfusion rate resulted in less 
extensive growth in human MSC expansion and attributed the growth inhibition 
to greater removal of growth-promoting factors produced by MSCs (Griffith and 
Swartz 2006; Zhao et al. 2007). On the other hand, it was reported in case of 
hematopoietic stem cell expansion that growth rate can be increased by 
removing inhibitory cytokines produced by their more differentiated progeny 
(Madlambayan et al. 2005; Madlambayan et al. 2006). 
The enzyme activity of pluripotent stem cells was evaluated whilst ESCs 
were scaled up through analysis of ALPase activity. All groups in three-
dimensional culture had lower ALPase activity than two-dimensional control at 
the beginning of culture. This situation can be speculated by the environmental 
adaptation period after cells are exposed to a new environment. During the 
encapsulation process, cells experience harsher conditions than two-
dimensional culture. After cells are encapsulated in the hydrogel, a certain 
period of time may be required to be adapted to the new environment. Among 
three-dimensional culture groups, the level of ALPase activity in the BSEL was 
lower than the Static on day 3. This may also be caused by a delay of the 
adaptation period of ESCs in the BSEL, the reason being that the STLV type of 
RWV system has a smaller aspect ratio (diameter/length) than the HARV, 
possibly resulting in more contacts and collisions between hydrogels (Gerecht-
Nir et al. 2004). However, from day 6, ESCs in both the well-mixed conditions 
showed increasing ALPase activity up to a similar level in the two-dimensional 
control, and the activity stabilized at a high level until the end of the culture 
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period. On the other hand, Static showed a decreasing trend after day 3. This 
aspect in Static group can be speculated by an insufficient mass transport and a 
lack of mixing causing irregular cell growth in hydrogels and spatial gradients of 
nutrient distribution including various physicochemical factors for the 
maintenance of ESCs’ functionality. 
The expressions of representative markers for the evaluation of the early 
developmental progress such as Oct4, Nanog, Rex1, and FGF5 were also 
relatively compared in all the experimental groups based on the normalisation 
of each expression level with the two-dimensional control. The various 
members of the POU family have a wide variety of functions, all of which are 
related to the development of an organism. Oct4 is one of the POU family 
transcription factors, which is considered a major regulator for maintenance of 
pluripotency in ESCs (Nichols et al. 1998; Niwa et al. 2000). It is also well known 
that Oct4 level gradually decreases in the induction of spontaneous 
differentiation in ESCs (Palmqvist et al. 2005). Recent discovery suggested 
Nanog is a member of the “stemness” markers, demonstrating that disruption 
of Nanog expression induces differentiation into the primitive endoderm lineage 
(Mitsui et al. 2003). It was also reported that high level of Nanog expression was 
observed in the pluripotent phase of ESC-culture albeit Oct4 level decreased 
(Chambers et al. 2003). Rex1 and FGF5 are known to be expressed in the 
specific stage of embryogenesis. In particular, it was reported that Rex1 is 
expressed in day 4.5 of blastocyst in mouse developmental process, and then 
down-regulated 1-2 days later in the embryonic ectoderm (Rogers et al. 1991; 
Rosner et al. 1990). FGF5 expression also in mouse development is first 
apparent in day 5 of post-implantation epiblast (Haub and Goldfarb 1991), 
suggesting that Rex1 is down-regulated but FGF5 is up-regulated after day 4.5 of 
mouse embryogenesis. Amplification of FGF5 gene however has not been 
detected in undifferentiated ESCs (Hamazaki et al. 2004; Zhang et al. 2005). 
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According to the findings above, the expression of FGF5 and Rex1 in vitro and in 
vivo represents a temporally distinct sub-population of differentiating ESCs 
within the Oct4 positive pool (Pelton et al. 2002). 
In terms of gene expression, the Static showed the lowest level in Rex1 
expression on day 11, which is even lower than the two-dimensional control. 
This can be explained by the poorly mixed conditions in the Static causing a fast 
depletion of LIF around the local area where hydrogels containing ESCs rested. 
The interesting finding in this study is the relatively low expression of Rex1 and 
significantly higher expression of FGF5 in the HARV on day 11. Although the 
HARV offers a well-mixed environment, it is still a fed-batch system similar to 
the Static. Indeed, ESCs cultured in the HARV showed high viability in cellular 
agglomerates and fast ESC-expansion rate until day 9 as shown in morphology 
observation and growth kinetics data. However, owing to these facts, the 
exhaustion of physicochemical factors, which help ESCs to keep “stemness”, 
would be accelerated in a batch, which eventually led to spontaneous 
differentiation as shown by the increasing FGF5 expression. On the other hand, 
the BSEL was able to maintain higher expression in most of pluripotency marker 
genes as well as lower expression of FGF5 until the late stage of culture likely 
due to the continuous perfusion of the fresh medium containing LIF.  
It is now commonly noted that the culture within three-dimensional 
conditions helps cellular phenotypes to display more in vivo mimicking structure 
and function (Cukierman et al. 2001). It was also interestingly demonstrated 
that three-dimensional culture conditions improved the self-renewal of mESCs 
with up-regulation of Nanog, providing the evidence about a role of 
dimensionality in the expansion of ESCs with maintaining their “stemness” (Nur-
E-Kamal et al. 2006). Our results correspond to those other studies especially in 
the comparison of gene expressions with two-dimensional control. The 
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experimental groups in this study generally showed their well-maintained 
“stemness” with higher (in both the mixed condition groups) or similar levels (in 
Static) of expression in pluripotency marker genes compared to two-
dimensional control. However, the expression of FGF5 in our three-dimensional 
culture groups, in particular, was much lower than that in two-dimensional 
control, such that the level of FGF5 expression in two-dimensional control was 
about seven times higher than that of HARV, although HARV showed the highest 
expression of FGF5 among the groups. 
 
 
 
.  
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6.4. Conclusions 
 
It was demonstrated in Chapter 4 that encapsulation using 
alginate/gelatin mixture can provide a physicochemically stable three-
dimensional environment to grow and differentiate ESCs during a prolonged 
culture period. In this chapter, a novel perfusion culture system (designed in 
Chapter 5) was examined in terms of three-dimensional scale-up of ESCs based 
on the established hydrogel encapsulation method. Various culture groups such 
as a fed-batch culture vessel, a static culture environment, and a commercially 
available perfusion bioreactor were compared with the newly developed 
bioreactor. In the results, it was successfully shown that the culture conditions 
for ESCs were well maintained in the new system that resulted in approximately 
120% better expansion than the fed batch condition sustaining high “stemness” 
during 13 days culture period. Furthermore, the culture was automatically 
processed and controlled by a computer system with real-time monitoring 
capabilities, so the incidence of experimental errors which could occur in 
manual operation of feeding system could also be reduced. 
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Chapter 7. Formation of Bone-
Tissue like Constructs from ESCs: 
Comparison Study (II) of BSEL, a 
Fed-Batch RWV, and Static 
Culture 
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7.1. Introduction 
 
Tissue engineering has the potential to have a profound impact on the 
practice of medicine and influence the economic development in the industry of 
biotechnology. Development of various tissue engineering strategies will change 
the focus from artificial organs and transplantation to growing replacement 
organs from the patient's own stem cells (Riley 2003). Regarding this fact, the 
design of a bioreactor system would have a crucial role in culturing large sized 
tissues/organs in conjunction with the automated medium perfusion to 
maintain oxygen and nutrient delivery throughout the growth period. 
In the last chapter, it was successfully shown that ESCs were three-
dimensionally scaled up sustaining high “stemness” for 13 days using the newly 
developed bioreactor (BSEL) amenable to the regular maintenance of the 
culture conditions by an automatable perfusion operation. In this chapter, 
three-dimensional osteogenesis from ESCs was achieved using BSEL system 
based on the optimised HepG2-CM application and hydrogel encapsulation 
technique demonstrated in Chapter 4.3. 
 
7.1.1. Aims 
The aim of this chapter is to demonstrate the construction of bone-tissue 
like structure from ESCs using BSEL. The productivity and functionality of the 
osteogenic constructs from BSEL were compared with those from a fed-batch 
RWV system (HARV) and three-dimensional static culture (Static). 
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7.1.2. Experimental plan 
ESCs were encapsulated within the alginate hydrogels, followed by the 
inoculation into three culture conditions namely BSEL, HARV, and Static. The 
encapsulated ESCs were cultured in HepG2-CM for the first three days, and then 
transferred to the condition of osteogenic differentiation as shown in Chapter 4. 
Cell growth kinetics and culture medium profiles including variations of oxygen 
concentration were examined throughout the culture period at various time 
intervals to monitor the culture conditions during osteogenesis. Various assays 
were also conducted to evaluate the bone-tissue like constructs from each 
culture condition after 29 day of culture, in terms of calcification/mineralisation 
(hydroxyapatite generation), osteogenic gene expressions, and mechanical 
strength as summarised in Figure 62. 
 
 
Figure 62. Experimental scheme of bone-tissue formation from ESC. 
 
A pre-incubation with HepG2-CM was applied to all culture conditions at 
least for 24 hours before the inoculation of encapsulated cells. 
After the cultures started, the systems of a fed-batch type such as HARV and 
3D-Differentiation (bone tissue formation): 
Experimental groups
Evaluation criteria
- HARV (fed-batch)
- 3D static (fed-batch)
- BSEL (perfusion)
- Cell growth: growth kinetics
- Mineralisation: calcified deposition,
hydroxyapatite distribution
- Osteogenic gene profile
- Mechanical property testing
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Static were fed by 55 ml of HepG2-CM every single day for the first three days. 
The BSEL was setup to feed cells by continuous HepG2-CM perfusion at a rate of 
0.7 µl/sec (approx. 60 ml/day) for 3 days. Osteogenic differentiation was 
triggered on day 4, and then dexamethasone was added to the osteogenic 
medium from day 21 to the end of the culture (day 29). In the HARV and Static, 
55 ml of osteogenic media were exchanged every two days. In terms of the BSEL 
in the osteogenic period, medium perfusion was operated at approximately 60 
ml/day at the same timing when the HARV and Static were fed. After 24 hours, 
medium perfusion was suspended until the next feeding time of the HARV and 
Static in order to have a similar amount of osteogenic medium supply in total. 
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7.2. Results 
 
7.2.1. Growth kinetics 
The growth kinetics of encapsulated ESCs during osteogenesis were 
investigated (Figure 63). The two well-mixed culture conditions (HARV and BSEL) 
showed faster growth rates than Static by day 9 of the culture period. In 
particular, ESCs in the BSEL showed the fastest expansion in the early stage of 
osteogenesis from day 5 to 9. However, in general, the growth rate of the 
encapsulated ESCs was diminished, which is likely due to the spatial restriction 
in the hydrogel beads after the density of cells reached about 3.5 X 10
5
 
cells/bead as well as the slow growing tendency in osteogenic differentiation. 
All groups showed a similar final cell density on day 29 at around 4.0 X 10
5
 
cells/bead. Statistics were analysed by a student t-test between the BSEL and 
HARV (p < 0.05). 
Figure 63. Growth kinetics of ESCs three-dimensionally cultured during 
osteogenesis. Statistical analyses were performed by a student t-test 
(n=3). Asterisks indicate p < 0.05. 
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7.2.2. Oxygen tension variation 
Oxygen tension in the medium collected from each culture condition was 
measured during the osteogenesis period. Oxygen concentrations in air (8.7 
mg/l, approx. 20%) and the fresh osteogenic medium (5.6 mg/l) were also 
measured as standards of the comparison and indicated by dotted lines in the 
graph (Figure 64). The cultures for the comparison of oxygen variation were 
separately carried out from the other studies. 
Day 3 represents the last day of ESC-expansion in HepG2-CM before the 
culture media were changed to osteogenic media for triggering differentiation. 
Osteogenesis in the HARV started with a lower oxygen condition than that in the 
other groups as shown in the oxygen variation of the HARV during the 
expansion period (Chapter 6.2.3). After the onset of osteogenesis, the HARV 
appeared to gradually decrease the oxygen tension until the end of culture 
period up to about 2.7 mg/l (4-5 % of oxygen tension). The oxygen levels in the 
BSEL and Static groups tended to stiffly decrease in the early period. However, 
the oxygen conditions were well maintained until the end of culture showing 
significantly higher levels than those in the HARV. 
The asterisk in the graph indicates the statistical differences between 
HARV and BSEL throughout the whole culture period, verified by a student t-test 
(p < 0.05). 
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Figure 64. Variations of oxygen tension during osteogenesis. Statistical 
analyses were performed by a student t-test (n=3). Asterisks indicate p < 0.05. 
 
7.2.3. Culturing medium profiles 
Culture media were collected from each group and analysed with a bio-
profiler during the osteogenesis period. Day 3 represents the last day of ESC-
expansion in HepG2-CM before the culture media were changed to osteogenic 
media for triggering differentiation. All cultures for medium-profiling were 
carried out separately from the other studies. A dotted line on each graph 
indicates the correspondent concentration of the fresh osteogenic medium. All 
the statistics were done between BSEL and HARV by a student t-test (p < 0.05). 
 
7.2.3.1. Nutrient (glucose and glutamine) consumption profiles 
Glucose levels measured from HepG2-CM on day 3 showed the 
difference in particular between the BSEL and the other fed-batch culture 
groups (HARV and Static). The measurements on day 3 showed that glucose 
levels in the BSEL were well maintained during the expansion period as 
demonstrated in the last chapter (initial level of glucose in HepG2-CM was 
about 12 mM in this study). On the other hand, the initial level of glucose in 
osteogenic medium was 5.6 mM. After the onset of osteogenesis, glucose levels 
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in all groups indicated almost zero, representing that most of the glucose was 
consumed.  
In terms of glutamine variations, the HARV and Static showed very low 
levels from the onset of osteogenesis to the end of culture. However, the BSEL 
maintained glutamine levels at about 1 mM (initial glutamine concentration of 
osteogenic medium was 2 mM) (Figure 65). 
 
Figure 65. Comparison of nutrient consumption during osteogenesis. 
Statistical analyses were performed by a student t-test (n=3). 
Asterisks indicate p < 0.05. 
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7.2.3.2. pH variation profile 
pH levels in the BSEL were well maintained at approximately 7.5 in the 
beginning. Although it showed an abrupt decrease after day 9, BSEL steadily 
maintained pH at about 7.2 until the end of culture period. The pH in HARV was 
maintained at lower levels about between 6.8 and 7 without huge variations 
during osteogenesis period (Figure 66). 
 
Figure 66. pH variations during osteogenesis. Statistical analyses were 
performed by a student t-test (n=3). Asterisks indicate p < 0.05. 
 
 
7.2.3.3. Metabolite (lactate and ammonia) accumulation profile 
HARV showed much higher levels of lactate than BSEL on day 3 
corresponding to the difference in glucose profiles (Chapter 7.2.3.1). In general, 
however, huge variations of the lactate levels were not observed in all groups 
during osteogenesis period (from day 9 to day 29). 
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BSEL. The culture condition in HARV contained higher than 3.5 mM of ammonia 
concentration in the middle of osteogenesis period (Figure 67). 
 
 
 
Figure 67. Comparisons of metabolite accumulation during osteogenesis. 
Statistical analyses were performed by a student t-test (n=3). 
Asterisks indicate p < 0.05. 
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7.2.4. Mineralisation quantification based on Alizarin Red S (ARS) 
staining 
Mineralisation in all groups was quantified by measuring the amount of 
calcified deposition using a modified alizarin red S assay (Gregory et al. 2004) 
(Figure 68). Until day 21, prior to the supplementation of dexamethasone in 
osteogenic medium, the BSEL and HARV showed significantly higher 
accumulation of calcified deposition than the Static. During 7 days of 
osteogenesis with dexamethasone treatment, the calcification process was 
largely accelerated in the two mixed condition groups. In particular, the BSEL 
showed 8 times higher mineralisation than the Static on Day 29. Statistics in 
each evaluation day were done by one-way ANOVA as indicated a single (p < 
0.05) and double (p < 0.001) asterisks in the graph. 
 
 
Figure 68. Mineralisation evaluation. Statistical analyses were performed by 
one-way ANOVA (n=3). Asterisks indicate p < 0.05 (single) and p < 
0.001 (double) respectively. 
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7.2.5. Gene expression profiles 
The expressions of osteogenic marker genes on day 29, such as type I 
collagen (Col1), Runx2 (RUNX2), and Osterix (Osx) were quantified by qPCR. A 
dotted line on each graph (lined on 1.0) corresponds to the level of gene 
expression from Static group on the same day. Statistical analysis in each 
comparison was performed by a student t-test between BSEL and HARV (p < 
0.05). In order to confirm the disappearance of “stemness” in the final products, 
pluripotency gene markers, such as Oct4 and Nanog, were investigated by RT-
PCR with the samples cultured for 13 days in BSEL with ESC-growth medium 
containing LIF (a) and osteogenic samples cultured for 29 days in BSEL (b). The 
osteogenic gene markers, such as Osx and RUNX2, were also verified (Figure 69). 
In terms of Col1 and RUNX2 expressions, significant differences were not found 
between HARV and BSEL. However, both the bioreactor culture groups showed 
even higher expressions than the Static group indicated on 1.0. In terms of Osx 
expression comparison, BSEL showed a significantly higher expression than the 
HARV as well as Static. In terms of verification of “stemness”, osteogenic 
samples cultured in BSEL for 29 days showed very little or none of Oct4 and 
Nanog expressions, whilst they were well expressed in the pluripotent samples 
cultured in BSEL for 13 days. On the contrary, the bone differentiation markers, 
Osx and RUNX2 were expressed only in the osteogenic samples. 
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Figure 69.Comparisons of gene expression on day 29 by qPCR and RT-PCR. 
Statistical analyses were performed by a student t-test (n=3). Double 
asterisks indicate p < 0.001. 
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7.2.6. Attenuated total reflection Fourier transform infrared (ATR 
FTIR) analysis 
Spatial hydroxyapatite composition in the mineralised hydrogel beads 
was analysed by attenuated total reflection Fourier transform infrared (ATR FTIR) 
imaging analysis (Kazarian and Chan 2003). Mineralised beads were collected on 
day 29, and the infrared images in which a whole bead can be shown were 
captured based on the spectral region of 1200-965 cm
-1
 which corresponds to 
the other FTIR studies of hydroxyapatite (Hwang et al. 2009; Karp et al. 2006). 
The registered area within the spectral region was represented with the colour 
gradients from yellow to red approaching to the peak in the spectra (PO4 at 
between 1026 and 1035 cm
-1
 as shown in Chapter 4.3.3). The relative amounts 
of hydroxyapatite in hydrogel beads were compared by calculating the 
percentage of the area that was registered as the presence of hydroxyapatite. 
Five samples randomly chosen in the experimental groups were measured, 
calculated, and statistically analysed using one-way ANOVA as shown with 
asterisks in the table (Figure 70). The hydrogels composed of undifferentiated 
ESCs (control) were measured as a negative control in the same way with the 
experimental groups. 
In the infrared image analysis, BSEL had the most composition of 
hydroxyapatite as shown with a large portion of red spots (Figure 70). The table 
showed that the osteogenic constructs from the BSEL bioreactor were 
composed of approximately five times higher percentage of hydroxyapatite in a 
bead than those from HARV. Control group reliably had a very small portion of 
the coloured spots in the image in correspondence with almost zero percentage 
of hydroxyapatite composition in a bead. Statistics were done by one-way 
ANOVA as indicated a single (p < 0.05) and double (p < 0.001) asterisks in the 
table (Figure 70). 
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Figure 70. Hydroxyapatite distribution and relative quantification using 
Attenuated total reflection Fourier transform infrared (ATR FTIR) 
analysis. Statistical analyses were performed by one-way ANOVA 
(n=5). Asterisks indicate p < 0.05 (single) and p < 0.001 (double) 
respectively. 
 
control BSEL
HARV STATIC
Control BSEL HARV STATIC
% of HA in a bead 0.30 ± 0.16 13.32 ± 2.76 2.68 ± 0.56 1.92 ± 0.94
*p < 0.05, **p < 0.001 ** * *
Control: alginate beads containing  undifferentiated ESCs cultured for 9 days
HA: hydroxy apatite
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7.2.7. Mechanical strength testing 
In order to examine how the mineralisation and hydroxyapatite 
composition affect the physical strength of the bone-like constructs, a 
mechanical compression testing was conducted with the samples on day 29 
from all groups. The force-displacement characteristics were measured from the 
samples as described in Chapter 3. 2. 11. In order to evaluate the property of 
stiffness, Young’s moduli were calculated based on the force-displacement plot 
fitted by linear regression (Figure 71). The Young’s modulus of alginate hydrogel 
without cells (Alginate bead) was also obtained as a standard of basic material. 
A control group (Control) was separately set using the hydrogels composed of 
undifferentiated ESCs with a similar cell density of the bone-tissue like 
constructs (about 3.5 - 4 X 10
5
 cells/bead). 
It was shown by the slopes of the fitted lines in the plot that more force 
was required to compress the samples from the BSEL than those from the HARV 
and Static (Figure 71), suggesting the highest stiffness was found in the samples 
from the BSEL. This result was consistently reflected in Young’s modulus 
comparison in the table of Figure 71. Briefly, BSEL had the highest Young’s 
modulus (572.1 kPa) among all groups. All mineralised groups had higher 
stiffness than Alginate bead and Control. However, interestingly, the alginate 
bead group showed higher mechanical strength than Control. 
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Figure 71. Mechanical strength analysis of bone-tissue like structure on day 29. 
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7.2.8. Immunocytochemistry with osteogenic markers 
Immunocytochemistry staining of OB-cadherin and Collagen type I was 
conducted with the samples from BSEL after 29 days of the osteogenic culture 
period (Figure 72). Both the osteogenic markers were dual-stained by FITC 
(Figure 72B) and Texas Red (Figure 72C) respectively as shown in Figure 72A. 
Each marker was separately stained along with DAPI as shown in Figure 72D 
(OB-cadherin, FITC) and Figure 72F (Collagen type I, Texas Red). Both markers 
showed their widely spread expressions around the cell colonies. 
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Figure 72. Immunocytochemistry of the BSEL group on day 29. 
OB-cadherin (B) and Collagen type I (C) were dual-stained with FITC 
and Texas Red respectively (A). The positively stained OB-cadherin 
and Collagen type I were also separately shown in (E) and (G). In all 
staining, nuclei of the cells were indicated with DAPI (blue) (a, d, e-1, 
f, g-1). (D) and (F) show the images merged with DAPI. Negative 
controls for FITC (e-2) and Texas Red (g-2) were conducted. The scale 
bars represent 100 µm. 
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7.3. Discussion 
 
Cells cultured in the Static group suffered a lack of mixing that can cause 
insufficient mass transport in the hydrogel as well as spatial gradients of the 
culture factors in a culture dish (a batch) as discussed in Chapter 6. It has been 
previously reported that the deposition of a mineralised matrix from stromal 
osteoblasts, statically cultured in poly (DL-lactic-co-glycolic acid) foams, only 
reached the depth of 240 µm from the top surface as a maximum penetration, 
also showing the hypoxic necrotic centre in the construct (Ishaug et al. 1997). 
Additionally, chondrocytes, cultured on poly (glycolic acid) meshes in a static 
condition, showed inhomogeneous glycosaminoglycan deposition restrictedly 
around the periphery of the construct (Martin et al. 1999). Therefore, it was 
readily expected in this study that low viability of cellular colonies was observed 
in the Static group as shown in Chapter 6, which resulted in a lack of 
functionality of the osteogenic constructs verified by most of the evaluations. 
In terms of growth kinetics, the BSEL group showed the fastest growth 
rate in the early differentiation period from day 5 to 9. The first possible reason 
about this result could be easily suggested from the different conditions of the 
medium-exchange between the fed-batch and perfusion types of bioreactor. 
When HepG2-CM was replaced by the osteogenic medium on day 3, BSEL could 
allow cells to be naturally adapted to the new culture medium as the medium-
exchange was accomplished within 24 hours by a slow rate of perfusion (0.7 
µl/sec). On the contrary, the cells in HARV may suffer from the abrupt exposure 
to the different culture environment by exchanging the entire culture medium 
in a vessel within a few minutes. 
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Furthermore, the profiles of metabolite accumulation in this study 
showed that ammonia concentration in HARV was maintained at very high 
levels between 2.0 and 3.5 mM during the culture period, while the ammonia 
concentrations in BSEL varied mostly between 1 and 1.5 mM. As discussed in 
Chapter 6, more than 2 mM of ammonia concentration was reported to be 
inhibitory to cell growth in mammalian cell cultures (Cormier et al. 2006b). 
Additionally, the lower levels of pH in the HARV during the culture period mostly 
below 7.0 could also interfere the regular metabolism of the cells whilst they 
progressed their specific differentiation (Cormier et al. 2006a). Therefore, the 
fast cell growth rate in the BSEL appears to be due to the effect of removing the 
accumulated metabolites and supplying the fresh medium by continuous 
perfusion. It is well known that cell to cell contacts can be densely organized by 
the fast proliferation of cells, followed by the efficient regulation of further 
differentiation (Smith 1992). With regard to this fact, the faster proliferation in 
the BSEL at the early stage of differentiation could also stimulate osteogenic 
differentiation more effectively resulting in the highest functionality of bone-
tissue like constructs among all groups. This result was also demonstrated in 
Chapter 4 such that the faster growth rate of HepG2-CM treated ESCs resulted 
in the improved differentiation in the following culture stage. 
Growth plates of the bone structure are known to be avascular structures 
(Rajpurohit et al. 1996). Therefore, it was reported that the low level of oxygen 
tension would mimic the cartilaginous environment in vivo, resulting in the 
effective bone morphogenesis in vitro (Simon and Keith 2008). In this study, 
however, the BSEL group demonstrated the best results in the evaluation of the 
osteogenic constructs although the oxygen tensions were maintained at higher 
levels than those in HARV, (about 12-3%). Various culturing factors are reported 
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to influence either a proliferative potential or differentiation of ESCs accordingly, 
in that a culture environment would be immediately affected by increasing cell 
numbers along with continuously releasing metabolites, growth factors, and 
other bio-molecules (King and Miller 2007). Likewise, it is postulated in this 
study that the regulation of differentiation of ESCs would be influenced more by 
the other culturing factors rather than by the oxygen condition, such as nutrient 
consumption, metabolite accumulation, and pH variance in a batch. 
Although numerous studies about ESC expansion and differentiation have 
been undertaken thus far, the optimal requirements of the basic medium for 
ESC culture are still not clear. In vivo, the normal concentration of glucose which 
circulates through blood vessels is approximately 1000 mg/l. However, 
supraphysiological glucose levels such as 4500 mg/l have been frequently 
employed for ESC derivation and maintenance in vitro. It was demonstrated that 
modified MEMα (Minimum Essential Medium alpha) containing 4500 mg/l of 
glucose improved the efficiency of ESC derivation remarkably in conjunction 
with the maintenance of their pluripotency, compared with the different media 
containing 1000 mg/l of glucose (Dulbecco's Modified Eagle Medium) (Kim et al. 
2009). On the other hand, the greatest rate of EB growth and differentiation 
was found not at a high glucose level (4500 mg/l), but at a physiologically 
normal glucose level (1000 mg/l)  (Khoo et al. 2005). In this study, ESCs were 
expanded in HepG2-CM formulated with high glucose DMEM, and differentiated 
in the osteogenic medium based on low glucose MEMα. MEMα was developed 
to support cells with high concentrations of various amino acids and vitamins, 
and sodium pyruvate etc. It was shown in the results of the medium profiles in 
this study that glucose levels reached almost 0 mM after the medium was 
changed to osteogenic medium and maintained at extremely low levels 
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throughout the entire osteogenesis period. This situation can be simply 
reasoned by a low level of the initial glucose concentration in the osteogenic 
medium (about 5 mM (1000 mg/l)), causing the early depletion of the glucose 
contents. As consistent to this low amount of glucose for cells to consume, 
lactate production was also low in all culture groups during osteogenesis period 
showing the levels between 5 and 10 mM. On the other hand, it was 
demonstrated that the early embryo development of human and mouse, pre-
implantation of blastocysts, was enhanced in the physiological glucose level, 
and furthermore, it showed high dependency on pyruvate or glutamine instead 
of glucose (Conaghan et al. 1993; Quinn 1995). The other study also suggested 
that ESCs in differentiation phase can survive in 0 mM of glucose adapting to 
other substrates present in the medium for metabolism such as pyruvate and 
glutamine (Khoo et al. 2005). In this study, the trends of the variances in 
glutamine levels showed a consistency to the reports above during osteogenesis, 
although the BSEL could manage to maintain the glutamine levels at about a 
half of the initial level by the medium perfusion. This high consumption of 
glutamine was not observed in the study of ESC-expansion in Chapter 6. 
Therefore, this study suggested that glutamine is likely to be more demanded in 
differentiation than in maintenance of ESCs, albeit other kinds of various 
substrates for ESC-culture still need to be reassessed over this phenomenon. 
Corresponding to the result of glutamine consumption, ammonia production 
during osteogenesis period was also higher than that in the pluripotent phase. 
In the analyses of osteogenic gene expressions, the highest Osterix 
expression was found in the BSEL whilst the expressions of other osteogenic 
markers such as type I collagen and Runx2 were not significantly different in 
both the bioreactor groups (HARV and BSEL). The significant difference in 
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Osterix expression between the two well-mixed condition groups was an 
interesting finding, although it was readily expected by many other clues stated 
previously that bioreactor cultures would show better functionality in 
osteogenic tissue generation than Static. Osterix is a recently identified zinc 
finger–containing transcription factor expressed in the osteoblasts of all the 
endochondral and membranous bones. On the other hand, Runx2 is a member 
of the runt family of transcription factors, which plays a crucial role in the early 
determination stage of the osteogenic lineage. It was previously reported that 
osteoblast differentiation was arrested in Osterix-null mutant mice followed by 
neither endochondral nor intramembranous bone formation whilst Runx2 was 
still expressed at the comparable levels to those in wild-type osteoblasts. This 
study suggested that the expression of Runx2 represents the differentiation into 
pre-osteoblasts that are still bi-potential, whereas Osterix regulates the later 
stage of osteoblast differentiation and bone formation acting downstream of 
Runx2 (Ducy et al. 1997; Komori et al. 1997; Nakashima et al. 2002). The 
osteogenic gene expressions in this study are in agreement with the previous 
studies, showing that the highest Osterix expression in the BSEL linked to the 
best functionality of the bone-tissue like constructs as verified by the analyses 
of mineralisation deposition, ATR FTIR, and mechanical strength. The cells in the 
HARV seemed to be in the stage of pre-osteoblast owing to a lack of Osterix 
expression, although Runx2 and type I collagen were expressed in a similar level 
with the BSEL. 
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7.4. Conclusions 
 
In this chapter, bone-tissue like constructs from ESCs have been 
effectively organised using a newly developed perfusion type of RWV bioreactor 
based on the previously established three-dimensional bioprocess for 
osteogenesis from ESCs. In comparison with a fed-batch type of RWV bioreactor 
and three-dimensional static culture conditions, the novel perfusion bioreactor 
finally showed the superior results in terms of the production of highly 
functional osteogenic constructs, proven by the largest mineralisation 
deposition and the stiffest mechanical strength as well as well-integrated 
hydroxyapatite composition. In conclusion, these results suggest an efficient 
methodology for the in vitro production of tissue-engineered osteogenic 
constructs from ESCs in a manner of “off-the-shelf” owing to the automated and 
reproducible operations of the new perfusion bioreactor system in conjunction 
with the optimised three-dimensional osteogenesis. 
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8.1. Introduction 
 
Nearly all patients suffering pains from large bone defects beyond their 
ability of self-regeneration require surgery such as bone graft transplantation 
and pinning (Standaert and Herring 2000). Many of the traditional strategies to 
repair the skeletal damages include the use of bone cements, metals and 
various prosthetic implant devices as well as autologous or allogeneic grafts, 
facilitating the healing of fractures with various degrees of success (Yaszemski et 
al. 1996). However, the approaches of current orthopaedic surgeries are not 
always satisfactory because a variety of failures from the synthetic devices were 
gradually revealed in the long term implantation (Boskey 2001; Kneser et al. 
2002). Likewise, the current therapies of autograft, allograft, and also xenograft 
transplantations still have inherent limitations, such as a lack of available graft 
quantity, donor site morbidity, and host immune rejection etc. (Luyten et al. 
2001). Therefore, the production of high quality bone tissues based on 
functional autogenous osteogenic cells would be an ideal alternative for the 
present orthopaedic clinics in agreement with the goal of bone tissue 
engineering (Yaszemski et al. 1996). For this purpose, many strategies for ESC-
differentiation towards osteogenesis have been investigated. However, 
although there have been many attempts of in vitro generation of the bone 
grafts constructed from ESCs, the clinical application is still in its infancy because 
of the difficulty in transferring academic studies to therapeutic surgery (Martin 
et al. 2004). 
In this chapter, in order to address the translational challenges in the 
bioprocess and in vivo testing for the purpose of clinical application, an animal 
model has been developed using functional bone grafts developed from an 
automated perfusion bioreactor system demonstrated in the last chapter. 
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8.1.1. Aims 
The aim of this chapter is to develop an animal model (rabbit cranial 
defect) as a pilot study to investigate the efficacy of the bone-tissue like 
structures constructed from the BSEL bioreactor in bone healing process of a 
large bone defect. 
 
8.1.2. Experimental and surgical procedures  
 
8.1.2.1. Experimental procedures 
Osteogenic constructs were generated from BSEL on basis of the 
methodologies consisting of hydrogel encapsulation and HepG2-CM optimised 
in Chapter 4.3. The osteogenic grafts were collected after 29 days of 
osteogenesis in BSEL, and immediately injected into the defects generated as 
described in the following sub-chapter. Alginate beads without cells were also 
injected into the other defects as a negative control. The defected sites were 
biopsied at 1, 2, and 8 weeks after the injection, and the progress of bone 
healing was periodically observed by X-ray micro-computed tomography, 
hematoxylin and eosin (H&E) staining, and immunohistochemistry of type I 
collagen. Immunohistochemistry of specific osteogenic markers was also 
performed with the biopsy at 8 weeks, such as insulin-like growth factor-1 and 
osteocalcin. 
 
8.1.2.2. Surgical procedures 
Adult New Zealand white rabbits approximately 3 kg in weight were 
prepared on basis of the criteria of the Animal Care Committee of Wonkwang 
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University. The detailed descriptions of the graft surgery methodologies can be 
found in Chapter 3.3, “In vivo Testing of Bone-like Tissues from Bioreactor”. 
Figure 73 briefly shows the surgery process. After the central region was incised, 
four holes (diameter: 8 mm, depth: 2-3 mm) were generated as the 
standardised cranial defects. The defects were filled with osteogenic constructs 
generated from BSEL and alginate beads (about 10 beads each) respectively. 
Finally, the defects were covered with fibrin glue in order to fix all the grafts 
within the holes. 
 
Figure 73. Surgical procedures. 
Incision on cranial area and exposure of cranial vault (A). 
Generation of the four round-shaped defects (diameter: 8 mm, 
depth: 2-3 mm) (B). Bead insertion (Left: osteogenic constructs, 
Right: alginate beads) (C). Fibrin glue fixation (D). 
A B
C D
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8.2. Results 
 
8.2.1. Biopsy isolation 
The defected cranial vaults were isolated at 1, 2, and 8 weeks following 
the implant insertion, and photographed in order to visually examine the 
inflammation around the defected sites (Figure 74). 
A few clues of inflammation were observed within the entire period on 
both the cranial and dural sides in all the biopsies. At 1 week, some of 
osteogenic beads were lost from the biopsy during the isolation procedure likely 
due to the insufficient period to have a firmed fixation of fibrin glue over the 
defected sites. At 2 weeks, it was found that all the grafts were well placed in 
the defects, and appeared to be harmonised with the host tissue although the 
shape of the mineralised beads was still maintained. All the defected sites were 
fully covered with fibrous connective tissues at 8 weeks. 
 
 
Figure 74. Biopsies of cranial vault at 1, 2, and 8 weeks after operation. 
(Left: osteogenic constructs, Right: alginate beads) 
1week 2weeks 8weeks
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8.2.2. Histological evaluations 
8.2.2.1. Hematoxylin and eosin (H&E) staining 
All biopsies were histologically examined by H&E staining. As shown in 
Figure 75 and 76, both the groups of osteogenic constructs and negative control 
showed their gradual bone regenerations over the time period. At 1 week 
(Figure 75A, B and 76A, B), the osteogenic constructs inserted in the defects 
tend to be parts of the newly generated bone tissues (NB), whereas the 
negative control still showed huge voids with less dense fibroblast-like cells in 
the fibrous interzones (FI). Traces of vascularisation were observed in the 
fibrous interzone areas of the defects of both groups from the early periods 
(indicated by arrows in the figures). As healing time passed by, cells appeared to 
be scattered like osteocytes and surrounded by ECMs, and the fibrous 
interzones were filled with the newly grown bone tissues. At 8 weeks (Figure 
75E, F and 76E, F), the integrity of the new bone tissues was likely shown to 
differ between both groups. 
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Figure 75. Hematoxylin and eosin staining of the group of osteogenic 
constructs at 1 week (A, B), 2 weeks (C, D), and 8 weeks (E, F). (NB: 
new bone, FI: fibrous interzone). 
Arrows indicate traces of vascularisation. Scale bars were 500 µm 
(A, C, E: 50X) and 100 µm (B, D, F: 200X) respectively. 
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Figure 76. Hematoxylin and eosin staining of the group of negative control at 
1 week (A, B), 2 weeks (C, D), and 8 weeks (E, F). (NB: new bone, FI: 
fibrous interzone). 
Arrows indicate traces of vascularisation. Scale bars were 500 µm (A, 
C, E: 50X) and 100 µm (B, D, F: 200X) respectively. 
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8.2.2.2. Immunohistochemistry for type I collagen 
The expressions and distributions of type I collagen were investigated 
over the healing time period in order to compare the progress of bone matrix 
formation between both the groups of osteogenic constructs (Figure 77A, C, E) 
and negative control (Figure 77B, D, F). The bone regeneration process of the 
negative control took place at a different starting point, being full of fibrous 
collagen matrix in the defects at 1 week, whilst the group of osteogenic 
constructs showed more extensive expression of type I collagen over tightly 
packed fibroblast-like cells in the fibrous interzone along with the new bone 
tissues (Figure 77A, B). At 2 weeks, type I collagen was strongly secreted at the 
edge areas of the newly generated bone tissues in both groups. However, the 
group of osteogenic constructs showed that type I collagen structures, which 
were well aligned in the fibrous interzones, seemed to be naturally harmonised 
within the new bone tissues, whilst randomly oriented collage fibres in many 
void regions were still observed in the negative control. At 8 weeks, the 
expression of type I collagen appeared to be regularly spread whilst showing 
strong secretions near the scattered cells in both groups. 
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Figure 77. Immunohistochemistry for type I collagen at 1 week (A, B), 2 weeks 
(C, D), and 8 weeks (E, F).  
A, C, E: the group of osteogenic constructs, B, D, F:  negative controls. 
(NB: new bone, FI: fibrous interzone). Arrows indicate fibrous 
collagen structures. Scale bars were 100 µm (200X). 
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8.2.2.3. Immunohistochemistry for insulin-like growth factor-1 and 
osteocalcin at 8 weeks 
Immunohistochemistry using osteogenic markers such as insulin-like 
growth factor-1 (IGF1) (Figure 78) and osteocalcin (OCL) (Figure 79) was also 
conducted with the biopsies from both groups at 8 weeks. The group of 
osteogenic constructs appeared to have more extensive expressions of both 
IGF1 and OCL than the negative control group as shown in Figure 78A, C and 
79A, C. The strong expression of both markers was found near the scattered 
cells as shown in the larger magnification (Figure 78B, D and 79B, D), whilst IGF1 
was also strongly expressed at the borders of the new bone tissues. 
 
Figure 78. Immunohistochemistry for insulin growth factor-1 at 8 weeks. 
A, B: the group of osteogenic constructs, C, D: negative controls. 
Scale bars were 250 µm (A, C: 100X) and 50 µm (B, D: 400X) 
respectively. 
A B
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Figure 79. Immunohistochemistry for osteocalcin at 8 weeks. 
A, B: the group of osteogenic constructs, C, D: negative controls. 
Scale bars were 250 µm (A, C: 100X) and 50 µm (B, D: 400X) 
respectively. 
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8.2.3. Micro-focus X-ray computed tomography (micro-CT) 
After biopsy isolation at 1, 2, and 8 weeks, the regeneration progress of 
the hardened mineralised tissues was periodically observed with a micro-CT 
scanning (Figure 80). At the first week, both the groups of osteogenic constructs 
and negative control showed few evidences of well-integrated bone tissues yet, 
although they appeared to start a natural bone healing process at the periphery 
of the defected sites. At 2 weeks, both the groups tend to show denser 
mineralised peripheral regions of the defects than those at 1 week likely due to 
the further progress of natural bone healing. However, the group of osteogenic 
constructs showed the mineralised portions in the middle of the defect in 
conjunction with the peripheral restoration. At 8 weeks, much larger 
mineralised regions were observed in the group of osteogenic constructs at 
overall area of the defect, whilst the defect of a negative control was still void 
only showing some regeneration of mineralised portions on the edge and 
bottom areas of the defect. Moreover, the traces of alginate beads were not 
observed in the negative control at 8 weeks. 
The micro-CT scanning of the biopsies at 8 weeks was three-
dimensionally reconstructed in order to have the volumetric views of the 
regeneration of mineralised tissues (Figure 81). As shown in the tilted views, the 
group of osteogenic constructs had thicker and bulkier regeneration of 
mineralised bone volume than a negative control. According to the volumetric 
analysis from a software based on the three-dimensionally reconstructed 
images (described in Chapter 3.3.3), the newly mineralised portions in the group 
of osteogenic constructs occupied about 22% volume of the hole, whereas 9% 
of hole was filled in a negative control. 
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Figure 80. Images of the mineralised portions within the defects 
periodically obtained by micro-CT scanning. 
The dotted circles represent the original defect size (about 8 
mm of diameter). 
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Osteogenic 
constructs
Alginate 
beads
211 
 
 
 
 
 
 
Figure 81. Bone regeneration in 8 weeks (three-dimensionally 
reconstructed from micro-CT). 
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8.3. Discussion 
 
Restoring skeletal continuity at the location of interest is the most 
essential mission to recover the mechanical function of bone tissues lost by 
injury or other reasons. The restoration of skeletal continuity, if the defect was 
too large to be healed by itself, normally requires bone transplantation 
(Yaszemski et al. 1996). However, bone transplantation either autologous or 
allogenous often involves such limitations, a lack of available graft quantity, 
donor site morbidity, and difficulties in harvesting tissues etc. In Chapter 7 of 
this thesis, an efficient methodology for the in vitro production of tissue-
engineered osteogenic constructs was suggested. Transplantable osteogenic 
grafts were manufactured from ESCs in a manner of “off-the-shelf” owing to the 
automated and reproducible operations of BSEL system in conjunction with the 
optimised three-dimensional bioprocess. Under the expectation that a clinically 
available stem cell source will be emerged along with the development of a 
novel bioprocessing technology, the osteogenic grafts constructed in BSEL were 
continuously introduced in animals to evaluate the contribution to bone healing. 
A bone fracture disrupts skeletal continuity and mechanical function, 
damages local blood vessels. Bone healing occurs in three distinct but 
overlapping stages: 1) the early inflammatory stage; 2) the repair stage; and 3) 
the late remodelling stage (Buckwalter and Mankin 1998; Burchardt and 
Enneking 1978). This recapitulates the processes of the endochondral 
ossification. 
The first event that occurs after a fracture is the haematoma formation 
followed by the activation of coagulation cascade to form fibrin clots. In the 
inflammatory stage, inflammatory cells arrive at the damaged sites and remove 
necrotic tissue. In this study, fibrin glue was used to fix the grafts within the 
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holes made as standardised defects as well as to promote the infiltration of 
various vasoactive mediators and growth factors into the defected sites. The 
animal model used in this study was likely to show adequate haematoma and 
inflammation on both the cranial and dural sides of the biopsies, which led us to 
expect the natural bone healing progress. 
The next stage of bone healing is the repair stage which consists of the 
cellular synthesis of new bone organic matrix, and the ossification to form new 
woven bone (Yaszemski et al. 1996). During the repair stage, fibroblasts begin to 
lay down a stroma that helps support vascular ingrowth, and osteoblasts appear 
with the vascular tissue (Burchardt 1987). Subsequently, collagen matrices are 
laid down whilst various osteoids such as proteoglycans and osteocalcin are 
secreted by osteoblast, followed by mineralisation to form a very weak primitive 
bone structure called a callus (Yaszemski et al. 1996). This callus plays a role as 
the new raw material for bone remodelling whilst forming a bridge of woven 
bone between fracture fragments. In this study, it was observed in H&E staining 
and immunohistochemistry for type I collagen that the general process of bone 
healing progressed over time period in a similar manner to the phenomenon 
stated above. However, the group of osteogenic constructs showed the faster 
progress in bone reconstruction than the negative control group likely due to 
the osteogenic grafts inserted in the defect. The inserted grafts appeared to be 
well-harmonised within the defected sites and promoted the formation of new 
bone tissues whilst effectively filling the fibrous interzones. Seemingly, many 
clues of the woven bone formation were observed in the negative control. 
However, most of them were less dense structures with randomly oriented 
collagen fibres, whereas the group of osteogenic constructs showed well-
aligned and packed type I collagen expressions with naturally being absorbed 
within the newly generated bone tissues at 2 weeks. 
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IGF1 is known to be present in osteoblastic cell cultures and bone matrix. 
The expression or activity of osteocalcin, alkaline phosphatase and collagen is 
affected by IGF1 (Canalis and Lian 1988; Chenu et al. 1990). IGF1 plays a key role 
in skeletal growth and remodelling (McCarthy and Centrella 2001). OCL is also 
popularly used as a bone marker, a bone calcium-binding protein synthesised by 
osteoblasts. In this study, the faster and enhanced bone regeneration in the 
group of osteogenic constructs was further supported by the extensive 
expressions of IGF1 and OCL at 8 weeks as shown in immunohistochemistry 
results. In particular, the strong expressions of IGF1 were observed near the 
borders between the fibrous interzone and new bone tissue, which commonly 
occurs in the incorporation of bone grafts mimicking endochondral ossification 
(Yaszemski et al. 1996). 
The final stage of bone healing is the remodelling stage which takes the 
longest time. The newly generated woven bone undergoes sequential 
resorption and deposition phases to become more organised lamellar bone with 
better-aligned organic and mineral components (Yaszemski et al. 1996). In this 
study, the hardened mineralised portions in the defects were periodically 
observed by a micro-CT scanning. Bone fracture healing normally begins at the 
edge regions of defect in order to have various supplies from either a neighbour 
bone tissue or connective tissue called periosteum during the first two phases 
of bone healing (the inflammatory and repair stages). However, the insertion of 
osteogenic grafts constructed from BSEL resulted in the spatially regular 
mineralisation at overall area of the defect, whilst a negative control showed 
partial mineralisation only on the edge and bottom areas of the defect. It seems 
that the bone remodelling process in the group of osteogenic constructs would 
more effectively keep on restoring the defect to its original shape and structure. 
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There are a few recent studies about animal models with ESCs, 
particularly about skeletal defect regeneration. Taiani et al. in 2010 attempted 
to form osteogenic cellular aggregates from ESCs using a stirred bioreactor and 
explored the influence of ESC-derived osteogenic cells to bone healing in vivo. In 
the results, the three-dimensional osteogenesis in a stirred bioreactor was not 
properly completed but still containing pluripotent cells causing disruption of 
the bone architecture in the defect whilst teratomas were formed (Taiani et al. 
2010). However, in this study, the osteogenic constructs developed in the BSEL 
bioreactor did not show pluripotency gene marker expression as shown in 
Chapter 7, and no evidences of either bone disruption or teratoma formation 
were observed in the defect sites. Jukes et al. in 2008 reported mature cartilage 
matrix could be formed in vivo within 21 days by implanting cartilage tissue-
engineered constructs from ESCs. This report suggested the cartilage matrix 
could be gradually replaced by new bone tissues during endochondral 
ossification (Jukes et al. 2008). In this study, the evidences of early new bone 
generation bridged by dense woven bone tissues were observed at 1 week 
suggesting that the bone healing process with the implant of our functional 
osteogenic constructs was more effectively promoted than the previous study. 
 
 
 
 
 
 
216 
 
8.4. Conclusions 
 
In this chapter, an animal model has been developed using the three-
dimensional osteogenic cellular constructs generated from BSEL. All the results 
of histological evaluations and micro-CT scanning suggested that the insertion of 
the functional osteogenic grafts into the generated bone defect in vivo 
promoted the bone healing progress with the effective regeneration of dense 
osteogenic tissues in conjunction with extensive mineralisation at overall area 
of the defect. 
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Chapter 9. Summary and 
Conclusions 
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A three-dimensional integrated bioprocess for ESC-culture was previously 
developed, which consists of an encapsulation technique using alginate/gelatin 
hydrogel and a RWV bioreactor system (Randle et al. 2007). In this project, 
HepG2-CM has been introduced in the bioprocess in order to improve the 
mesodermal derivation from ESCs which could lead to higher productivity in 
skeletal lineage differentiation. It has been shown in Chapter 4 that the selective 
cardiomyogenesis and osteogenesis from ESCs were respectively achieved in the 
three-dimensional culture by determination of the most effective time course. 
The limitations, however, still existed in the use of a fed-batch type of 
bioreactor. This, thus, led us to develop a novel perfusion RWV bioreactor 
system which is amenable to continuous medium feeding by a computer-
controlled, automatable operation in conjunction with the effective gas-
exchange as demonstrated in Chapter 5. The newly developed system enabled 
the RWV unit to have the followings: 
1) Convenient gas exchange through a gas-permeable membrane 
mounted on the surface of the culture vessel 
2) Efficient oxygenation, nutrient supply, and metabolite removal by 
continuous perfusion of the culture medium  
3) Avoidance of the experimental errors from the manual operation 
processes by an automation system 
These benefits, consequently, resulted in a nicely maintained culture 
condition throughout the entire culture period as well as convenient adaptation 
in various culture environments by controlling culturing factors at real time. In 
particular, this new culture system has successfully demonstrated the significant 
improvement in three-dimensional ESC-expansion and differentiation (shown in 
Chapter 6 and 7). Briefly, 120% better ESC-expansion along with the 
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maintenance of high “stemness” has been achieved in the new perfusion 
system compared to the results from the fed-batch system. Furthermore, in 
terms of three-dimensional osteogenesis, the osteogenic constructs generated 
from the new perfusion system appeared to be well-integrated as bone-tissue 
like structures, which showed approximately 270% better mechanical strength 
than those from the fed-batch bioreactor owing to a larger amount of 
mineralised deposition and higher composition of hydroxyapatite in the cellular 
constructs. 
To date, there have been only few in vivo studies using ESCs, especially in 
bone restoration. This led this project to end up with developing an animal 
model based on the functional osteogenic constructs from ESCs generated by 
the new bioreactor system. The animal study in this project evaluated the actual 
contribution of the osteogenic constructs to the restoring progress in large bone 
defects. The grafts cultured for 29 days in the new perfusion system were 
inserted into the generated large bone defect and observed to be well 
harmonised in the host tissue followed by the general bone healing process. In 
results, it was shown during 8 weeks of period that the osteogenic grafts 
effectively promoted the bone restoration at overall areas of the large defect 
along with highly integrated mineralisation, whilst the negative control, alginate 
beads without cells, showed a relatively slower healing progress only on the 
edge regions of the defects by self-curing process of the animal. 
The desired bioreactor system in the future would be a closed-loop 
system, thereby performing the different processing phases within a single and 
automated system. Autologous transplantation could be achieved through the 
ideal bioprocess without any logistical issues of transferring specimens between 
locations. Additionally, operator handling would be minimised throughout the 
whole culture process, thus contributing to the significant economical benefit 
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for the cost of tissue engineered products. Therefore, the development of 
bioreactor systems could facilitate the distribution of powerful therapeutic 
approaches that would otherwise remain confined within the context of 
academic studies or restricted to elite social classes or systems (Martin et al. 
2004). A variety of the results in this study suggested the feasibility of 
transferring the laboratory-based practices based on ESCs to in vivo study. This 
methodology of “off-the-shelf” production of ESC-based skeletal tissues would 
potentially be advanced to the therapeutic procedures in various orthopaedic 
surgeries along with the development of the effective strategies for controlling 
specific differentiation of ESCs. 
Determining optimal operation conditions of the perfusion system can be 
suggested for the future study. Perfusion rates can be optimised depending on 
the culture stages regarding ESC-growth and differentiation. In addition, skeletal 
systems show sensitive mechanobiological responses in vivo. Therefore, there 
have been numerous studies about mechanical stimulation for the effective 
skeletal tissue generation in vitro. In the BSEL bioreactor, ultrasound stimulation 
among many mechanical stimulation methods can be considered due to its 
efficacy to be mounted on the existing culture vessel. Combining the mechanical 
stimulation module, the BSEL system is expected to produce functional 
mineralised tissues with higher quality. 
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Appendix 1. Standard curves 
 
Appendix 1.1. ρNPP standard curve 
In order to calibrate ALPase activity, a standard curve was generated 
using a standard ρ-nitrophenol solution (Sigma-Aldrich). The solution was 
serially diluted to have the proportion to the absorbance read at 405 nm. The 
same conditions were applied to the measurement of experimental samples. 
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Appendix 1.2. DNA quantification standard curve 
Because cells and ECMs were very strongly agglomerated as a tissue-like 
structure after prolonged ostegenesis, it was hard to dissociate them as a single-
cell level to count. In order to find the cell numbers from the three-dimensional 
complexes, DNA quantification method was introduced with the following 
standard curve. Cells for the standard curve were collected from two-
dimensional culture, counted by a haematocytometre, and serially measured 
from 5,000 cells to 9,000,000 cells. 
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Appendix 2. Characterisation of HepG2-CM treated ESCs 
on two-dimensional culture 
 
Appendix 2.1. Cell morphology observation 
Normal mESCs appeared to be round-shaped and three-dimensionally 
colonised whereas mESCs in HepG2-CM (cmESCs) tend to be spiky/polygonal-
shaped and two-dimensionally spread on day 3 as demonstrated in the previous 
works. 
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Appendix 2.2. Alkaline phosphatase (ALPase) staining 
ALPase staining on cmESCs was performed to observe their maintenance 
of pluripotency during culture time. The cell colonies in which cmESCs were 
densely colonised showed the positive staining (red colour). mESCs cultured in 
the normal growth medium for 6 days were also stained as a control. 
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Appendix 2.3. Immunocytochemistry with Oct4 
Immunocytochemistry with Oct4 was performed to confirm the 
pluripotency of both mESCs and cmESCs after 6 days of culture. 
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Appendix 2.4. Comparison of growth kinetics 
Growth kinetics was examined to verify the fast proliferation of cmESCs 
as demonstrated in the previous works. 
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Appendix 2.5. EB formation and gene expression profiles 
In order to confirm the enhanced mesoderm formation from cmESCs 
during EB period, various gene profiles were investigated over EB-culture period. 
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Appendix 3. Media analysis from Synthecon system 
 
Because of a lack of cell viability in Synthecon system, the culture process 
was halted on day 6. Variation of culture parameters such as pH, glucose, and 
lactate was relatively maintained not because of medium perfusion but because 
of few cells remaining alive in the culture chamber. Oxygen tensions in 
Synthecon were measured up to day 13. However, the trend of oxygen 
concentration variations also corresponds to the other parameters without the 
clue of consumption during the culture period. 
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Appendix 4. Negative control for PCR analyses 
 
Negative controls of each primer were conducted for reliable PCR 
analyses. Within all the same RT-PCR processes, water was put in the master 
mix of PCR reagents instead of cDNA templates, and none of amplification was 
observed verifying the reliability of the primers. 
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